Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
16e58f48af650329b495321a26b56e625f511d9dee5a9bdc02ec1d9bd7cf77f4.png
complex
<table><tr><td>Effects and limitations of management contract</td><td>Public sector perspective</td><td>private sector perspective</td></tr><tr><td rowspan="5">Effects</td><td>By introducing competitive forces, contracting puts pressure on both public and private providers in terms of both service and price.</td><td>Contracting expands market opportunities to include public sector clients or customers.</td></tr><tr><td>Expanding the range of activities subject to contracting encourages the private sector to expand the services it provides in areas desired by government.</td><td>Contracting allows a private provider to capture a market to be protected from competitors at least for the term of the contract.</td></tr><tr><td>Contracting both requires and promotes better planning and policy development by improving the flow of information about volumes of goods, services, costs, quality, responsiveness, population served, health needs and other issues.</td><td>Contracting can provide a reliable and timely source of revenue, encouraging investments necessary to support quality and innovation and ensuring longer term viability.</td></tr><tr><td>Contracting provides government with a mechanism for purchasing needed health services at an agreed on and therefore predictable price.</td><td>The contract term may provide adequate time to justify investments in the capital and personnel needed to support contractual obligations.</td></tr><tr><td>Contracting promotes transparency, constrains conflicts of interest and reduces opportunity for graft and corruption.</td><td></td></tr><tr><td rowspan="10">Limitations</td><td>Qualified private providers may not be available.</td><td>The costs of entering the market to compete successfully for government contracts may be too high.</td></tr><tr><td>Qualified bidders may not be interested in contracting with government.</td><td>The market may be too unstable or the contract period too short to support needed capital investments.</td></tr><tr><td>Competition may be weak or non existent.</td><td>Transaction costs, the costs of securing and managing the contract may be too high.</td></tr><tr><td>Government may discourage bidders by shifting too much risk to providers.</td><td rowspan="7">There may be no legal resource if government fails to fulfill its contractual obligations.</td></tr><tr><td>Successful contractors could compete with the public sector for health personnel.</td></tr><tr><td>Governmental capacity to negotiate contracts may be weak.</td></tr><tr><td>Government's managerial and bureaucratic overhead may increase.</td></tr><tr><td>Government may agree to disadvantages contract terms.</td></tr><tr><td>Long term contracts may restrict government flexibility.</td></tr><tr><td>Costs may be higher than anticipated.</td></tr></table>
772b165aa6f4730bcf96b4ea4d16d34bef666bf22253825c1c351c25588991b0.png
simple
<table><tr><td></td><td>No. herds</td><td>End of one year study period</td><td>Herd size Cow years/year</td><td>Calculated bulk tank somatic cell count</td><td>Milk production Kg ECM/day</td><td>Mastitis treatments % cows treated/cow year</td><td>% of cows with infection risk &gt; 50%</td></tr><tr><td>Conventional</td><td>20</td><td>03&#8211;2000</td><td>83</td><td>283</td><td>25.7<sup>a</sup></td><td>74<sup>a</sup></td><td>42</td></tr><tr><td>Organic before 1995</td><td>18</td><td>03&#8211;2000</td><td>88</td><td>296</td><td>22.1<sup>c</sup></td><td>48<sup>b</sup></td><td>38</td></tr><tr><td>Converting herds before conversion</td><td>19</td><td>04&#8211;1999 or 04&#8211;2000</td><td>87</td><td>317</td><td>24.6<sup>a,b</sup></td><td>61<sup>a,b</sup></td><td>42</td></tr><tr><td>Converting herds first year after conversion</td><td>19</td><td>04&#8211;2000 or 04&#8211;2001</td><td>101</td><td>337</td><td>23.3<sup>c</sup></td><td>52<sup>a,b</sup></td><td>44</td></tr><tr><td>Converting herds second year after conversion</td><td>19</td><td>04&#8211;2001 or 04&#8211;2002</td><td>107</td><td>327</td><td>23.8*</td><td>48<sup>a,b</sup></td><td>45</td></tr><tr><td>Conventional herds in full research project</td><td>109</td><td>03&#8211;2000</td><td>85</td><td>309</td><td>24.4<sup>b</sup></td><td>55*</td><td>43</td></tr></table>
62d6bbdd8229910bb84125346cf05327096d8b161715d34f46ca9e4af27e1cea.png
complex
<table><tr><td rowspan="3">History of blood donation</td><td colspan="2">Blood donation total attitude</td><td rowspan="3"><i>P</i> value<sup>*</sup></td></tr><tr><td colspan="2">score (4&#8211;20)</td></tr><tr><td>Median</td><td>Mean rank</td></tr><tr><td>Yes</td><td>16.5</td><td>196.0</td><td rowspan="2">&lt;0.001</td></tr><tr><td>No</td><td>16</td><td>157.2</td></tr></table>
f69d03ef802b9de3b7c129e1227023a36ed14cd04a4cc45541ddcdd48006b59f.png
simple
<table><tr><td>Sample ID</td><td>MW of standard protein bands (KDa)</td></tr><tr><td><i>C. muytjensii</i>ATCC 51329</td><td>66, 80 &amp; 150</td></tr><tr><td><i>C. sakazakii</i>ATCC 29544</td><td>66, 125</td></tr><tr><td>MP04.1</td><td>66 &amp; 80</td></tr><tr><td>MP08.5</td><td>66, 80,125 &amp; 150</td></tr><tr><td>MP10.2</td><td>150</td></tr><tr><td>HR11.3</td><td>66, 80,125 &amp; 150</td></tr><tr><td>BC52.2</td><td>66, 80,125 &amp; 150</td></tr><tr><td>SP62.1</td><td>66, 80,125 and 150</td></tr></table>
3f242c2a8e349b7a9ee7ec0a4f9a48accbe38988d5fe3751888a6c7b91a632a1.png
simple
<table><tr><td></td><td>Cumulated Dose (&#956;Gy) @ 0.152 m</td><td>Cumulated Dose (&#956;Gy) @ 0.305 m</td><td>Cumulated Dose (&#956;Gy) @ 0.914 m</td></tr><tr><td>1 hr</td><td>87.3</td><td>56.0</td><td>9.9</td></tr><tr><td>2 hr</td><td>147.0</td><td>94.3</td><td>16.6</td></tr><tr><td>3 hr</td><td>188.0</td><td>120.6</td><td>21.2</td></tr><tr><td>4 hr</td><td>216.1</td><td>138.6</td><td>24.4</td></tr><tr><td>5 hr</td><td>235.3</td><td>150.9</td><td>26.6</td></tr></table>
8c29f0ee26730031c546b6ea34c78282266afb5a43ccc8b34a6da3f10b745e87.png
complex
<table><tr><td colspan="6">Percentage of 13-to 17-Year-OldGirls Completing HPV Vaccine Series, U.S., 2012</td></tr><tr><td>Range</td><td>State</td><td>Percent</td><td>Range</td><td>State</td><td>Percent</td></tr><tr><td>&#8805;50%</td><td>Rhode Island</td><td>57.7</td><td></td><td>Kentucky</td><td>34.9</td></tr><tr><td></td><td>Delaware</td><td>50.4</td><td></td><td>Missouri</td><td>34.5</td></tr><tr><td>40&#8211;49%</td><td>Vermont</td><td>46.2</td><td></td><td>New Hampshire</td><td>34.5</td></tr><tr><td></td><td>Pennsylvania</td><td>44.6</td><td></td><td>Minnesota</td><td>33.1</td></tr><tr><td></td><td>Hawaii</td><td>43.4</td><td></td><td>Michigan</td><td>32.2</td></tr><tr><td></td><td>Connecticut</td><td>43.6</td><td></td><td>Ohio</td><td>31.9</td></tr><tr><td></td><td>Washington</td><td>43.5</td><td></td><td>South Dakota</td><td>31.8</td></tr><tr><td></td><td>Massachusetts</td><td>43</td><td></td><td>New Jersey</td><td>31.6</td></tr><tr><td></td><td>Maine</td><td>41.8</td><td></td><td>Alaska</td><td>31.4</td></tr><tr><td></td><td>Montana</td><td>41.6</td><td></td><td>Alabama</td><td>31.1</td></tr><tr><td></td><td>North Dakota</td><td>40.9</td><td></td><td>Maryland</td><td>30.9</td></tr><tr><td></td><td>Louisiana</td><td>40.5</td><td></td><td>New Mexico</td><td>30.3</td></tr><tr><td>30&#8211;39%</td><td>New York</td><td>39.7</td><td></td><td>Texas</td><td>30.3</td></tr><tr><td></td><td>Oregon</td><td>38.6</td><td></td><td>Wyoming</td><td>30.3</td></tr><tr><td></td><td>District Columbia</td><td>38.5</td><td>&#8804;29%</td><td>Georgia</td><td>29</td></tr><tr><td></td><td>Oklahoma</td><td>38.4</td><td></td><td>Tennessee</td><td>28.6</td></tr><tr><td></td><td>Colorado</td><td>38</td><td></td><td>Virginia</td><td>27.9</td></tr><tr><td></td><td>Wisconsin</td><td>37.5</td><td></td><td>Idaho</td><td>27.8</td></tr><tr><td></td><td>Nebraska</td><td>37.3</td><td></td><td>South Carolina</td><td>26.6</td></tr><tr><td></td><td>Nevada</td><td>37.2</td><td></td><td>Florida</td><td>25.3</td></tr><tr><td></td><td>Arizona</td><td>36.9</td><td></td><td>Kansas</td><td>25.1</td></tr><tr><td></td><td>West Virginia</td><td>36.1</td><td></td><td>Utah</td><td>24.1</td></tr><tr><td></td><td>North Carolina</td><td>35.5</td><td></td><td>Illinois</td><td>21.1</td></tr><tr><td></td><td>California</td><td>35.8</td><td></td><td>Arkansas</td><td>18.3</td></tr><tr><td></td><td>Iowa</td><td>35.6</td><td></td><td>Mississippi</td><td>12.1</td></tr><tr><td></td><td>Indiana</td><td>35.2</td><td></td><td></td><td></td></tr></table>
231cdf1a0ea3b28e2c8d6f4c5a7e139a82c15f9550452ecd462d5702d9273b24.png
simple
<table><tr><td>Diagnosis</td><td>Tumour biopsy</td><td>Perilesional skin</td><td>Total</td></tr><tr><td> </td><td>No. of positive/total (%)</td><td>No. of positive/total (%)</td><td>No. of positive/total (%)</td></tr><tr><td>BCC</td><td>31/50 (62)</td><td>24/50 (48)</td><td>55/100 (55)</td></tr><tr><td>SCC</td><td>8/9 (89)</td><td>6/9 (67)</td><td>14/18 (78)</td></tr><tr><td>Total</td><td>39/59 (66)</td><td>30/59 (51)</td><td>69/118 (58)</td></tr></table>
939624b035bd44315b97f2f0dd7e39bc287af39728867e99b70bdfefc58c182b.png
complex
<table><tr><td rowspan="2">Approach</td><td colspan="10">Number of Links</td></tr><tr><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td><td>9</td><td>10</td><td>All</td></tr><tr><td>ELM</td><td>2.8596</td><td>2.2980</td><td>2.8878</td><td>3.5223</td><td>2.5630</td><td>2.7815</td><td>2.7059</td><td>3.0009</td><td>3.5630</td><td>2.7811</td></tr><tr><td>WKNN</td><td>3.3536</td><td>2.5236</td><td>2.7971</td><td>3.6393</td><td>2.8896</td><td>2.9103</td><td>2.9982</td><td>3.5008</td><td>3.5673</td><td>2.9991</td></tr><tr><td>SVM</td><td>3.0095</td><td>2.3325</td><td>2.9633</td><td>3.2321</td><td>2.7520</td><td>2.5356</td><td>3.5029</td><td>3.3308</td><td>3.3569</td><td>3.0007</td></tr><tr><td>BPNN</td><td>3.8998</td><td>2.7892</td><td>3.6630</td><td>3.2079</td><td>2.8535</td><td>3.5505</td><td>2.4936</td><td>3.3291</td><td>2.7851</td><td>3.3332</td></tr></table>
58d485417c4bc3aaa03d2c73385e487733c5bb806645df9f96aacf6818be0b4a.png
complex
<table><tr><td rowspan="2">PAH</td><td rowspan="2">TEF</td><td>Surgeon</td><td> </td><td>AT</td><td> </td></tr><tr><td>PAH<sub>Gas</sub></td><td>PAH<sub>Particle</sub></td><td>PAH<sub>Gas</sub></td><td>PAH<sub>Particle</sub></td></tr><tr><td>Naphthalene</td><td>0.001</td><td>1055</td><td>1.6</td><td>584</td><td>1.1</td></tr><tr><td>Acenaphthylene</td><td>0.001</td><td>5.8</td><td>ND</td><td>3.5</td><td>ND</td></tr><tr><td>Acenaphthene</td><td>0.001</td><td>19.9</td><td>ND</td><td>14.6</td><td>ND</td></tr><tr><td>Fluorene</td><td>0.001</td><td>55.4</td><td>0.8</td><td>42.2</td><td>0.5</td></tr><tr><td>Phenanthrene</td><td>0.001</td><td>84.3</td><td>3.2</td><td>68.3</td><td>2.2</td></tr><tr><td>Anthracene</td><td>0.01</td><td>22.2</td><td>5.6</td><td>16.7</td><td>4.0</td></tr><tr><td>Fluoranthene</td><td>0.001</td><td>18.9</td><td>3.8</td><td>14.2</td><td>2.7</td></tr><tr><td>Pyrene</td><td>0.001</td><td>17.8</td><td>5.4</td><td>13.3</td><td>4.1</td></tr><tr><td>Benzo[a]anthracene</td><td>0.1</td><td>ND</td><td>2.7</td><td>ND</td><td>1.3</td></tr><tr><td>Chrysene</td><td>0.01</td><td>ND</td><td>3.0</td><td>ND</td><td>1.4</td></tr><tr><td>Benzo[b]fluoranthene</td><td>0.1</td><td>ND</td><td>2.6</td><td>ND</td><td>1.3</td></tr><tr><td>Benzo[k]fluoranthene</td><td>0.1</td><td>ND</td><td>1.5</td><td>ND</td><td>0.7</td></tr><tr><td>BaP</td><td>1</td><td>ND</td><td>1.7</td><td>ND</td><td>1.1</td></tr><tr><td>Indeno[cd]pyrene</td><td>0.1</td><td>ND</td><td>1.8</td><td>ND</td><td>1.0</td></tr><tr><td>Dibenzo[ah]anthracene</td><td>5</td><td>ND</td><td>1.8</td><td>ND</td><td>1.1</td></tr><tr><td>Benzo[ghi]peryrene</td><td>0.01</td><td>ND</td><td>2.1</td><td>ND</td><td>1.5</td></tr><tr><td colspan="2">BaP<sub>eq</sub></td><td>1.5</td><td>11.4</td><td>0.9</td><td>7.2</td></tr><tr><td colspan="2">Calculated lifetime cancer risk (&#215;10<sup>-6</sup>) based on 24-hr exposure<sup>a</sup></td><td>131</td><td>992</td><td>78</td><td>626</td></tr><tr><td colspan="2">Risk of unit-hour exposure (&#215;10<sup>-6</sup>)</td><td colspan="2">46.8</td><td colspan="2">29.3</td></tr><tr><td colspan="2">Average operation time (hour/day)</td><td colspan="2">2.5</td><td colspan="2">9.2</td></tr><tr><td colspan="2">Estimated lifetime cancer risk (&#215;10<sup>-6</sup>)</td><td colspan="2">117</td><td colspan="2">270</td></tr></table>
70028b8052a1218c02b22a8b0c973ea3d4c3530c95297c9b1056cc5e2be216cc.png
complex
<table><tr><td rowspan="2">Variable</td><td rowspan="2">Category</td><td colspan="2">Fresh samples <i>n</i> (%)</td><td rowspan="2">Paraffin-embedded samples <i>n</i> (%)</td></tr><tr><td>Non-metastatic</td><td>Metastatic</td></tr><tr><td>Age</td><td>&lt; 50 year</td><td>5 (50)</td><td>2 (20)</td><td>8 (15.4)</td></tr><tr><td></td><td>&#8805; 50 year</td><td>5 (50)</td><td>8 (80)</td><td>44 (84.6)</td></tr><tr><td>Gender</td><td>Male</td><td>7 (70)</td><td>10 (100)</td><td>31 (59.6)</td></tr><tr><td></td><td>Female</td><td>3 (30)</td><td>0</td><td>21 (40.4)</td></tr><tr><td>Smoking habit</td><td>No</td><td>4 (40)</td><td>2 (20)</td><td>23 (44.2)</td></tr><tr><td></td><td>Yes</td><td>6 (60)</td><td>8 (80)</td><td>29 (55.8)</td></tr><tr><td>Alcohol consumption</td><td>No</td><td>3 (30)</td><td>1 (10)</td><td>15 (28.8)</td></tr><tr><td></td><td>Yes</td><td>7 (70)</td><td>9 (90)</td><td>37 (71.2)</td></tr><tr><td>Clinical stage</td><td>T1 + T2</td><td>9 (90)</td><td>4 (40)</td><td>32 (61.5)</td></tr><tr><td></td><td>T3 + T4</td><td>1 (10)</td><td>6 (60)</td><td>20 (38.5)</td></tr><tr><td>Lymph nodes</td><td>N0</td><td>9 (90)</td><td>3 (30)</td><td>40 (76.9)</td></tr><tr><td></td><td>N+</td><td>1 (10)</td><td>7 (70)</td><td>12 (23.1)</td></tr><tr><td>Recurrence or metastasis</td><td>No</td><td>10 (100)</td><td>0</td><td>40 (76.9)</td></tr><tr><td></td><td>Yes</td><td>0</td><td>10 (100)</td><td>12 (23.1)</td></tr><tr><td>Status</td><td>Alive</td><td>10 (100)</td><td>6 (60)</td><td>45 (86.5)</td></tr><tr><td></td><td>Died</td><td>0</td><td>4 (40)</td><td>7 (13.5)</td></tr></table>
8f12784b9c22ae3cc69378364db89d0e085437656dfdc8725bbd46773579c163.png
complex
<table><tr><td>Enrichment Categories</td><td><i>p</i>-Value</td><td>FDR</td><td>Related Genes</td></tr><tr><td colspan="4">GO processes</td></tr><tr><td>Negative regulation of eicosanoid secretion</td><td>7.5 &#215; 10<sup>&#8722;9</sup></td><td>3.0 &#215; 10<sup>&#8722;6</sup></td><td>Hrh2, F2rl2</td></tr><tr><td>Glucocorticoid biosynthetic process</td><td>1.6 &#215; 10<sup>&#8722;8</sup></td><td>3.8 &#215; 10<sup>&#8722;6</sup></td><td>Cacna1h, Hsd3b1</td></tr><tr><td>Negative regulation of fatty acid transport</td><td>4.1 &#215; 10<sup>&#8722;8</sup></td><td>7.6 &#215; 10<sup>&#8722;6</sup></td><td>Hrh2, F2rl2</td></tr><tr><td>System process</td><td>4.5 &#215; 10<sup>&#8722;7</sup></td><td>4.5 &#215; 10<sup>&#8722;5</sup></td><td>Actc1, Lmod3, Cacng1, Des, Dcdc2, Tnni2, Hrh2, Myog, Cacna1h, Lmod2, F2rl2, Mb, Rasl10b, Olr1714</td></tr><tr><td>Response to hormone</td><td>1.1 &#215; 10<sup>&#8722;6</sup></td><td>8.5 &#215; 10<sup>&#8722;5</sup></td><td>Actc1, Lyn, Slco1b2 Dmbt1, Hsd3b1, Myog, Cacna1h, Hrh2, Myb, F2rl2</td></tr><tr><td>Cellular component morphogenesis</td><td>1.2 &#215; 10<sup>&#8722;6</sup></td><td>8.9 &#215; 10<sup>&#8722;5</sup></td><td>Actc1, Cacna1h, Hrh2, F2rl2, Lyn, Dcdc2, Lmod2, Lmod3, Ntn1</td></tr><tr><td>Regulation of neurotransmitter secretion</td><td>2.5 &#215; 10<sup>&#8722;6</sup></td><td>1.5 &#215; 10<sup>&#8722;4</sup></td><td>Cacna1h, Cacng1, Hrh2</td></tr><tr><td>Calcium ion transmembrane transport</td><td>3.6 &#215; 10<sup>&#8722;6</sup></td><td>2.0 &#215; 10<sup>&#8722;4</sup></td><td>Cacna1h, Cacng1, Hrh2</td></tr><tr><td>Positive regulation of gamma-aminobutyric acid secretion</td><td>3.9 &#215; 10<sup>&#8722;6</sup></td><td>2.1 &#215; 10<sup>&#8722;4</sup></td><td>Hrh2, F2rl2</td></tr><tr><td>Calcium ion transport</td><td>5.1 &#215; 10<sup>&#8722;6</sup></td><td>2.5 &#215; 10<sup>&#8722;4</sup></td><td>Cacna1h, Cacng1, F2rl2, Hrh2</td></tr><tr><td colspan="4">Diseases (in biomarkers)</td></tr><tr><td>Autistic disorder</td><td>1.5 &#215; 10<sup>&#8722;5</sup></td><td>8.9 &#215; 10<sup>&#8722;4</sup></td><td>Cacna1h, Hrh2, F2rl2</td></tr><tr><td>Child development disorders, pervasive</td><td>1.6 &#215; 10<sup>&#8722;5</sup></td><td>9.0 &#215; 10<sup>&#8722;4</sup></td><td>Cacna1h, Hrh2, F2rl2</td></tr><tr><td>Communication disorders</td><td>6.1 &#215; 10<sup>&#8722;5</sup></td><td>2.3 &#215; 10<sup>&#8722;3</sup></td><td>Dcdc2, Hrh2</td></tr><tr><td>Language disorders</td><td>6.1 &#215; 10<sup>&#8722;5</sup></td><td>2.3 &#215; 10<sup>&#8722;3</sup></td><td>Dcdc2, Hrh2</td></tr><tr><td>Mental disorders diagnosed in childhood</td><td>8.8 &#215; 10<sup>&#8722;5</sup></td><td>3.0 &#215; 10<sup>&#8722;3</sup></td><td>Cacna1h, Dcdc2, Hrh2</td></tr><tr><td>Tourette syndrome</td><td>1.3 &#215; 10<sup>&#8722;4</sup></td><td>4.1 &#215; 10<sup>&#8722;3</sup></td><td>Hrh2, F2rl2</td></tr><tr><td>Tic disorders</td><td>1.3 &#215; 10<sup>&#8722;4</sup></td><td>4.2 &#215; 10<sup>&#8722;3</sup></td><td>Hrh2, F2rl2</td></tr><tr><td>Epilepsy, absence</td><td>1.7 &#215; 10<sup>&#8722;4</sup></td><td>4.8 &#215; 10<sup>&#8722;3</sup></td><td>Cacna1h, Cacng1</td></tr><tr><td>Neurotoxicity syndromes</td><td>2.1 &#215; 10<sup>&#8722;4</sup></td><td>4.8 &#215; 10<sup>&#8722;3</sup></td><td>Hrh2, F2rl2</td></tr><tr><td>Pathological conditions, signs and symptoms</td><td>5.6 &#215; 10<sup>&#8722;4</sup></td><td>9.1 &#215; 10<sup>&#8722;3</sup></td><td>Des, Dcdc2, Ntn1, Cacng1, Cacna1h, Hsd3b1, Tnni2, F2rl2, Mb, Dmbt1, Actc1, Nags, Napb</td></tr></table>
8ec8d1ae12d8ceeab263a69c1bc2144b9c83572baff364830d19b430eda26ccb.png
simple
<table><tr><td>Organism</td><td>&lt;1 mo</td><td>1-11 mos</td><td>1-55 yrs</td><td>6-12 yrs</td><td>&gt; 12 yrs</td><td>Age Unk</td><td>Total</td><td>% of total</td></tr><tr><td>Streptococcus pneumoniae</td><td>2</td><td>31</td><td>27</td><td>17</td><td>87</td><td>42</td><td>187</td><td>37.18</td></tr><tr><td>Neisseria species</td><td>2</td><td>5</td><td>14</td><td>18</td><td>56</td><td>12</td><td>107</td><td>21.27</td></tr><tr><td>Haemophilus species</td><td>0</td><td>18</td><td>24</td><td>2</td><td>9</td><td>6</td><td>59</td><td>11.73</td></tr><tr><td>Staphylococcus</td><td>0</td><td>10</td><td>6</td><td>2</td><td>11</td><td>7</td><td>36</td><td>7.16</td></tr><tr><td>Others Gram negative</td><td>0</td><td>11</td><td>2</td><td>0</td><td>7</td><td>2</td><td>22</td><td>4.39</td></tr><tr><td>Escherichia coli</td><td>1</td><td>2</td><td>1</td><td>0</td><td>15</td><td>3</td><td>22</td><td>4.37</td></tr><tr><td>Streptococcus species</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>19</td><td>3.77</td></tr><tr><td>Other Gram positives</td><td>0</td><td>4</td><td>3</td><td>1</td><td>5</td><td>0</td><td>13</td><td>2.6</td></tr><tr><td>Enterococcus species</td><td>0</td><td>3</td><td>0</td><td>2</td><td>1</td><td>3</td><td>9</td><td>1.79</td></tr><tr><td>Acinetobacter species</td><td>0</td><td>4</td><td>0</td><td>2</td><td>2</td><td>0</td><td>8</td><td>1.59</td></tr><tr><td>ESBL&#8217;s Klebsiella pneumoniae</td><td>4</td><td>2</td><td>0</td><td>0</td><td>0</td><td>1</td><td>7</td><td>1.39</td></tr><tr><td>Klebsiella</td><td>0</td><td>1</td><td>1</td><td>0</td><td>4</td><td>1</td><td>7</td><td>1.39</td></tr><tr><td>Pseudomonas species</td><td>0</td><td>2</td><td>2</td><td>1</td><td>2</td><td>0</td><td>7</td><td>1.39</td></tr><tr><td>Total</td><td>9</td><td>93</td><td>80</td><td>45</td><td>199</td><td>77</td><td>503</td><td>100.02</td></tr></table>
189496a3df1dc1d3bad3493019dbc5e22914d86d18ff58ff4a8c16e6fdb41443.png
complex
<table><tr><td>Ecological</td><td></td><td colspan="3">Levels</td><td colspan="3">Change in change</td></tr><tr><td>Model</td><td>Dependent variable</td><td>PCNSDP</td><td>PCDE</td><td>HCR</td><td>PCNSDP</td><td>PCDE</td><td>HCR</td></tr><tr><td rowspan="2">1</td><td rowspan="2">Stunting prevalence</td><td>&#8722;1.92**</td><td>&#8211;</td><td>&#8211;</td><td>&#8722;0.87</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>(0.45)</td><td>&#8211;</td><td>&#8211;</td><td>(0.69)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td rowspan="2">2</td><td rowspan="2">Stunting prevalence</td><td>&#8211;</td><td>&#8722;5.41**</td><td>&#8211;</td><td>&#8211;</td><td>1.39</td><td>&#8211;</td></tr><tr><td>&#8211;</td><td>(0.89)</td><td>&#8211;</td><td>&#8211;</td><td>(1.47)</td><td>&#8211;</td></tr><tr><td rowspan="2">3</td><td rowspan="2">Stunting prevalence</td><td>&#8211;</td><td>&#8211;</td><td>0.55**</td><td>&#8211;</td><td>&#8211;</td><td>0.20</td></tr><tr><td>&#8211;</td><td>&#8211;</td><td>(0.08)</td><td>&#8211;</td><td>&#8211;</td><td>(0.14)</td></tr></table>
29504a3818a65fe6f63b2d618f25125a44d201a550282874f012180fc6cbed2a.png
simple
<table><tr><td>ID</td><td>Annotation</td><td>290 vs. 5532 fold change</td><td>290 vs. 5532 &#8211; <i>p</i>-value corrected FDR</td><td>Normalized expression means 290</td><td>Normalized expression means 5532</td></tr><tr><td>APOBEC3A</td><td>Probable DNA dC- &gt; dU-editing enzyme APOBEC-3A</td><td>1.80E+308</td><td>0.022</td><td>0.000</td><td>8.304</td></tr><tr><td>BLZF1</td><td>Golgin-45</td><td>1.80E+308</td><td>0.000</td><td>0.000</td><td>19.258</td></tr><tr><td>BTBD11</td><td>Ankyrin repeat and BTB/POZ domain-containing protein BTBD11</td><td>1.80E+308</td><td>0.000</td><td>0.000</td><td>17.621</td></tr><tr><td>CRLF2</td><td>Uncharacterized protein</td><td>1.80E+308</td><td>0.000</td><td>0.000</td><td>75.314</td></tr><tr><td>CSF1</td><td>Uncharacterized protein</td><td>1.80E+308</td><td>0.022</td><td>0.000</td><td>8.313</td></tr><tr><td>CXCL10</td><td>C-X-C motif chemokine 10</td><td>1.80E+308</td><td>0.000</td><td>0.000</td><td>134.604</td></tr><tr><td>CXCL11</td><td>C-X-C motif chemokine 11</td><td>1.80E+308</td><td>0.000</td><td>0.000</td><td>27.796</td></tr><tr><td>DDX58</td><td>DEAD (Asp-Glu-Ala-Asp) box polypeptide 58</td><td>1.80E+308</td><td>0.013</td><td>0.000</td><td>9.386</td></tr><tr><td>DDX60</td><td>Probable ATP-dependent RNA helicase DDX60</td><td>1.80E+308</td><td>0.000</td><td>0.000</td><td>17.559</td></tr><tr><td>DDX60L</td><td>Probable ATP-dependent RNA helicase DDX60-like</td><td>1.80E+308</td><td>0.048</td><td>0.000</td><td>6.609</td></tr><tr><td>EIF2AK2</td><td>Interferon-induced, double-stranded RNA-activated protein kinase</td><td>1.80E+308</td><td>0.006</td><td>0.000</td><td>11.043</td></tr><tr><td>EPSTI1</td><td></td><td>1.80E+308</td><td>0.013</td><td>0.000</td><td>9.460</td></tr><tr><td>GPNMB</td><td>Transmembrane glycoprotein NMB</td><td>1.80E+308</td><td>0.001</td><td>0.000</td><td>16.139</td></tr><tr><td>GYPA</td><td>Glycophorin-A</td><td>1.80E+308</td><td>0.000</td><td>0.000</td><td>33.703</td></tr><tr><td>HERC6</td><td>Probable E3 ubiquitin-protein ligase HERC6</td><td>1.80E+308</td><td>0.030</td><td>0.000</td><td>7.652</td></tr><tr><td>IDO1</td><td>Uncharacterized protein</td><td>1.80E+308</td><td>0.000</td><td>0.000</td><td>38.529</td></tr><tr><td>IFI35</td><td>Interferon-induced 35 kDa protein</td><td>1.80E+308</td><td>0.000</td><td>0.000</td><td>23.808</td></tr><tr><td>IFI44L</td><td>Interferon-induced protein 44-like</td><td>1.80E+308</td><td>0.009</td><td>0.000</td><td>10.133</td></tr><tr><td>IFIT1</td><td>Uncharacterized protein</td><td>1.80E+308</td><td>0.000</td><td>0.000</td><td>39.978</td></tr><tr><td>IFIT3</td><td>Interferon-induced protein with tetratricopeptide repeats 3</td><td>1.80E+308</td><td>0.006</td><td>0.000</td><td>11.063</td></tr><tr><td>IFIT5</td><td>Interferon-induced protein with tetratricopeptide repeats 5</td><td>1.80E+308</td><td>0.001</td><td>0.000</td><td>14.751</td></tr><tr><td>IFITM1</td><td>Interferon-induced transmembrane protein 1</td><td>1.80E+308</td><td>0.000</td><td>0.000</td><td>41.506</td></tr><tr><td>NT5C3</td><td>Cytosolic 5&#8242;-nucleotidase 3</td><td>1.80E+308</td><td>0.026</td><td>0.000</td><td>7.949</td></tr><tr><td>PARP9</td><td>Uncharacterized protein</td><td>1.80E+308</td><td>0.032</td><td>0.000</td><td>7.461</td></tr><tr><td>PLSCR1</td><td>Phospholipid scramblase 1</td><td>1.80E+308</td><td>0.002</td><td>0.000</td><td>13.466</td></tr><tr><td>RSAD2</td><td>Radical <i>S</i>-adenosyl methionine domain-containing protein 2</td><td>1.80E+308</td><td>0.003</td><td>0.000</td><td>12.711</td></tr><tr><td>SEPP1</td><td>Uncharacterized protein</td><td>1.80E+308</td><td>0.000</td><td>0.000</td><td>20.263</td></tr><tr><td>SLC39A8</td><td>Zinc transporter ZIP8</td><td>1.80E+308</td><td>0.033</td><td>0.000</td><td>7.413</td></tr><tr><td>SPARC</td><td>Uncharacterized protein</td><td>1.80E+308</td><td>0.013</td><td>0.000</td><td>9.466</td></tr><tr><td>XAF1</td><td>XIAP-associated factor 1</td><td>1.80E+308</td><td>0.003</td><td>0.000</td><td>12.311</td></tr><tr><td>SP110</td><td>Uncharacterized protein</td><td>6.58E+00</td><td>0.000</td><td>242.916</td><td>1598.704</td></tr><tr><td>SAMD9</td><td>Uncharacterized protein</td><td>&#8211;3.18E+00</td><td>0.010</td><td>27.623</td><td>8.683</td></tr><tr><td>ADAM19</td><td>Uncharacterized protein</td><td>&#8211;3.18E+00</td><td>0.008</td><td>29.217</td><td>9.184</td></tr><tr><td>DSG2</td><td>Desmoglein-2</td><td>&#8211;6.36E+00</td><td>0.000</td><td>33.496</td><td>5.264</td></tr><tr><td>SLCO5A1</td><td>Uncharacterized protein</td><td>&#8211;1.27E+01</td><td>0.000</td><td>47.197</td><td>3.709</td></tr><tr><td>PGAP1</td><td>GPI inositol-deacylase</td><td>&#8211;1.91E+01</td><td>0.000</td><td>51.117</td><td>2.678</td></tr><tr><td>SIGLEC1</td><td>Sialoadhesin</td><td>&#8211;5.09E+01</td><td>0.000</td><td>112.694</td><td>2.214</td></tr><tr><td>BRIP1</td><td>Fanconi anemia group J protein</td><td>&#8211;1.80E+308</td><td>0.000</td><td>23.188</td><td>0.000</td></tr><tr><td>SGPP2</td><td>Sphingosine-1-phosphate phosphatase 2</td><td>&#8211;1.80E+308</td><td>0.000</td><td>1262.355</td><td>0.000</td></tr></table>
6895bf511efaa15bd3b06048fb062f298ebf3bbacfcbfaf601c685e5ce76cd12.png
simple
<table><tr><td>TRT</td><td>Day 10-PC</td><td>Day 23-PC</td><td>Day 28-PC</td><td>Day 36-PC</td><td>Day 50-PC</td><td>Day 10-Stx 1</td><td>Day 10-Stx 2</td><td>Day 10-eae</td><td>Day 23-Stx 1</td><td>Day 23-Stx 2</td><td>Day 23-eae</td><td>Day 28-Stx 1</td><td>Day 28-Stx 2</td><td>Day 28-eae</td></tr><tr><td>Sb1/2e</td><td>4.22 ab</td><td>4.11 a</td><td>3.25 a</td><td>2.48 a</td><td>1.00 a</td><td>6.12 ab</td><td>5.67 a</td><td>7.10 abc</td><td>4.71 a</td><td>3.34 a</td><td>6.12 a</td><td>4.81 ab</td><td>2.86 ab</td><td>5.97 ab</td></tr><tr><td>sb1e</td><td>3.91 ab</td><td>4.07 a</td><td>3.22 a</td><td>2.00 ab</td><td>1.00 a</td><td>5.72 ab</td><td>4.72 ab</td><td>6.77 abc</td><td>4.21 a</td><td>2.57 a</td><td>6.00 a</td><td>7.11 a</td><td>3.90 ab</td><td>5.41 ab</td></tr><tr><td>sI1/2e</td><td>3.39 abc</td><td>3.74 a</td><td>1.00 a</td><td>1.00 b</td><td>1.00 a</td><td>6.73 a</td><td>5.57 a</td><td>7.87 a</td><td>5.73 a</td><td>3.88 a</td><td>6.51 a</td><td>4.95 ab</td><td>2.85 ab</td><td>5.88 ab</td></tr><tr><td>sI1e</td><td>3.88 ab</td><td>3.93 a</td><td>2.92 a</td><td>1.00 b</td><td>1.00 a</td><td>6.09 ab</td><td>4.19 abc</td><td>7.09 abc</td><td>5.43 a</td><td>3.73 a</td><td>6.66 a</td><td>5.65 ab</td><td>3.36 ab</td><td>6.81 a</td></tr><tr><td>so0e</td><td>4.99 a</td><td>3.48 a</td><td>4.16 a</td><td>2.84 a</td><td>3.53 a</td><td>6.34 a</td><td>4.75 ab</td><td>7.41 ab</td><td>5.07 a</td><td>3.17 a</td><td>4.37 a</td><td>4.42 ab</td><td>4.16 ab</td><td>5.29 ab</td></tr><tr><td>cb1/2e</td><td>3.65 ab</td><td>3.96 a</td><td>3.21 a</td><td>1.00 b</td><td>2.18 a</td><td>4.09 bc</td><td>1.00 e</td><td>3.59 bc</td><td>4.59 a</td><td>2.88 a</td><td>3.55 a</td><td>3.90 b</td><td>1.00 b</td><td>2.44 b</td></tr><tr><td>cb1e</td><td>3.67 ab</td><td>2.25 a</td><td>2.17 a</td><td>1.00 b</td><td>1.00 a</td><td>5.09 abc</td><td>3.10 cd</td><td>5.98 abc</td><td>4.48 a</td><td>3.57 a</td><td>4.47 a</td><td>4.45 ab</td><td>3.41 ab</td><td>2.44 b</td></tr><tr><td>cI1/2e</td><td>1.00 c</td><td>1.99 a</td><td>1.25 a</td><td>1.00 b</td><td>1.00 a</td><td>4.67 abc</td><td>2.45 d</td><td>4.30 abc</td><td>4.39 a</td><td>2.44 a</td><td>3.79 a</td><td>3.61 b</td><td>2.60 ab</td><td>3.19 b</td></tr><tr><td>cI1e</td><td>4.16 ab</td><td>4.44 a</td><td>0.58 a</td><td>1.00 b</td><td>1.00 a</td><td>5.34 abc</td><td>3.98 bc</td><td>6.65 abc</td><td>4.78 a</td><td>3.36 a</td><td>4.75 a</td><td>4.16 b</td><td>1.22 ab</td><td>5.02 ab</td></tr><tr><td>co0e</td><td>1.41 bc</td><td>3.85 a</td><td>3.01 a</td><td>2.59 a</td><td>3.10 a</td><td>3.27 c</td><td>2.44 d</td><td>3.08 c</td><td>5.32 a</td><td>2.57 a</td><td>6.24 a</td><td>4.10 b</td><td>5.86 a</td><td>3.50 ab</td></tr></table>
0a6220548389be97a95eb80f23b914ad461c510ab3599f984fdd3eabb2c656b0.png
complex
<table><tr><td>Follow-up periods</td><td colspan="6"><i>P </i>value for lab data</td></tr><tr><td></td><td>Hemoglobin</td><td>TLC</td><td>Platelets</td><td>Bilirubin</td><td>ALT</td><td>AST</td></tr><tr><td>Before therapy versus after 1 month</td><td>0.00</td><td>0.78</td><td>0.19</td><td>0.00</td><td>0.00</td><td>0.00</td></tr><tr><td>After 1 month versus after 3 months</td><td>0.285</td><td>0.06</td><td>0.25</td><td>0.00</td><td>0.00</td><td>0.00</td></tr><tr><td>After 3 months versus after 6 months</td><td>0.15</td><td>0.11</td><td>0.35</td><td>0.002</td><td>0.001</td><td>0.00</td></tr><tr><td>After 6 months versus after 1 year</td><td>0.97</td><td>0.16</td><td>0.303</td><td>0.00</td><td>0.013</td><td>0.00</td></tr></table>
0edfbf23bde84ecccb59387786cf2def27d7fa579bfb2a3f9cfbc0c6e1417b15.png
complex
<table><tr><td>Dependent Variable:</td><td colspan="3">Mal_Tot</td><td></td><td colspan="3">Mal_Tot</td><td></td></tr><tr><td>Type of Model</td><td>PRM</td><td></td><td>NBRM</td><td></td><td>PRM</td><td></td><td>NBRM</td><td></td></tr><tr><td>Nobs</td><td>47</td><td></td><td>47</td><td></td><td>47</td><td></td><td>47</td><td></td></tr><tr><td>DF</td><td>42</td><td></td><td>42</td><td></td><td>42</td><td></td><td>42</td><td></td></tr><tr><td>ENSO Measure</td><td colspan="3">ENSO_Avg</td><td></td><td colspan="3">ENSO_Dom</td><td></td></tr><tr><td>Model</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Deviance</td><td>114465.6</td><td></td><td>47.3</td><td></td><td>119277.8</td><td></td><td>47.4</td><td></td></tr><tr><td>Deviance/DF</td><td>2725.37</td><td></td><td>1.13</td><td></td><td>2839.95</td><td></td><td>1.13</td><td></td></tr><tr><td>Parameters</td><td>PRM</td><td>S</td><td>NBRM</td><td>S</td><td>PRM</td><td>S</td><td>NBRM</td><td>S</td></tr><tr><td>Intercept</td><td>9.6067</td><td>***</td><td>9.5399</td><td>***</td><td>9.5926</td><td>***</td><td>9.5293</td><td>***</td></tr><tr><td>Trend1</td><td>0.0650</td><td>***</td><td>0.0677</td><td>***</td><td>0.0657</td><td>***</td><td>0.0683</td><td>***</td></tr><tr><td>Trend2</td><td>-0.1545</td><td>***</td><td>-0.1640</td><td>***</td><td>-0.1541</td><td>***</td><td>-0.1625</td><td>***</td></tr><tr><td>Vextre</td><td>-0.7768</td><td>***</td><td>-0.7941</td><td>***</td><td>-0.8539</td><td>***</td><td>-0.8901</td><td>***</td></tr><tr><td>ENSO Measure</td><td>0.1512</td><td>***</td><td>0.1626</td><td>**</td><td>0.0937</td><td>**</td><td>0.0893</td><td>**</td></tr><tr><td>Dispersion&#9827;</td><td></td><td></td><td>0.0386</td><td></td><td></td><td></td><td>0.0414</td><td></td></tr><tr><td>Tests</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>W:BLT vs (BLT + ENSO ]</td><td>29602.6</td><td>***</td><td>9.2</td><td>***</td><td>24790.4</td><td>***</td><td>5.9</td><td>**</td></tr></table>
d454a00ec371a502223a6f83ca7d9ddb25c2605ef83ee84236aff0b92ab23d5f.png
simple
<table><tr><td>Species</td><td>GenBank Accession</td><td>Reference</td></tr><tr><td><i>Bathymodiolus azoricus</i></td><td>AF334663</td><td>[70]</td></tr><tr><td><i>B. thermophilus</i></td><td>AF334664</td><td>[70]</td></tr><tr><td><i>Crassostrea virginica 1</i></td><td>AB206328</td><td>[58]</td></tr><tr><td><i>Crassostrea virginica 2</i></td><td>AB252064</td><td>[57]</td></tr><tr><td><i>Crassostrea virginica 3</i></td><td>AB427186</td><td>This paper</td></tr><tr><td><i>Calyptogena sp. SB2001_1</i></td><td>AF334666</td><td>[70]</td></tr><tr><td><i>Calyptogena sp. SB2001_2</i></td><td>AF334667</td><td>[70]</td></tr><tr><td><i>Crassostrea gigas 1</i></td><td>AB179775</td><td>[96]</td></tr><tr><td><i>Crassostrea gigas 2</i></td><td>AB288344</td><td>[97]</td></tr><tr><td><i>Crassostrea gigas 3</i></td><td>AB307634</td><td>[65]</td></tr><tr><td><i>Crassostrea gigas 4</i></td><td>CU994883</td><td>Favrel, direct submission</td></tr><tr><td><i>Chlamys islandica</i></td><td>AJ250028</td><td>[52]</td></tr><tr><td><i>Eisenia andrei</i></td><td>DQ339138</td><td>Joskova et al. direct submission</td></tr><tr><td><i>Hirudo medicinalis</i></td><td>U24122</td><td>[98]</td></tr><tr><td><i>Mytilus edulis 1</i></td><td>AF334662</td><td>[70]</td></tr><tr><td><i>Mytilus edulis 2</i></td><td>DQ268868</td><td>Caponera and Rawson direct submission</td></tr><tr><td><i>Mytilus galloprovincialis 1</i></td><td>AF334665</td><td>[70]</td></tr><tr><td><i>Mytilus galloprovincialis 2</i></td><td>AB298451</td><td>Itoh et al. direct submission</td></tr><tr><td><i>Ostrea edulis</i></td><td>AB179776</td><td>[96]</td></tr><tr><td><i>Tapes japonica</i></td><td>AB091383</td><td>[64]</td></tr></table>
a892d16baf692a95eba4e046c263ee6a84fbd5dbb69d6388b40b91954886aa2e.png
simple
<table><tr><td>Day of follow up</td><td>0</td><td>1</td><td>2</td><td>3</td><td>7</td><td>14</td><td>21</td><td>28</td></tr><tr><td>Patients assessed at visit</td><td>176</td><td>173</td><td>172</td><td>172</td><td>172</td><td>171</td><td>171</td><td>171</td></tr><tr><td>Loss to follow up</td><td>0</td><td>3</td><td>1</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td></tr></table>
1278d9fe0cb1d629f8ac82be638c2e00b12461d9925144815fdf73025a76309e.png
simple
<table><tr><td>Term</td><td>MAPP Network Research Definition</td></tr><tr><td>Urologic chronic pelvic pain syndrome (UCPPS)</td><td>General term to describe idiopathic chronic pelvic pain of urologic origin in men or women. In MAPP Network studies, this includes men and women with IC/BPS, or men with CP/CPPS (see below).</td></tr><tr><td>Interstitial cystitis/bladder pain syndrome (IC/BPS)</td><td>Chronic unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms, in the absence of infection or other identifiable causes.</td></tr><tr><td>Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)</td><td>Chronic idiopathic pelvic pain or discomfort in males, commonly in the perineum, suprapubic region, penis, or testicles, which is often exacerbated by ejaculation or urination.</td></tr><tr><td>Non-Urologic Associated Syndromes (NUAS)</td><td>General term used to describe symptom-based non-urologic syndromes which co-occur with UCPPS at a rate greater than observed in the general population. Within the MAPP Network, initial efforts have focused on studying specific NUAS (fibromyalgia, irritable bowel syndrome, chronic fatigue syndrome), though other examples exist (e.g. vulvodynia, temperomandibular joint disorder, and migraine headaches, among others).</td></tr></table>
d15fd30871e1d1f18d22324108a3a94a5e200884571af741c6c7d2b6d49ab25f.png
simple
<table><tr><td>Name of classifier</td><td>MNC</td><td>DNC</td><td>TNC</td><td>IPknot<sup>*</sup></td><td>IPknot<sup>#</sup></td></tr><tr><td>BayesNet</td><td>0.073</td><td>0.084</td><td>0.284</td><td>-</td><td>0.397</td></tr><tr><td>NaiveBayes</td><td>0.057</td><td>0.074</td><td>0.058</td><td>0.315</td><td>0.398</td></tr><tr><td>MultilayerPerceptron</td><td>0.060</td><td>0.075</td><td>0.128</td><td>0.314</td><td>0.429</td></tr><tr><td>IBk</td><td>0.057</td><td>0.074</td><td>0.089</td><td>0.314</td><td>0.407</td></tr><tr><td>libSVM</td><td>0.060</td><td>0.079</td><td>0.108</td><td>0.214</td><td>0.056</td></tr><tr><td>SMO</td><td>0.073</td><td>0.081</td><td>0.102</td><td>0.283</td><td>0.422</td></tr><tr><td>RandomForest</td><td>0.055</td><td>0.079</td><td>0.121</td><td>0.400</td><td>0.433</td></tr></table>
67a994879262a82e5614941ed5b969dc23d19ea0b3a3f0ece405aa876a98dc60.png
complex
<table><tr><td>Dose</td><td>Direction</td><td>Striatum</td><td>Hippocampus</td><td>Cortex</td></tr><tr><td rowspan="2">10 mg/kg</td><td>Up in YAC128, Down with pridopidine</td><td>3.58E-04</td><td>3.78E-04</td><td>2.40E-04</td></tr><tr><td>Down in YAC128, Up with pridopidine</td><td>3.64E-04</td><td>4.99E-02</td><td>2.40E-04</td></tr><tr><td rowspan="2">30 mg/kg</td><td>Up in YAC128, Down with pridopidine</td><td>3.15E-04</td><td>3.46E-04</td><td>2.35E-04</td></tr><tr><td>Down in YAC128, Up with pridopidine</td><td>3.37E-04</td><td>3.53E-03</td><td>2.35E-04</td></tr></table>
05fe72691cce660a0885c0061bb7b84e8e83057ee19bacc836daad2835dd3096.png
complex
<table><tr><td rowspan="2">Saccade Behavior</td><td rowspan="2">Leading Vehicle</td><td colspan="5">Speed (km/h)</td></tr><tr><td>60</td><td>70</td><td>80</td><td>90</td><td>100</td></tr><tr><td rowspan="2">Mean saccade duration (ms)</td><td>Truck</td><td>46.21</td><td>55.92</td><td>58.55</td><td>65.89</td><td>102.51</td></tr><tr><td>Car</td><td>45.24</td><td>45.99</td><td>51.07</td><td>59.22</td><td>97.69</td></tr><tr><td rowspan="2">Saccade frequency (Hz)</td><td>Truck</td><td>1.02</td><td>1.04</td><td>1.09</td><td>1.18</td><td>1.04</td></tr><tr><td>Car</td><td>1.15</td><td>1.27</td><td>1.22</td><td>1.17</td><td>1.24</td></tr><tr><td rowspan="2">Mean saccade angle (&#176;)</td><td>Truck</td><td>9.14</td><td>13.64</td><td>14.77</td><td>21.24</td><td>39.63</td></tr><tr><td>Car</td><td>6.36</td><td>8.69</td><td>13.61</td><td>17.28</td><td>33.61</td></tr></table>
4150ab36a9ee6c162aaa94097be7d715ac816367d064e26f4b165385e5a1cd50.png
simple
<table><tr><td>Number</td><td>Age (years)</td><td>Sex</td><td>Primary hematological disorder</td><td>Organs involved by tuberculosis</td><td>Diagnosis of tuberculosis</td><td>Treatment/Outcome of tuberculosis</td></tr><tr><td>1</td><td>55</td><td>Male</td><td>Chronic myeloid leukemia</td><td>Intestine, mesentry and abdominal lymph nodes</td><td>Positive lymph node histology and cultures</td><td>Given/Successful</td></tr><tr><td>2</td><td>40</td><td>Male</td><td>Acute myeloid leukemia</td><td>Lungs</td><td>Positive sputum cultures</td><td>Given/Successful</td></tr><tr><td>3</td><td>19</td><td>Female</td><td>Acute myeloid leukemia</td><td>Lungs</td><td>Positive sputum cultures</td><td>Given/Successful</td></tr><tr><td>4</td><td>20</td><td>Female</td><td>Hodgkin's lymphoma</td><td>Lungs, liver and abdominal lymph nodes</td><td>Positive sputum cultures</td><td>Given/Successful</td></tr><tr><td>5</td><td>33</td><td>Female</td><td>Thrombocytopenic purpura</td><td>Cervical lymph nodes</td><td>Positive lymph node cultures</td><td>Given/Successful</td></tr><tr><td>6</td><td>70</td><td>Male</td><td>Hairy cell leukemia</td><td>Lungs, liver, spleen, cerebrospinal fluid and bone marrow</td><td>Positive cultures(4 sites) and bone marrow histology</td><td>Given/Unsuccessful *Multi-drug resistance</td></tr><tr><td>7</td><td>32</td><td>Male</td><td>Multiple Myeloma</td><td>Lungs</td><td>Positive sputum cultures</td><td>Given/Successful</td></tr><tr><td>8</td><td>36</td><td>Female</td><td>Essential thrombocythemia</td><td>Lungs</td><td>Positive sputum cultures</td><td>Given/Successful</td></tr><tr><td>9</td><td>24</td><td>Male</td><td>Acute myeloid leukemia</td><td>Lungs, bone marrow and liver.</td><td>Positive bronchial lavage</td><td>Not given/Death</td></tr><tr><td>10</td><td>45</td><td>Male</td><td>Severe aplastic anemia</td><td>Lungs</td><td>Positive sputum cultures</td><td>Not given/Lost follow up</td></tr><tr><td>11</td><td>70</td><td>Male</td><td>Myelodysplastic syndrome</td><td>Lungs and cervical lymph nodes</td><td>Empirical/positive lymph node histology</td><td>Given/Successful</td></tr><tr><td>12</td><td>62</td><td>Male</td><td>Polycythemia rubra vera</td><td>Cervical lymph nodes</td><td>Empirical/positive lymph node histology</td><td>Given/Successful</td></tr><tr><td>13</td><td>38</td><td>Male</td><td>Acute myeloid leukemia</td><td>Lungs, bone marrow, psoas muscle and vertebrae.</td><td>Empirical/positive muscle and bone marrow histology</td><td>Given/Successful</td></tr><tr><td>14</td><td>52</td><td>Female</td><td>Chronic myeloid leukemia</td><td>Lungs</td><td>Empirical/positive serology</td><td>Given/Successful</td></tr><tr><td>15</td><td>59</td><td>Male</td><td>Myelodysplastic syndrome</td><td>Lungs</td><td>Empirical/positive serology</td><td>Given/Successful</td></tr><tr><td>16</td><td>75</td><td>Male</td><td>Myelodysplastic syndrome</td><td>Cervical spine</td><td>Empirical</td><td>Given/Successful</td></tr><tr><td>17</td><td>60</td><td>Female</td><td>Myelofibrosis</td><td>Lungs</td><td>Empirical</td><td>Given/Successful</td></tr><tr><td>18</td><td>65</td><td>Male</td><td>Chronic myeloid leukemia</td><td>Lungs</td><td>Empirical</td><td>Given/Successful</td></tr></table>
cbc0817ae331f048dd498a897dc9e7bd457adcca841473e5b0e3c8feb9e2ead6.png
complex
<table><tr><td rowspan="2">Clinical parameter</td><td colspan="2">AFAP1&#8208;AS1</td><td rowspan="2">Chi&#8208;squared test P value</td></tr><tr><td>High no. cases</td><td>Low no. cases</td></tr><tr><td>Age (years)</td><td></td><td></td><td>0.449</td></tr><tr><td>&#8804;64</td><td>25</td><td>12</td><td></td></tr><tr><td>&gt;64</td><td>25</td><td>8</td><td></td></tr><tr><td>Gender</td><td></td><td></td><td>0.451</td></tr><tr><td>Male</td><td>37</td><td>13</td><td></td></tr><tr><td>Female</td><td>13</td><td>7</td><td></td></tr><tr><td>Smoking state</td><td></td><td></td><td>0.880</td></tr><tr><td>Yes</td><td>24</td><td>10</td><td></td></tr><tr><td>No</td><td>26</td><td>10</td><td></td></tr><tr><td>Drinking state</td><td></td><td></td><td>0.508</td></tr><tr><td>Yes</td><td>41</td><td>15</td><td></td></tr><tr><td>No</td><td>9</td><td>5</td><td></td></tr><tr><td>Tumor size</td><td></td><td></td><td>0.040</td></tr><tr><td>&#8804;3 cm</td><td>14</td><td>12</td><td></td></tr><tr><td>3&#8211;5 cm</td><td>29</td><td>7</td><td></td></tr><tr><td>&gt;5 cm</td><td>7</td><td>1</td><td></td></tr><tr><td>Tumor stage</td><td></td><td></td><td>&lt;0.01</td></tr><tr><td>I</td><td>2</td><td>11</td><td></td></tr><tr><td>II</td><td>27</td><td>4</td><td></td></tr><tr><td>III</td><td>21</td><td>5</td><td></td></tr></table>
4b8969e51043de2c7994f7a52f69ba7f17259dd02d0b849e146f805289952cec.png
simple
<table><tr><td>Imprecision</td><td>Event</td><td>Original Text</td><td>English Translation</td></tr><tr><td></td><td>Basel, Jul. 1480</td><td>&#8220;Anno 1480 circa Magdalenae ingens fuit aquarum inundatio. Rhenus in tantum crevit, quod ad lateres usque inferioris muri Minoris Basileae circa litus ascendit. Etiam homines in ponte stantes facile in Reno manus lavare poterunt.&#8221; [<i>Bernoulli</i>, 1915, p. 210]</td><td>In 1480, around Magdalena('s day) there was a huge flood of waters. The Rhine rose to the sides of the lower walls of Lesser Basel, near the shore. People standing on the bridge could wash their hands in the Rhine.</td></tr><tr><td>small</td><td>Meiningen, Jan. 1820</td><td>&#8220;Nachdem (18. Jan.) mehrere Tage strenge Ka&#776;lte gewesen war, trat Thauwetter ein und am 20. Jan. war in Folge desselben die Werra aus den Ufern getreten da&#223;das Wasser die Chaussee am obern Rafen u&#776;berstieg.&#8221; (Chronik)</td><td>After that for some days strong coldness occurred, and then melting, and as a consequence on 20 January the Werra left its bed and the water exceeded the promenade on the upper stage.</td></tr><tr><td></td><td>Szeged, Jul. 1816</td><td>&#8220;Ala&#769;bb in a Te(kinte)tes N(eme)s Tana&#769;csnak Kegyes rendele&#769;se&#769;hez ke&#769;ppest ala&#769;zatossan jelentem hogy a Tisza vize, a Maros vi&#769;ze&#769;nek szo&#776;rnyu&#776; e&#769;s az idein legnagyobb mostani kio&#776;nte&#769;se mia&#769;ll szu&#776;ntelen a&#769;rad u&#769;gy hogy a mu&#769;lt Julius 8ik napja&#769;tu&#769;l fogva 2 Hu&#776;velknyire Fo&#776;lmagossodott melly szere&#769;nt a Tisza&#769;nak az idei legnagyobb arada&#769;sa&#769;tu&#769;l fogva esett apada&#769;sa 20 Hu&#776;velknyit te&#769;szen. Szeged 12ik Julii 816. Vedres Istva&#769;n&#8221;</td><td>Letter to the Locumtenential Council: Below, following the order of the esteemed noble council, I report that the water of the Tisza, due to the horrible and in this greatest present inundation of the waters of the Maros, is constantly increasing, and so from the (past) 8 July it increased with 2 inches and thus, the total decrease of the water level of the Tisza compared to the highest levels takes 20 inches. Szeged, 12 July 1816. Istvan Vedres</td></tr><tr><td></td><td>Basel, Jul. 1570</td><td>&#8220;Umb dise zeit ist auch der Rhein so gro&#223;worden/da&#223;er innerhalb der Statt von dreyen Rhein&#8208;Thoren under der Bruck zusamen geflossen/und die Brucken einem Holz&#8208;flo&#223;auff dem Wasser gleich gesehen.&#8221; [<i>Gro&#223;</i>, 1624, p. 210]</td><td>Around this time the Rhine was also so large that it flowed together under the bridge through the three Rhine&#8208;gates in the downtown, and the bridge looked like a wooden raft on the river.</td></tr><tr><td>medium</td><td>Meiningen, Jun. 1816</td><td>&#8220;Dreimal trat die Werra aus den Ufern; der ganze Grund stand gegen 14 Tage auf dem Halme aus und die wenige Frucht, die man a&#776;rndtete und feucht einfuhr, gab schlechtes Brod.&#8221; (Chronik, p. 197)</td><td>The Werra left its banks three times; water was on the whole ground covering the stalks and the little grain people harvested, gave bad bread.</td></tr><tr><td></td><td>Szeged, 1741</td><td>&#8220;... preter quod enim quod eadem exundatio agris seminaturas Prata et Pendentes in Vinejs agris fructus in Locis praeterea Marusio et Tibisco Vicinis totaliter perfuderit, et in nihilum redegerit etiam in forejs quod Miser Incola n(on) sui sustentatione conservabat inundavit et Usui humani redidit inutile&#8221; (CsCP)</td><td>..., and beyond that the same inundation completely flooded the arable lands (with crops), pastures, vineyards and orchards along the Maros and Tisza rivers, and gave nothing to people, and became useless for human use.</td></tr><tr><td></td><td>Basel, 1268</td><td>&#8220;Renus crevit usque adeo, quod omnes pontes destruxit.&#8221; (Ann., p. 193)</td><td>The Rhine rose so much that it destroyed all bridges.</td></tr><tr><td>large</td><td>Meiningen, May 1818</td><td>&#8220;Nach anhaltenden Regenwetter trat die Werra aus den Ufern. Am 18. Mai war die Ueberschwemmung am bedeutendsten.&#8221; (Chronik, p.205)</td><td>After persistent rainy weather the Werra left its banks. The flooding was the most significant on 18 May.</td></tr><tr><td></td><td>Szeged, 1731</td><td>3o. &#8220;Ioanni Hegedu&#776;s, ex quo exundatio aquarum modernam Domum residentionalem destruxisset,...&#8221; (SzCP)</td><td>The house of Janos Hegedu&#776;s has been destroyed by the recent flood,...</td></tr></table>
e493d8310bae2ba34b41a962353eda659ea9f2f09c517877926f862a1663c466.png
simple
<table><tr><td> </td><td>n</td><td>Minimum</td><td>Maximum</td><td>Mean</td><td>Std Deviation</td></tr><tr><td>Age (months)</td><td>20</td><td>6.00</td><td>59.00</td><td>39.3500</td><td>18.65</td></tr><tr><td>Weight (Kg)</td><td>20</td><td>6.7</td><td>23.4</td><td>14.9</td><td>4.5</td></tr><tr><td>Temp(<sup>0</sup>C)</td><td>20</td><td>35.3</td><td>39.7</td><td>37.8</td><td>1.4</td></tr><tr><td>Par./200 wbc</td><td>20</td><td>56</td><td>3577</td><td>985</td><td>986</td></tr><tr><td>Parasites/&#956;l</td><td>20</td><td>2240</td><td>143,080</td><td>39,400</td><td>39450</td></tr><tr><td>Hb (g/dl)</td><td>20</td><td>6.3</td><td>12.9</td><td>9.1</td><td>1.7</td></tr></table>
28df553108167c620a05136d33f34ed9a89099cbc93755bf333ea5ff9ab2c001.png
complex
<table><tr><td></td><td></td><td colspan="3">Low prescribers (<i>n</i> = 408)</td><td colspan="3">High prescribers (<i>n</i> = 408)</td></tr><tr><td></td><td></td><td>Number</td><td>Percent</td><td>[95% confidence interval]</td><td>Number</td><td>Percent</td><td>[95% confidence interval]</td></tr><tr><td rowspan="2">Gender</td><td>Female</td><td>116</td><td>28.4</td><td>[24.2&#8211;33.1]</td><td>118</td><td>28.9</td><td>[24.6&#8211;33.6]</td></tr><tr><td>Male</td><td>292</td><td>71.6</td><td>[66.9&#8211;75.8]</td><td>290</td><td>71.1</td><td>[66.4&#8211;75.4]</td></tr><tr><td rowspan="2">Practice location</td><td>Rural</td><td>110</td><td>27.0</td><td>[22.8&#8211;31.6]</td><td>80</td><td>19.6</td><td>[15.9&#8211;23.9]</td></tr><tr><td>Urban</td><td>298</td><td>73.0</td><td>[68.4&#8211;77.2]</td><td>328</td><td>80.4</td><td>[76.1&#8211;84.0]</td></tr><tr><td rowspan="2">GP partially particular mode of practice</td><td>Yes</td><td>40</td><td>9.8</td><td>[7.2&#8211;13.2]</td><td>13</td><td>3.2</td><td>[1.8&#8211;5.5]</td></tr><tr><td>No</td><td>368</td><td>90.2</td><td>[86.9&#8211;92.9]</td><td>395</td><td>96.8</td><td>[94.5&#8211;98.2]</td></tr><tr><td rowspan="2">Cessation of activity during the year 2010</td><td>Yes</td><td>7</td><td>1.7</td><td>[0.8&#8211;3.7]</td><td>7</td><td>1.7</td><td>[0.8&#8211;3.7]</td></tr><tr><td>No</td><td>401</td><td>98.3</td><td>[96.3&#8211;99.2]</td><td>401</td><td>98.3</td><td>[96.3&#8211;99.2]</td></tr><tr><td></td><td></td><td><i>Mean</i></td><td></td><td><i>[Standard deviation]</i></td><td><i>Mean</i></td><td></td><td><i>[Standard deviation]</i></td></tr><tr><td>Age of GPs</td><td></td><td>52.6</td><td></td><td>[9.39]</td><td>52.8</td><td></td><td>[8.10]</td></tr><tr><td>Cumulative years of medical practice</td><td></td><td>19.83</td><td></td><td>[10.71]</td><td>20.5</td><td></td><td>[9.7146]</td></tr><tr><td>Number of consultations and home visits</td><td></td><td>3,982</td><td></td><td>[1,994]</td><td>3,863</td><td></td><td>[1,758]</td></tr><tr><td>Number of different patients per year</td><td></td><td>1,106</td><td></td><td>[538]</td><td>1,012</td><td></td><td>[396]</td></tr><tr><td>Number of registered patients</td><td></td><td>701</td><td></td><td>[406]</td><td>732</td><td></td><td>[346]</td></tr><tr><td>Mean age of patients</td><td></td><td>46.3</td><td></td><td>[6.02]</td><td>45</td><td></td><td>[6.1]</td></tr><tr><td>Number of patients with low income</td><td></td><td>60</td><td></td><td>[79]</td><td>45</td><td></td><td>[48]</td></tr><tr><td>Number of patients with chronic disease</td><td></td><td>145</td><td></td><td>[91]</td><td>144</td><td></td><td>[80]</td></tr><tr><td>Number of days of Sickness certificates prescribed</td><td></td><td>3,608</td><td></td><td>[2,537]</td><td>3,571</td><td></td><td>[2,225]</td></tr><tr><td>Number of patients prescribed a sickness certificate</td><td></td><td>100 [64]</td><td></td><td></td><td>94</td><td></td><td>[50]</td></tr><tr><td>Total volume of reimbursement (number of units)</td><td></td><td>28,247</td><td></td><td>[17,316]</td><td>26,565</td><td></td><td>[14,477]</td></tr><tr><td>Number of prescriptions orders</td><td></td><td>3,847 [2,122]</td><td></td><td></td><td>3,808</td><td></td><td>[1,859]</td></tr><tr><td>% &#8805; 70 new AD</td><td></td><td>0.86</td><td></td><td>[0.34]</td><td>0.95</td><td></td><td>[0.20]</td></tr><tr><td>Number of DDD</td><td></td><td>9,163</td><td></td><td>[6298]</td><td>14,848</td><td></td><td>[8,200]</td></tr><tr><td>AD prescription ratio</td><td></td><td>0.30</td><td></td><td>[0.09]</td><td>0.60</td><td></td><td>[0.27]</td></tr></table>
e47a8901ee0b2f91bbb34033f9603e660bbc4369b0467a3314f0860c6b5e8742.png
complex
<table><tr><td>Prognostic factor</td><td>N</td><td>Dead over 5 years (%)</td><td>Hazard ratio (95 % CI)</td><td>p</td></tr><tr><td><i>Model-1</i></td><td></td><td></td><td></td><td></td></tr><tr><td>CD8 response to Her-2</td><td></td><td></td><td>0.198 (0.05&#8211;1.17)</td><td><i>0.018</i></td></tr><tr><td> Yes</td><td>37</td><td>11</td><td></td><td></td></tr><tr><td> No</td><td>33</td><td>24</td><td></td><td></td></tr><tr><td>Metastasis</td><td></td><td></td><td>3.647 (0.89&#8211;14.88)</td><td>0.071</td></tr><tr><td> No</td><td>32</td><td>15</td><td></td><td></td></tr><tr><td> Yes</td><td>42</td><td>57</td><td></td><td></td></tr><tr><td>pDCs</td><td></td><td></td><td>0.292 (0.07&#8211;1.17)</td><td>0.083</td></tr><tr><td> &#8804;Median</td><td>36</td><td>25</td><td></td><td></td></tr><tr><td> &gt;Median</td><td>34</td><td>9</td><td></td><td></td></tr><tr><td>Radiotherapy</td><td></td><td></td><td>0.107 (0.027&#8211;0.41)</td><td><i>0.001</i></td></tr><tr><td> Yes</td><td>57</td><td>11</td><td></td><td></td></tr><tr><td> No</td><td>18</td><td>44</td><td></td><td></td></tr><tr><td>Chemotherapy</td><td></td><td></td><td>&lt;0.001 (&lt;0.001&#8211;1.67e+130)</td><td>0.941</td></tr><tr><td> Yes</td><td>30</td><td>3</td><td></td><td></td></tr><tr><td> No</td><td>42</td><td>31</td><td></td><td></td></tr><tr><td colspan="5"><i>Model-2</i></td></tr><tr><td>CD8 response to Her-2</td><td></td><td></td><td>0.145 (0.02&#8211;0.81)</td><td><i>0.029</i></td></tr><tr><td> Yes</td><td>34</td><td>12</td><td></td><td></td></tr><tr><td> No</td><td>28</td><td>21</td><td></td><td></td></tr><tr><td>pDCs</td><td></td><td></td><td>0.093 (0.011&#8211;0.809)</td><td><i>0.031</i></td></tr><tr><td> &#8804;Median</td><td>31</td><td>23</td><td></td><td></td></tr><tr><td> &gt;Median</td><td>31</td><td>3</td><td></td><td></td></tr><tr><td>Radiotherapy</td><td></td><td></td><td>0.091 (0.017&#8211;0.492)</td><td><i>0.005</i></td></tr><tr><td> Yes</td><td>53</td><td>9</td><td></td><td></td></tr><tr><td> No</td><td>13</td><td>38</td><td></td><td></td></tr><tr><td>Chemotherapy</td><td></td><td></td><td>&lt;0.001 (&lt;0.001&#8211;1.9e+157)</td><td>0.949</td></tr><tr><td> Yes</td><td>30</td><td>3</td><td></td><td></td></tr><tr><td> No</td><td>34</td><td>26</td><td></td><td></td></tr></table>
353f75b933e1c364205dac255341a6bb4cba94968a7cd49c2625ef2e9db0a2ab.png
simple
<table><tr><td> </td><td>Total group (n = 1,304)</td><td>No sexual violence (n = 806)</td><td>Rape (n = 183)</td><td>Non-consensual sex (n = 315)</td><td><i>F/&#967;</i><sup><i>2</i></sup></td></tr><tr><td>Age<sup>&#8224;</sup></td><td>15.89 (1.54)</td><td>15.73 (1.49)</td><td>16.34 (1.51)</td><td>16.04 (1.63)</td><td>13.90*</td></tr><tr><td>Socio-economic status</td><td> </td><td> </td><td> </td><td> </td><td>21.076*</td></tr><tr><td>Bric house</td><td>600 (46.4%)</td><td>404 (50.5%)</td><td>86 (47.5%)</td><td>110 (35.3%)</td><td> </td></tr><tr><td>Non bric house</td><td>693 (53.6%)</td><td>396 (49.5%)</td><td>95 (52.5%)</td><td>202 (64.7%)</td><td> </td></tr><tr><td>Parental availability</td><td> </td><td> </td><td> </td><td> </td><td>22,10*</td></tr><tr><td>Both parents alive</td><td>991 (74.9%)</td><td>622 (78.2%)</td><td>112 (61.5%)</td><td>232 (75.1%)</td><td> </td></tr><tr><td>One or both parents deceased</td><td>333 (25.2%)</td><td>173 (21.8%)</td><td>70 (38.5%)</td><td>77 (24.9%)</td><td> </td></tr></table>
968640c4ba6c3fb64e266b1f1d42ad3713fadb52855046474422f7177820b7ed.png
complex
<table><tr><td>Item</td><td></td><td>N</td><td colspan="2">Time 1 (Pre)</td><td colspan="2">Time 3 (6 Month)</td><td colspan="2">Mean change*</td><td>P value*</td></tr><tr><td></td><td></td><td></td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>Mean</td><td>95% CI</td><td></td></tr><tr><td>1</td><td>I am confident that I have the interview skills to use my time well with suicidal clients.</td><td>59</td><td>51.69</td><td>21.60</td><td>68.83</td><td>16.33</td><td>17.14</td><td>12.88 &#8211; 21.39</td><td>0.000</td></tr><tr><td>2</td><td>After seeing a client once I would be confident that I could recognise potential suicide risk.</td><td>59</td><td>37.44</td><td>21.33</td><td>58.05</td><td>20.07</td><td>20.61</td><td>14.96 &#8211; 26.26</td><td>0.000</td></tr><tr><td>3</td><td>I feel confident that I could differentiate a mild depression from a suicide risk.</td><td>59</td><td>49.95</td><td>23.14</td><td>68.37</td><td>16.20</td><td>18.42</td><td>13.29 &#8211; 23.56</td><td>0.000</td></tr><tr><td>4</td><td>I am confident in dealing with the needs of suicidal clients.</td><td>59</td><td>42.75</td><td>21.95</td><td>65.98</td><td>17.16</td><td>23.24</td><td>18.53 &#8211; 27.95</td><td>0.000</td></tr><tr><td></td><td>Total</td><td>59</td><td>181.83</td><td>74.59</td><td>261.24</td><td>61.20</td><td>79.41</td><td>63.55 &#8211; 95.26</td><td>0.000</td></tr></table>
913f1f27b10e7a4453fbfa2f221d363f385cf0ed7ca023864eb2fa1923938222.png
complex
<table><tr><td>Author, year</td><td>Study population (period)</td><td>Definition of HDP-related SAMM</td><td>Case fatality rate (Number of deaths/cases)</td><td colspan="2">Mortality reduction<sup>a</sup></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Natural case fatality</td></tr><tr><td></td><td></td><td></td><td></td><td>25%</td><td>42%</td></tr><tr><td>Mantel et al, 1998[73]</td><td>Kalafong and Pretoria hospitals, South Africa (1996-1998)</td><td>Hypertension with organ failure</td><td>20.8% (10/48)</td><td>16.7%</td><td>50.4%</td></tr><tr><td>Khosla et al 2000[74]</td><td>One hospital, Rohtak, India (1998)</td><td>Eclampsia</td><td>17.7% (11/62)</td><td>29.0%</td><td>57.8%</td></tr><tr><td>Pattinson et al, 2003[75]</td><td>Three regions, South Africa (year not stated)</td><td>Hypertension with organ failure</td><td>20.7% (30/145)</td><td>17.2%</td><td>50.7%</td></tr><tr><td>Kaye et al 2003[76]</td><td>Mulago hospital, Uganda (2000)</td><td>Eclampsia/pre-eclampsia with organ failure</td><td>14.3% (3/21)</td><td>42.9%</td><td>66.0%</td></tr><tr><td>Oladapo et al 2007[77]</td><td>Olabisi Onabanjo hospital, southwest Nigeria (2002-2004)</td><td>Eclampsia and severe pre-eclampsia with clinical/laboratory indications for termination of pregnancy to save the woman's live</td><td>14.9% (21/141)</td><td>40.4%</td><td>64.5%</td></tr><tr><td>Adisasmita et al 2008[78]</td><td>Four hospitals in West-Java, Indonesia (2003-2004)</td><td>Eclampsia and pre-eclampsia with organ failure</td><td>3.9% (22/563)</td><td>84.4%</td><td>90.7%</td></tr><tr><td>Roost et al 2009[79]</td><td>Four public hospitals in La Paz and El Alto, Bolivia (2006-2007)</td><td>Eclampsia and pre-eclampsia based on clinical and management criteria</td><td>0.5% (1/184)</td><td>98.0%</td><td>98.8%</td></tr></table>
bf927ec997fa9bf50b3e974866562f05d2073b89117151178ac01ed255ca19da.png
simple
<table><tr><td>Characteristic</td><td>Number of patients(%)</td></tr><tr><td>Sex</td><td></td></tr><tr><td>Female</td><td>318 (29.1)</td></tr><tr><td>Male</td><td>775 (70.9)</td></tr><tr><td>Age (years)</td><td></td></tr><tr><td>Median</td><td></td></tr><tr><td>(range)</td><td>47 (15-90)</td></tr><tr><td>&#8804; 47</td><td>568</td></tr><tr><td>&gt; 47</td><td>517</td></tr><tr><td>Missing</td><td>8</td></tr><tr><td>Follow-up time (months)</td><td></td></tr><tr><td>Median</td><td>67 (1-120)</td></tr><tr><td>(range)</td><td></td></tr><tr><td>Clinical stage</td><td></td></tr><tr><td>I-II</td><td>315 (29.0)</td></tr><tr><td>III-IV</td><td>773 (71.0)</td></tr><tr><td>Missing</td><td>5</td></tr><tr><td>Relapse</td><td></td></tr><tr><td>No</td><td>1001 (91.7)</td></tr><tr><td>Yes</td><td>91 (8.3)</td></tr><tr><td>Missing</td><td>1</td></tr><tr><td>Metastasis</td><td></td></tr><tr><td>No</td><td>984 (90.1)</td></tr><tr><td>Yes</td><td>108 (9.9)</td></tr><tr><td>Missing</td><td>1</td></tr><tr><td>Therapeutic modality</td><td></td></tr><tr><td>Radiotherapy</td><td>766 (70.6)</td></tr><tr><td>Chemotherapy</td><td>10 (0.9)</td></tr><tr><td>Radiochemotherapy</td><td>309 (28.5)</td></tr><tr><td>Missing</td><td>8</td></tr><tr><td>WHO histological classification</td><td></td></tr><tr><td>NKUC</td><td>853 (78.3)</td></tr><tr><td>NKDC</td><td>206 (18.9)</td></tr><tr><td>KSCC</td><td>30 (2.8)</td></tr><tr><td>Missing</td><td>4</td></tr><tr><td>OS rate (%)</td><td></td></tr><tr><td>5-year</td><td>69.1</td></tr></table>
735e39658711219c2d97de6f49dcf5022e4023cc7a408111ab1928e91d63db1c.png
complex
<table><tr><td>Group</td><td>Quintile</td><td colspan="2">Total PA</td><td colspan="2">Moderate PA</td><td colspan="2">Vigorous PA</td><td colspan="2">MVPA</td></tr><tr><td> </td><td> </td><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td></tr><tr><td colspan="10">Boys (2 to 6 years)</td></tr><tr><td rowspan="5">n = 524</td><td>Q1</td><td>2.58</td><td>1.07 to 6.18</td><td>1.26</td><td>0.55 to 2.88</td><td>1.23</td><td>0.46 to 3.26</td><td>1.39</td><td>0.56 to 3.45</td></tr><tr><td>Q2</td><td>1.59</td><td>0.65 to 3.91</td><td>1.27</td><td>0.57 to 2.83</td><td>2.91</td><td>1.25 to 6.82</td><td>2.21</td><td>0.95 to 5.15</td></tr><tr><td>Q3</td><td>1.31</td><td>0.55 to 3.16</td><td>1.17</td><td>0.51 to 2.66</td><td>1.98</td><td>0.79 to 4.93</td><td>1.98</td><td>0.85 to 4.58</td></tr><tr><td>Q4</td><td>2.21</td><td>0.98 to 4.98</td><td>1.23</td><td>0.56 to 2.69</td><td>2.14</td><td>0.89 to 5.15</td><td>1.62</td><td>0.68 to 3.85</td></tr><tr><td>Q5 (reference)</td><td>1</td><td> </td><td>1</td><td> </td><td>1</td><td> </td><td>1</td><td> </td></tr><tr><td colspan="10">Girls (2 to 6 years)</td></tr><tr><td rowspan="5">n = 470</td><td>Q1</td><td>1.03</td><td>0.43 to 2.47</td><td>0.77</td><td>0.32 to 1.85</td><td>2.54</td><td>0.88 to 7.29</td><td>1.23</td><td>0.48 to 3.17</td></tr><tr><td>Q2</td><td>0.76</td><td>0.32 to 1.85</td><td>0.80</td><td>0.33 to 1.93</td><td>2.71</td><td>0.96 to 7.70</td><td>1.18</td><td>0.45 to 3.08</td></tr><tr><td>Q3</td><td>0.81</td><td>0.34 to 1.90</td><td>0.69</td><td>0.29 to 1.67</td><td>1.68</td><td>0.55 to 5.15</td><td>1.26</td><td>0.50 to 3.13</td></tr><tr><td>Q4</td><td>0.72</td><td>0.31 to 1.63</td><td>0.67</td><td>0.28 to 1.62</td><td>2.29</td><td>0.82 to 6.37</td><td>1.20</td><td>0.48 to 2.98</td></tr><tr><td>Q5 (reference)</td><td>1</td><td> </td><td>1</td><td> </td><td>1</td><td> </td><td>1</td><td> </td></tr><tr><td colspan="10">Boys (6 to 9 years)</td></tr><tr><td rowspan="5">n = 1,038</td><td>Q1</td><td>3.26</td><td>1.74 to 6.10</td><td>3.58</td><td>1.95 to 6.55</td><td>3.82</td><td>2.05 to 7.16</td><td>3.77</td><td>2.04 to 6.96</td></tr><tr><td>Q2</td><td>1.70</td><td>0.89 to 3.25</td><td>1.38</td><td>0.75 to 2.53</td><td>2.70</td><td>1.45 to 5.14</td><td>1.98</td><td>1.04 to 3.77</td></tr><tr><td>Q3</td><td>2.00</td><td>1.06 to 3.79</td><td>1.29</td><td>0.70 to 2.38</td><td>2.01</td><td>1.04 to 3.89</td><td>1.32</td><td>0.67 to 2.59</td></tr><tr><td>Q4</td><td>1.10</td><td>0.55 to 2.20</td><td>0.50</td><td>0.24 to 1.06</td><td>1.78</td><td>0.88 to 3.59</td><td>1.23</td><td>0.61 to 2.46</td></tr><tr><td>Q5 (reference)</td><td>1</td><td> </td><td>1</td><td> </td><td>1</td><td> </td><td>1</td><td> </td></tr><tr><td colspan="10">Girls (6 to 9 years)</td></tr><tr><td rowspan="4">n = 987</td><td>Q1</td><td>1.72</td><td>0.90 to 3.30</td><td>2.54</td><td>1.33 to 4.86</td><td>2.49</td><td>1.37 to 4.52</td><td>2.95</td><td>1.55 to 5.61</td></tr><tr><td>Q2</td><td>2.47</td><td>1.34 to 4.56</td><td>2.78</td><td>1.46 to 5.24</td><td>1.90</td><td>1.03 to 3.50</td><td>2.70</td><td>1.43 to 5.10</td></tr><tr><td>Q3</td><td>1.87</td><td>1.01 to 3.45</td><td>2.44</td><td>1.29 to 4.62</td><td>1.78</td><td>0.94 to 3.39</td><td>2.11</td><td>1.11 to 4.12</td></tr><tr><td>Q4</td><td>1.31</td><td>0.69 to 2.51</td><td>1.13</td><td>0.56 to 2.28</td><td>1.18</td><td>0.59 to 2.34</td><td>1.27</td><td>0.64 to 2.52</td></tr><tr><td> </td><td>Q5 (reference)</td><td>1</td><td> </td><td>1</td><td> </td><td>1</td><td> </td><td>1</td><td> </td></tr></table>
ca8b2161d74a9ac53cafc61edf54e2dc9bc3524609285e4438269d623d60212b.png
simple
<table><tr><td>Parameter</td><td>Benign (n = 102)</td><td>Malignant (n = 11)</td><td>P value</td></tr><tr><td>Age</td><td>58.9 &#177; 16.4</td><td>48.8 &#177; 18.7</td><td>0.059</td></tr><tr><td>Female gender</td><td>66 (64.7)</td><td>5 (45.5)</td><td>0.209</td></tr><tr><td>Urgent intervention</td><td>22 (21.6)</td><td>10 (90.9)</td><td>&lt;0.01</td></tr><tr><td>Coronary artery disease</td><td>8 (7.8)</td><td>0 (0.0)</td><td>0.335</td></tr><tr><td>Valvular heart disease</td><td>12 (11.8)</td><td>0 (0.0)</td><td>0.229</td></tr><tr><td>Congenital heart disease</td><td>0 (0.0)</td><td>1 (9.1)</td><td>0.742</td></tr><tr><td>Thromboembolic disease</td><td>3 (2.9)</td><td>0 (0.0)</td><td>0.564</td></tr></table>
202e89041409c1bb5b871b76ec48ddda1f665d0249ef69cf0a5a3aa2e336482a.png
simple
<table><tr><td>Hospital</td><td>Case (male/female)</td><td>Percentage of total</td></tr><tr><td>Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine</td><td>178 (111/67)</td><td>5.03%</td></tr><tr><td>Guanganmen Hospital affiliated to China Academy of Chinese Medical Science</td><td>564 (363/201)</td><td>15.95%</td></tr><tr><td>Huairou Hospital of Traditional Chinese Medicine</td><td>121 (77/44)</td><td>3.42%</td></tr><tr><td>Beijing Hospital of Traditional Chinese Medicine</td><td>220 (142/78)</td><td>6.22%</td></tr><tr><td>People's Hospital affiliated to Beijing University</td><td>107 (72/35)</td><td>3.03%</td></tr><tr><td>Tongzhou Hospital of Traditional Chinese Medicine</td><td>160 (98/62)</td><td>4.52%</td></tr><tr><td>Tongren Hospital affiliated to Capital University of Medical Sciences</td><td>260 (162/98)</td><td>7.35%</td></tr><tr><td>Wangjing Hospital affiliated to China Academy of Chinese Medical Science</td><td>93 (58/35)</td><td>2.63%</td></tr><tr><td>Xiyuan Hospital affiliated to China Academy of Chinese Medical Science</td><td>462 (304/158)</td><td>13.06%</td></tr><tr><td>China-Japan Friendship Hospital</td><td>632 (425/207)</td><td>17.87%</td></tr><tr><td>Beijing Hospital of Integrated Traditional Chinese with Western Medicine</td><td>124 (80/44)</td><td>3.51%</td></tr><tr><td>Anzhen Hospital affiliated to Capital University of Medical Sciences</td><td>616 (422/194)</td><td>17.42%</td></tr></table>
93f8fafea6b3ecca4bc1bc91985204af2bbe6df6beac28ab0a29702b09c632be.png
complex
<table><tr><td>Cluster of Life Sciences</td><td>BMBS - Biomedicine and Molecular BiosciencesFA - Food and AgricultureFPS - Forests, their Products and Services</td></tr><tr><td>Cluster of Natural Sciences</td><td>CMST - Chemistry and Molecular Sciences and TechnologiesESSEM - Earth System Science and Environmental ManagementMPNS - Materials, Physical and Nanosciences</td></tr><tr><td>Cluster of Science and Society</td><td>ISCH - Individuals, Societies, Cultures and HealthICT - Information and Communication TechnologiesTUD - Transport and Urban Development</td></tr><tr><td colspan="2">Trans Domain area (not a separate Domain currently) &#8211; allows for multidisciplinary proposals which cannot be submitted to a single Domain.</td></tr></table>
136a5227d7659f62d2266f10f2c2a81a5cdf5fa83ae236695e731f2a5bd14b28.png
simple
<table><tr><td>Chronic Disease (outcome variables)</td><td>Frequent mental distress (FMD) Beta (SE)<sup>1</sup></td><td>Obesity Beta (SE)<sup>1</sup></td></tr><tr><td>Diabetes</td><td>0.55 (0.03)<sup>2</sup></td><td>1.17 (0.02)<sup>2</sup></td></tr><tr><td>High Blood Pressure</td><td>0.54 (0.02)<sup>2</sup></td><td>0.99 (0.02)<sup>2</sup></td></tr><tr><td>Coronary Heart Disease</td><td>0.90 (0.04)<sup>2</sup></td><td>0.41 (0.03)<sup>2</sup></td></tr><tr><td>Stroke</td><td>0.93 (0.04)<sup>2</sup></td><td>0.18 (0.04)<sup>2</sup></td></tr><tr><td>Asthma</td><td>0.62 (0.03)<sup>2</sup></td><td>0.42 (0.02)<sup>2</sup></td></tr><tr><td>Arthritis</td><td>0.87 (0.02)<sup>2</sup></td><td>0.61 (0.02)<sup>2</sup></td></tr></table>
fea56b72082c0a771f1d3fb68292f1fb2878936e638e582071338673f10d18ae.png
simple
<table><tr><td>Factor</td><td>Factor level</td><td>Frequency (n)</td><td>Percentage</td><td>Chi-square</td><td>df</td><td>Significance</td></tr><tr><td>Habitat stability</td><td>Permanent</td><td>214</td><td>63.13</td><td></td><td></td><td></td></tr><tr><td></td><td>Temporary</td><td>125</td><td>36.87</td><td>22.317</td><td>1</td><td>0.000</td></tr><tr><td>Habitat origin</td><td>Man-made</td><td>326</td><td>96.17</td><td></td><td></td><td></td></tr><tr><td></td><td>Natural</td><td>13</td><td>3.83</td><td>0.873</td><td>1</td><td>0.350</td></tr><tr><td>Water origin</td><td>Surface run-off</td><td>279</td><td>82.30</td><td></td><td></td><td></td></tr><tr><td></td><td>Underground</td><td>60</td><td>17.70</td><td>5.254</td><td>1</td><td>0.022</td></tr><tr><td>Habitat size</td><td>&lt;10</td><td>45</td><td>13.27</td><td></td><td></td><td></td></tr><tr><td></td><td>&gt;100</td><td>50</td><td>14.75</td><td></td><td></td><td></td></tr><tr><td></td><td>10 - 100</td><td>244</td><td>71.98</td><td>9.822</td><td>2</td><td>0.007</td></tr><tr><td>Water movement</td><td>No</td><td>301</td><td>88.79</td><td></td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>38</td><td>11.21</td><td>0.768</td><td>1</td><td>0.381</td></tr><tr><td>Vegetation</td><td>Absent</td><td>149</td><td>43.95</td><td></td><td></td><td></td></tr><tr><td></td><td>Present</td><td>190</td><td>56.05</td><td>11.547</td><td>1</td><td>0.001</td></tr></table>
458b283d7bf4badabb0701b032f04deee1fea1f11d8f3e699cb1efc7e7454d4e.png
simple
<table><tr><td></td><td>Combined SMI group (n = 230)</td><td>Glasgow City (n = 8,094)</td><td>P<sup>1</sup></td><td>Scotland (n = 54,590)</td><td>P<sup>2</sup></td></tr><tr><td>Cause of death (n, %)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Cerebrovascular disease</td><td>8 (3.5%)</td><td>304 (3.8%)</td><td>p = 0.833</td><td>2186 (4.0%)</td><td>p = 0.685</td></tr><tr><td>Cardiovascular disease</td><td>34 (14.8%</td><td>1069 (13.2%)</td><td>p = 0.546</td><td>7465 (13.7%)</td><td>p = 0.626</td></tr><tr><td>Cancer</td><td>33 (14.3%)</td><td>2211 (27.3%)</td><td>p &lt; 0.001</td><td>18129 (33.2%)</td><td>p &lt; 0.001</td></tr><tr><td>Respiratory disease</td><td>24 (10.4%)</td><td>606 (7.5%)</td><td>p = 0.096</td><td>3451 (6.3%)</td><td>p = 0.001</td></tr><tr><td>Alcohol Related</td><td>15 (6.5%)</td><td>1032 (12.8%)</td><td>p = 0.005</td><td>5319 (9.7%)</td><td>p = 0.099</td></tr><tr><td>Accidental deaths</td><td>11 (4.8%)</td><td>400 (4.9%)</td><td>p = 0.912</td><td>2882 (5.3%)</td><td>p = 0.734</td></tr><tr><td>Suicide</td><td>34 (14.8%)</td><td>568 (7.0%)</td><td>p &lt; 0.001</td><td>3533 (6.5%)</td><td>p &lt; 0.001</td></tr><tr><td>Mental &amp; behavioural disorder due to drugs</td><td>18 (7.8%)</td><td>412 (5.1%)</td><td>p = 0.065</td><td>1756 (3.2%)</td><td>p &lt; 0.001</td></tr><tr><td>Other</td><td>53 (23.0%)</td><td>1492 (18.4%)</td><td>p = 0.076</td><td>9869 (18.1%)</td><td>p = 0.05</td></tr><tr><td>Male (n,%)</td><td>156 (67.8%)</td><td>5218 (64.5%)</td><td>p = 0.298</td><td>33772 (61.9%)</td><td>p = 0.063</td></tr><tr><td>Deaths/age group (n, %)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>16-24</td><td>3 (1.3)</td><td>238 (2.9)</td><td>p = 0.144</td><td>1902 (3.5)</td><td>p = 0.07</td></tr><tr><td>25-34</td><td>18 (7.8)</td><td>559 (6.9)</td><td>p = 0.588</td><td>3186 (5.8)</td><td>p &lt; 0.001</td></tr><tr><td>35-44</td><td>38 (16.5)</td><td>1250 (15.4)</td><td>p = 0.656</td><td>6841 (12.5)</td><td>p &lt; 0.001</td></tr><tr><td>45-54</td><td>72 (31.3)</td><td>2171 (26.8)</td><td>p = 0.131</td><td>13841 (25.4)</td><td>p = 0.039</td></tr><tr><td>55-64</td><td>99 (43.0)</td><td>3876 (47.9)</td><td>p = 0.147</td><td>28820 (52.8)</td><td>p = 0.003</td></tr><tr><td>Deaths/Socioeconomic Status (n, %)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>1-Most affluent</td><td>11 (4.8%)</td><td>257 (3.2%)</td><td>p = 0.173</td><td>5974 (10.9%)</td><td>p = 0.003</td></tr><tr><td>2-</td><td>15 (6.5%)</td><td>450 (5.6%)</td><td>p = 0.531</td><td>8244 (15.1%)</td><td>p = 0.0003</td></tr><tr><td>3-</td><td>34 (14.8%)</td><td>732 (9.0%)</td><td>p = 0.003</td><td>10338 (18.9%)</td><td>p = 0.108</td></tr><tr><td>4-</td><td>64 (27.8%)</td><td>1286 (15.9%)</td><td>p &lt; 0.001</td><td>12643 (23.2%)</td><td>p = 0.09</td></tr><tr><td>5-Most deprived</td><td>106 (46.1%)</td><td>5369 (66.3%)</td><td>p &lt; 0.001</td><td>17391 (31.9%)</td><td>p &lt; 0.001</td></tr></table>
7ba8cfa8a2ccbc1e37ea8cefcb1c6f0be4fe04732d07efec23d7776bddea4d86.png
complex
<table><tr><td>Haplotype</td><td>Freq (case)</td><td>Freq (control)</td><td><i>P</i></td><td>OR (95% CI)</td></tr><tr><td colspan="5">rs12068264|rs11576175</td></tr><tr><td> CA</td><td>0.1685 (61)</td><td>0.203 (82)</td><td></td><td>1.000 (Reference)</td></tr><tr><td> TG</td><td>0.4088 (149)</td><td>0.3416 (139)</td><td>0.076</td><td>1.441 (0.962&#8211;2.158)</td></tr><tr><td> CG</td><td>0.4227 (154)</td><td>0.4554 (185)</td><td>0.576</td><td>1.119 (0.754&#8211;1.660)</td></tr><tr><td colspan="5">rs16924934|rs2273773|rs3818291</td></tr><tr><td> ATA</td><td>0.1703 (62)</td><td>0.1749 (71)</td><td></td><td>1.000 (Reference)</td></tr><tr><td> ACG</td><td>0.294 (107)</td><td>0.2389 (97)</td><td>0.295</td><td>1.263 (0.815&#8211;1.957)</td></tr><tr><td> GTG</td><td>0.1703 (62)</td><td>0.1626 (66)</td><td>0.768</td><td>1.076 (0.662&#8211;1.749)</td></tr><tr><td> ATG</td><td>0.3654 (133)</td><td>0.4236 (172)</td><td>0.560</td><td>0.886 (0.588&#8211;1.333)</td></tr></table>
496b3c4834fd018eac0c5cb180d1628133c5fa272de72713167db9c4a4c68cc1.png
complex
<table><tr><td rowspan="2">Compounds</td><td rowspan="2">pIC<sub>50</sub></td><td colspan="2">CoMFA</td><td colspan="2">CoMSIA</td><td colspan="2">HQSAR</td></tr><tr><td>Pred.</td><td>Res.</td><td>Pred.</td><td>Res.</td><td>Pred.</td><td>Res.</td></tr><tr><td>1</td><td>4.1</td><td>4.078</td><td>0.022</td><td>4.331</td><td>&#8722; 0.231</td><td>4.204</td><td>&#8722; &#8722; 0.104</td></tr><tr><td>2</td><td>5.9111</td><td>6.049</td><td>&#8722; 0.1379</td><td>5.627</td><td>0.2841</td><td>5.664</td><td>0.2471</td></tr><tr><td>3</td><td>6.1301</td><td>6.188</td><td>&#8722; 0.0579</td><td>6.395</td><td>&#8722; 0.2649</td><td>6.276</td><td>&#8722; 0.1459</td></tr><tr><td>4</td><td>6.3595</td><td>6.276</td><td>0.0835</td><td>6.591</td><td>&#8722; 0.2315</td><td>6.116</td><td>0.2435</td></tr><tr><td>5</td><td>7.3279</td><td>7.202</td><td>0.1259</td><td>7.036</td><td>0.2919</td><td>7.246</td><td>0.0819</td></tr><tr><td>6</td><td>6.6556</td><td>6.629</td><td>0.0266</td><td>6.501</td><td>0.1546</td><td>6.187</td><td>0.4686</td></tr><tr><td>7</td><td>6.7645</td><td>6.841</td><td>&#8722; 0.0765</td><td>6.83</td><td>&#8722; 0.0655</td><td>6.711</td><td>0.0535</td></tr><tr><td>8</td><td>6.1791</td><td>6.58</td><td>&#8722; 0.4009</td><td>6.383</td><td>&#8722; 0.2039</td><td>6.514</td><td>&#8722; 0.3349</td></tr><tr><td>9</td><td>6.4389</td><td>6.309</td><td>0.1299</td><td>6.426</td><td>0.0129</td><td>6.481</td><td>&#8722; 0.0421</td></tr><tr><td>10</td><td>6.514</td><td>6.621</td><td>&#8722; 0.107</td><td>6.896</td><td>&#8722; 0.382</td><td>6.679</td><td>&#8722; 0.165</td></tr><tr><td>11</td><td>4.9746</td><td>4.915</td><td>0.0596</td><td>4.848</td><td>0.1266</td><td>5.429</td><td>&#8722; 0.4544</td></tr><tr><td>12</td><td>6.7144</td><td>6.637</td><td>0.0774</td><td>6.693</td><td>0.0214</td><td>6.276</td><td>0.4384</td></tr><tr><td>14</td><td>7.4089</td><td>7.066</td><td>0.3429</td><td>7.289</td><td>0.1199</td><td>7.246</td><td>0.1629</td></tr><tr><td>15</td><td>6.8538</td><td>6.866</td><td>&#8722; 0.0122</td><td>6.671</td><td>0.1828</td><td>7.192</td><td>&#8722; 0.3382</td></tr><tr><td>16</td><td>5.6197</td><td>5.749</td><td>&#8722; 0.1293</td><td>5.633</td><td>&#8722; 0.0133</td><td>5.685</td><td>&#8722; 0.0653</td></tr><tr><td>17</td><td>6.0731</td><td>6.05</td><td>0.0231</td><td>5.902</td><td>0.1711</td><td>5.795</td><td>0.2781</td></tr><tr><td>18</td><td>6.3036</td><td>6.35</td><td>&#8722; 0.0464</td><td>6.293</td><td>0.0106</td><td>6.204</td><td>0.0996</td></tr><tr><td>19</td><td>5.1469</td><td>5.118</td><td>0.0289</td><td>5.17</td><td>&#8722; 0.0231</td><td>5.435</td><td>&#8722; 0.2881</td></tr><tr><td>21</td><td>5.1466</td><td>5.122</td><td>0.0246</td><td>5.133</td><td>0.0136</td><td>5.193</td><td>&#8722; 0.0464</td></tr><tr><td>22</td><td>5.083</td><td>5.005</td><td>0.078</td><td>5.075</td><td>0.008</td><td>5.326</td><td>&#8722; 0.243</td></tr><tr><td>23</td><td>5.313</td><td>5.335</td><td>&#8722; 0.022</td><td>5.141</td><td>0.172</td><td>5.26</td><td>0.053</td></tr><tr><td>24</td><td>5.334</td><td>5.402</td><td>&#8722; 0.068</td><td>5.329</td><td>0.005</td><td>5.383</td><td>&#8722; 0.049</td></tr><tr><td>26</td><td>5.3665</td><td>5.387</td><td>&#8722; 0.0205</td><td>5.543</td><td>&#8722; 0.1765</td><td>5.199</td><td>0.1675</td></tr><tr><td>28</td><td>5.337</td><td>5.368</td><td>&#8722; 0.031</td><td>5.312</td><td>0.025</td><td>5.181</td><td>0.156</td></tr><tr><td>30</td><td>5.3665</td><td>5.436</td><td>&#8722; 0.0695</td><td>5.382</td><td>&#8722; 0.0155</td><td>5.244</td><td>0.1225</td></tr><tr><td>31</td><td>5.337</td><td>5.281</td><td>0.056</td><td>5.24</td><td>0.097</td><td>5.614</td><td>&#8722; 0.277</td></tr><tr><td>33</td><td>5.3767</td><td>5.373</td><td>0.0037</td><td>5.405</td><td>&#8722; 0.0283</td><td>5.773</td><td>&#8722; 0.3963</td></tr><tr><td>34</td><td>5.3565</td><td>5.327</td><td>0.0295</td><td>5.333</td><td>0.0235</td><td>5.357</td><td>&#8722; 0.0005</td></tr><tr><td>35</td><td>5.2757</td><td>5.265</td><td>0.0107</td><td>5.414</td><td>&#8722; 0.1383</td><td>5.238</td><td>0.0377</td></tr><tr><td>36</td><td>4.8913</td><td>4.898</td><td>&#8722; 0.0067</td><td>4.771</td><td>0.1203</td><td>4.777</td><td>0.1143</td></tr><tr><td>37</td><td>4.8548</td><td>4.858</td><td>&#8722; 0.0032</td><td>4.88</td><td>&#8722; 0.0252</td><td>4.844</td><td>0.0108</td></tr><tr><td>40</td><td>5.134</td><td>5.225</td><td>&#8722; 0.091</td><td>5.387</td><td>&#8722; 0.253</td><td>4.9</td><td>0.234</td></tr><tr><td>41</td><td>4.793</td><td>4.713</td><td>0.08</td><td>4.787</td><td>0.006</td><td>4.845</td><td>&#8722; 0.052</td></tr><tr><td>42</td><td>5.2757</td><td>5.194</td><td>0.0817</td><td>5.162</td><td>0.1137</td><td>5.357</td><td>&#8722; 0.0813</td></tr><tr><td>43</td><td>5.1157</td><td>5.075</td><td>0.0407</td><td>5.164</td><td>&#8722; 0.0483</td><td>5.087</td><td>0.0287</td></tr><tr><td>44</td><td>5.602</td><td>5.628</td><td>&#8722; 0.026</td><td>5.587</td><td>0.015</td><td>5.484</td><td>0.118</td></tr><tr><td>45</td><td>4.9625</td><td>4.98</td><td>&#8722; 0.0175</td><td>4.982</td><td>&#8722; 0.0195</td><td>5</td><td>&#8722; 0.0375</td></tr></table>
094aa221ab8edabfd42cf1b02883b76a37c447132b0172fbfbde61128f3b86ba.png
simple
<table><tr><td>Demographic characteristics</td><td>Value</td></tr><tr><td>Age in years, mean (range)</td><td>55.9 (42 to 79)</td></tr><tr><td>Race, <i>n</i> (%)</td><td></td></tr><tr><td>White</td><td>4 (50)</td></tr><tr><td>African heritage</td><td>2 (25)</td></tr><tr><td>Asian - Japanese/East Asian/Southeast Asian heritage</td><td>1 (13)</td></tr><tr><td>Asian - Central/South Asian heritage</td><td>1 (13)</td></tr><tr><td>Baseline ECOG performance status, <i>n</i> (%)</td><td></td></tr><tr><td>0</td><td>6 (77)</td></tr><tr><td>2</td><td>2 (25)</td></tr><tr><td>Time since diagnosis (years), median (range)</td><td>4.5 (1 to 9)</td></tr></table>
1e3074383e47208ac2fbdc809fff9af3a7431baacd4047b2c79487dcc6d40d23.png
simple
<table><tr><td>Trial</td><td>Hb (g/L)</td><td>Ferritin (<i>&#956;</i>g/L)</td><td>TSAT (%)</td><td>BM iron</td></tr><tr><td>Auerbach 2004 [26]</td><td>&#8804;105</td><td>&#8804;200</td><td>&#8804;19*</td><td> ND</td></tr><tr><td>Auerbach 2010 [31]</td><td>&#8804;100</td><td>&#8805;10</td><td>&#8805;15</td><td> ND</td></tr><tr><td>Bastit et al. [29]</td><td>&lt;110</td><td>10&#8211;800</td><td>&#8805;15</td><td> ND</td></tr><tr><td>Hedenus et al. [28]</td><td>90&#8211;110</td><td>&lt;800</td><td>&#8212;</td><td> +</td></tr><tr><td>Henry et al. [27]</td><td>&lt;110</td><td>100&#8211;900</td><td>15&#8211;35</td><td> ND</td></tr><tr><td>Pedrazzoli et al. [30]</td><td>&lt;110</td><td>100&#8211;800</td><td>20&#8211;40</td><td> ND</td></tr><tr><td>Steensma et al. [32]</td><td>&lt;110</td><td>&#8805;20</td><td>&lt;60</td><td> ND</td></tr></table>
b42d9a98a28d9b8b578a548b21e60b8124aecaadf027b48b0fcd89e37937bb95.png
simple
<table><tr><td>Kidney tissue</td><td>Treatment</td><td>1 h</td><td>24 h</td><td>48 h</td><td>72 h</td></tr><tr><td>Cortex</td><td>CG</td><td>19.0 &#177; 2.3</td><td>18.9 &#177; 2.1</td><td>19.2 &#177; 2.2</td><td>18.9 &#177; 2.7</td></tr><tr><td> </td><td>DN PC</td><td>24.5 &#177; 3.6*</td><td>24.5 &#177; 4.3*</td><td>24.7 &#177; 4.5*</td><td>25.4 &#177; 3.7*</td></tr><tr><td> </td><td>DN 200</td><td>31.1 &#177; 3.2*</td><td>31.3 &#177; 4.9*</td><td>30.9 &#177; 3.6*</td><td>28.9 &#177; 4.3*</td></tr><tr><td> </td><td>DN 240</td><td>33.3 &#177; 4.6*</td><td>34.8 &#177; 4.8*</td><td>34.0 &#177; 3.1*</td><td>33.5 &#177; 7.9*</td></tr><tr><td> </td><td>DN 300</td><td>41.7 &#177; 5.1*</td><td>41.9 &#177; 3.4*</td><td>40.1 &#177; 5.5*</td><td>39.2 &#177; 4.0*</td></tr><tr><td> </td><td>DN 350</td><td>46.7 &#177; 5.2*</td><td>50.2 &#177; 5.8*</td><td>48.9 &#177; 5.7*</td><td>43.7 &#177; 6.0*</td></tr><tr><td> </td><td>DN 400</td><td>50.1 &#177; 5.6*</td><td>57.6 &#177; 5.3*</td><td>53.9 &#177; 6.1*</td><td>47.4 &#177; 5.5*</td></tr><tr><td>Outer medulla</td><td>CG</td><td>20 &#177; 4.2</td><td>22.7 &#177; 4.8</td><td>22.4 &#177; 5.4</td><td>21.6 &#177; 5.1</td></tr><tr><td> </td><td>DN PC</td><td>29.9 &#177; 4.4*</td><td>30.7 &#177; 5.1*</td><td>28.2 &#177; 5.8*</td><td>29.5 &#177; 5.4*</td></tr><tr><td> </td><td>DN 200</td><td>38.1 &#177; 4.6*</td><td>40.1 &#177; 6.2*</td><td>37.5 &#177; 4.8*</td><td>33.8 &#177; 5.8*</td></tr><tr><td> </td><td>DN 240</td><td>42.3 &#177; 3.5*</td><td>43.3 &#177; 5.7*</td><td>40.3 &#177; 4.2*</td><td>37.3 &#177; 3.5*</td></tr><tr><td> </td><td>DN 300</td><td>53.4 &#177; 5.2*</td><td>57.9 &#177; 5.6*</td><td>48.8 &#177; 4.8*</td><td>45.4 &#177; 5.2*</td></tr><tr><td> </td><td>DN 350</td><td>60.6 &#177; 6.3*</td><td>72.4 &#177; 5.7*</td><td>62.9 &#177; 5.5*</td><td>56.5 &#177; 5.3*</td></tr><tr><td> </td><td>DN 400</td><td>67.6 &#177; 5.6*</td><td>80.4 &#177; 6.3*</td><td>74.7 &#177; 6.1*</td><td>67.7 &#177; 5.8*</td></tr><tr><td>Inner medulla</td><td>CG</td><td>20.2 &#177; 2.4</td><td>20.0 &#177; 3.6</td><td>21.8 &#177; 2.7</td><td>20.5 &#177; 3.2</td></tr><tr><td> </td><td>DN PC</td><td>22.7 &#177; 4.7*</td><td>24.5 &#177; 3.8*</td><td>24.3 &#177; 4.0*</td><td>22.9 &#177; 3.4*</td></tr><tr><td> </td><td>DN 200</td><td>27.2 &#177; 3.3*</td><td>30.6 &#177; 4.0*</td><td>26.2 &#177; 2.7*</td><td>25.0 &#177; 3.5*</td></tr><tr><td> </td><td>DN 240</td><td>30.4 &#177; 3.8*</td><td>33.6 &#177; 5.8*</td><td>31.9 &#177; 4.2*</td><td>29.9 &#177; 5.2*</td></tr><tr><td> </td><td>DN 300</td><td>42.8 &#177; 5.2*</td><td>44.2 &#177; 5.0*</td><td>38.8 &#177; 4.9*</td><td>32.7 &#177; 4.8*</td></tr><tr><td> </td><td>DN 350</td><td>49.2 &#177; 5.7*</td><td>50.2 &#177; 4.8*</td><td>47.3 &#177; 5.8*</td><td>39.4 &#177; 5.1*</td></tr><tr><td> </td><td>DN 400</td><td>55.2 &#177; 5.4*</td><td>57.2 &#177; 5.3*</td><td>55.3 &#177; 6.3*</td><td>46.4 &#177; 5.7*</td></tr></table>
103dbf17350355d29f4994f0bd2a57039482587d47e6087d78b04ea50381699b.png
complex
<table><tr><td rowspan="2"></td><td>Healthy volunteers</td><td>ObT2D</td><td>HV/ObT2D</td></tr><tr><td>(n = 19)</td><td>(n = 20)</td><td>p value</td></tr><tr><td>Intra-myocardium dixon fat fraction (%)</td><td>7.9 &#177; 3.7</td><td>6.0 &#177; 1.5</td><td></td></tr><tr><td>Dixon 3D epicardial fat volume (mL)</td><td>176.4 &#177; 68.6</td><td>273.8 &#177; 64.0</td><td>***</td></tr><tr><td>Indexed dixon 3D epicardial fat volume (mL/m<sup>2</sup>)</td><td>89.7 &#177; 25.2</td><td>123.6 &#177; 23.4</td><td>***</td></tr><tr><td>Dixon 3D epicardial fat fraction (%)</td><td>21.0 &#177; 4.0</td><td>28.4 &#177; 5.5</td><td>***</td></tr></table>
760bebfa0c0781c3c2645372d4885f83e19b66cbd91a6b75f5c5e8752894513f.png
complex
<table><tr><td rowspan="2">Name</td><td rowspan="2">Chr</td><td rowspan="2">Bins<sup>a</sup></td><td colspan="2">QTL confidence interval, bp</td><td rowspan="2">LOD<sup>b</sup></td><td rowspan="2">R<sup>2</sup></td><td rowspan="2">Additive Effect<sup>c</sup></td></tr><tr><td>Left border</td><td>Right border</td></tr><tr><td><i>QTLGLSchr1</i></td><td>1</td><td>1.07-1.09</td><td>211,331,752</td><td>263,220,725</td><td>4.724933</td><td>0.045507</td><td>0.045507</td></tr><tr><td><i>QTLGLSchr6</i></td><td>6</td><td>6.01-6.04</td><td>26,909,746</td><td>120,538,443</td><td>6.9741</td><td>0.06859</td><td>32.11692</td></tr><tr><td><i>QTLGLSchr7</i></td><td>7</td><td>7.01-7.02</td><td>11,570,701</td><td>124,949,426</td><td>5.2492</td><td>0.052803</td><td>24.17346</td></tr><tr><td><i>QTLGLSchr8</i></td><td>8</td><td>8.02-8.04</td><td>14,069,105</td><td>118,971,618</td><td>22.83246</td><td>0.265049</td><td>105.1474</td></tr></table>
340262d87015f0f00af5b1d69e85da0b57e35c874e9cd5c4397b261f401711c0.png
complex
<table><tr><td colspan="8">Stage 1: selection of study sites</td></tr><tr><td>Region</td><td>Country</td><td>Estimated no. ART clinics (yr. of assessment)</td><td>Estimated no. adult ART enrollees at ART clinics</td><td>No. eligible clinics*</td><td>Estimated no. study-eligible adult ART enrollees at eligible clinics</td><td>Site sampling technique</td><td>No. clinics selected</td></tr><tr><td rowspan="5">Southern Africa</td><td>Mozambique</td><td>379 (2014)</td><td>582,000</td><td>254</td><td>446,379</td><td>Census</td><td>254</td></tr><tr><td>Namibia</td><td>213 (2014)</td><td>165,468</td><td>213</td><td>165,468</td><td>Census</td><td>213</td></tr><tr><td>Swaziland</td><td>31 (2009)</td><td>50,767</td><td>31</td><td>50,767</td><td>PPS</td><td>16</td></tr><tr><td>Zimbabwe</td><td>104 (2008)</td><td>103,806</td><td>70</td><td>93,811</td><td>PPS</td><td>40</td></tr><tr><td>Zambia</td><td>322 (2007)</td><td>65,383</td><td>129</td><td>58,845</td><td>Purposive</td><td>6</td></tr><tr><td rowspan="2">East Africa</td><td>Tanzania</td><td>210 (2007)</td><td>41,920</td><td>85</td><td>37,728</td><td>Purposive</td><td>6</td></tr><tr><td>Uganda</td><td>286 (2007)</td><td>45,946</td><td>114</td><td>41,351</td><td>Purposive</td><td>6</td></tr><tr><td>West Africa</td><td>Nigeria<sup>&#8224;&#8224;</sup></td><td>178 (2009)</td><td>168,335</td><td>139</td><td>167,438</td><td>PPS</td><td>35</td></tr><tr><td>Caribbean</td><td>Haiti</td><td>200 (2015)</td><td>65,000</td><td>191</td><td>60,705</td><td>Census</td><td>191</td></tr><tr><td>Southeast Asia</td><td>Vietnam</td><td>173 (2009)</td><td>28,090</td><td>120</td><td>25,000</td><td>PPS</td><td>30</td></tr><tr><td>Total</td><td>&#8212;</td><td>2,096</td><td>1,316,715</td><td>1,346</td><td>1,147,492</td><td>&#8212;</td><td>797</td></tr><tr><td colspan="8">Stage 2: selection of study patients</td></tr><tr><td>Region</td><td>Country</td><td>Age-eligibility criteria (age at ART initiation) (yrs)</td><td>ART enrollment years covered by analysis</td><td>Patient sampling technique at selected clinics</td><td>Planned sample size*</td><td>No. eligible medical recordsanalyzed</td><td>Date of data collection</td></tr><tr><td rowspan="5">Southern Africa</td><td>Mozambique</td><td>&#8805;15</td><td>2004&#8211;2013</td><td>Census</td><td>446,379</td><td>446,379</td><td>Dec 2014</td></tr><tr><td>Namibia</td><td>&#8805;15</td><td>2004&#8211;2012</td><td>Census</td><td>165,468</td><td>165,468</td><td>Dec 2013</td></tr><tr><td>Swaziland</td><td>&#8805;15</td><td>2004&#8211;2010</td><td>SRS</td><td>2,500</td><td>2,510</td><td>Nov 2011&#8211;Feb 2012</td></tr><tr><td>Zimbabwe</td><td>&#8805;15</td><td>2007&#8211;2009</td><td>SRS</td><td>4,000</td><td>3,896<sup>&#8224;</sup></td><td>Jan&#8211;Jun 2010</td></tr><tr><td>Zambia</td><td>&#8805;18</td><td>2004&#8211;2009</td><td>SRS</td><td>1,500</td><td>1,214<sup>&#167;</sup></td><td>Apr&#8211;Jul 2010</td></tr><tr><td rowspan="2">East Africa</td><td>Tanzania</td><td>&#8805;18</td><td>2004&#8211;2009</td><td>SRS</td><td>1,500</td><td>1,421<sup>&#182;</sup></td><td>Apr&#8211;Jul 2010</td></tr><tr><td>Uganda</td><td>&#8805;18</td><td>2004&#8211;2009</td><td>SRS</td><td>1,500</td><td>1,466**</td><td>Apr&#8211;Jul 2010</td></tr><tr><td>West Africa</td><td>Nigeria<sup>&#8224;&#8224;</sup></td><td>&#8805;15</td><td>2004&#8211;2011</td><td>SRS</td><td>3,500</td><td>3,496</td><td>Dec 2012&#8211;Aug 2013</td></tr><tr><td>Caribbean</td><td>Haiti</td><td>&#8805;15</td><td>2004&#8211;2015</td><td>Census</td><td>60,705</td><td>60,705</td><td>Jun 2016</td></tr><tr><td>Southeast Asia</td><td>Vietnam</td><td>&#8805;15</td><td>2005&#8211;2009</td><td>SRS</td><td>7,587</td><td>7,583<sup>&#167;&#167;</sup></td><td>Jan&#8211;Jun 2010</td></tr><tr><td>Total</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>694,639</td><td>694,138</td><td>&#8212;</td></tr></table>
9ff8872e63025f9539d6a6ac0e69d9e0420164aee155140bef31ad2610df7564.png
complex
<table><tr><td>CT technique description</td><td colspan="2">Injection activity (MBq)</td><td colspan="2">Effective dose (mSv)</td><td colspan="2">Effective dose per unit activity (mSv/MBq)</td></tr><tr><td></td><td>Male</td><td>Female</td><td>Male</td><td>Female</td><td>Male</td><td>Female</td></tr><tr><td>Standard CT</td><td>455 &#177; 30</td><td>450 &#177; 26</td><td>8.1 &#177; 1.2</td><td>10.1 &#177; 1.4</td><td>0.018 &#177; 0.002</td><td>0.022 &#177; 0.002</td></tr><tr><td>Diagnostic CT</td><td>455 &#177; 25</td><td>454 &#177; 51</td><td>8.1 &#177; 0.8</td><td>9.9 &#177; 1.6</td><td>0.018 &#177; 0.002</td><td>0.022 &#177; 0.003</td></tr></table>
506d7af91bed04831c8b452ee052fc5433d0d70ec55befaa522e77ad078a0886.png
simple
<table><tr><td>Gene Ontology<sup>a</sup></td><td>DAVID<sup>b</sup></td></tr><tr><td>Biological process</td><td></td></tr><tr><td> Cell adhesion (GO:0007155)</td><td>0.0000148</td></tr><tr><td> Cell communication</td><td>0.000632</td></tr><tr><td>G-protein signaling, coupled to cyclic nucleotide second messenger</td><td>0.001940<sup>c</sup></td></tr><tr><td> System development (GO:0048731)</td><td>0.000000016</td></tr><tr><td>Central nervous system development</td><td>0.000293<sup>c</sup></td></tr><tr><td> Organ development (GO:0048513)</td><td>0.000017</td></tr><tr><td>Cellular compartment</td><td></td></tr><tr><td> Integral to membrane (GO:0016021)</td><td>0.0000018</td></tr><tr><td> Integral to plasma membrane (GO:0005887)</td><td>0.000000026</td></tr><tr><td> Dystrophin-associated glycoprotein complex</td><td>0.002081<sup>c</sup></td></tr><tr><td>Sarcoglycan complex</td><td>0.004398<sup>c</sup></td></tr><tr><td>Molecular function</td><td></td></tr><tr><td> Signal transducer activity (GO:0004871)</td><td>0.0000025</td></tr><tr><td> Transmembrane receptor activity (GO:0004888)</td><td>0.0000274</td></tr><tr><td>Transmembrane receptor protein phosphatase activity</td><td>0.003811<sup>c</sup></td></tr><tr><td>Amine receptor activity</td><td>0.004557<sup>c</sup></td></tr><tr><td>Hematopoietin/interferon-class (D200-domain) cytokine receptor activity</td><td>0.001526<sup>c</sup></td></tr><tr><td> Phosphoinositide binding</td><td>0.000737<sup>c</sup></td></tr><tr><td>GPI anchor binding</td><td>0.003257<sup>c</sup></td></tr><tr><td> Calcium-release channel activity</td><td>0.004102<sup>c</sup></td></tr><tr><td> Delayed rectifier potassium channel activity</td><td>0.001212<sup>c</sup></td></tr><tr><td>Enriched KEGG pathways</td><td>PE<sup>b</sup></td></tr><tr><td> Cell adhesion molecules (CAMs)</td><td>0.00000036</td></tr><tr><td> Neuroactive ligand-receptor interaction</td><td>0.000542</td></tr><tr><td> Allograft rejection</td><td>0.001545</td></tr><tr><td> Type I diabetes mellitus</td><td>0.003487</td></tr></table>
5c005d95406c99296920e6430db88edcb6a4ee6eb2322a4f29efeb986c62bdb7.png
complex
<table><tr><td rowspan="2">Outcome and instrument</td><td rowspan="2">Method</td><td colspan="3">Data collection time</td></tr><tr><td>T0</td><td>T1</td><td>T2</td></tr><tr><td>Perceived health</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>SF-36</td><td>Interview caregiver or mailed questionnaire</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Objective burden</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Short version iBMG</td><td>Interview caregiver or mailed questionnaire</td><td>x</td><td>x</td><td>x</td></tr><tr><td>instrument objective burden informal care</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Subjective burden</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Carer-Qol</td><td>Interview caregiver or mailed questionnaire</td><td>x</td><td>x</td><td>x</td></tr><tr><td>SRB</td><td>Interview caregiver or mailed questionnaire</td><td>x</td><td>x</td><td>x</td></tr><tr><td>CSI+</td><td>Interview caregiver or mailed questionnaire</td><td>x</td><td> </td><td>x</td></tr><tr><td>Perseverance time</td><td>Interview caregiver or mailed questionnaire</td><td>x</td><td> </td><td>x</td></tr><tr><td>ASIS</td><td>Interview caregiver or mailed questionnaire</td><td>x</td><td> </td><td>x</td></tr><tr><td>Quality of life</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>SF-36</td><td>Interview caregiver or mailed questionnaire</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Cantril&#8217;s self-anchoring ladder</td><td>Interview caregiver or mailed questionnaire</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Use of community services</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Self-reported</td><td>Interview caregiver or mailed questionnaire</td><td>x</td><td>x</td><td>x</td></tr><tr><td>CSAI</td><td>Interview caregiver or mailed questionnaire</td><td>x</td><td> </td><td>x</td></tr></table>
30f1c4f9cd25c2afdb5d58ed1f500c32087e98a26d94dff7326a6ea1facfb5ab.png
simple
<table><tr><td>Strategy</td><td>Treatment</td><td>Genomic Profile</td><td>Phase</td><td>N</td><td>ORR (%)</td><td>PFS (M)</td><td>OS (M)</td><td>Clinical Development</td><td>Reference</td></tr><tr><td>BRAF monotherapy</td><td>Vemurafenib</td><td>BRAFmut</td><td>I/II</td><td>21</td><td>5</td><td>2.1</td><td>7.7</td><td>Complete</td><td>NCT00405587 [93]</td></tr><tr><td>BRAF monotherapy</td><td>Vemurafenib</td><td>BRAFmut</td><td>II</td><td>10</td><td>0</td><td>4.5</td><td>9.3</td><td>Complete</td><td>NCT01524978 [94]</td></tr><tr><td>BRAF + MEK</td><td>Dabrafenib + Trametinib</td><td>BRAFmut</td><td>I/II</td><td>43</td><td>12</td><td>3.5</td><td>(&#8722;)</td><td>Complete</td><td>NCT01726738 [88]</td></tr><tr><td>BRAF + EGFR</td><td>Vemurafenib + Cetuximab</td><td>BRAFmut</td><td>II</td><td>27</td><td>4</td><td>3.7</td><td>7.1</td><td>Complete</td><td>NCT01524978 [94]</td></tr><tr><td>BRAF + EGFR</td><td>Vemurafenib + Panitumumab</td><td>BRAFmut</td><td>Pilot</td><td>15</td><td>13</td><td>3.2</td><td>7.6</td><td>Complete</td><td>NCT01791309 [89]</td></tr><tr><td>BRAF + EGFR</td><td>Encorafenib + Cetuximab</td><td>BRAFmut</td><td>II</td><td>50</td><td>22</td><td>4.2</td><td>12.4</td><td>Ongoing</td><td>NCT01719380 [90]</td></tr><tr><td>BRAF + EGFR</td><td>Dabrafenib + Panitumumab</td><td>BRAFmut</td><td>I/II</td><td>20</td><td>10</td><td>3.4</td><td>(&#8722;)</td><td>Ongoing</td><td>NCT01750918 [85]</td></tr><tr><td>BRAF + EGFR</td><td>BMS-908662 + Cetuximab</td><td>Kras mut or BRAF mut</td><td>I/II</td><td>17 *</td><td>(&#8722;)</td><td>(&#8722;)</td><td>(&#8722;)</td><td>Ongoing</td><td>NCT01086267</td></tr><tr><td>BRAF + EGFR + CT</td><td>Vemurafenib + Cetuximab + irinotecan</td><td>BRAFmut</td><td>I</td><td>12</td><td>50</td><td>(&#8722;)</td><td>(&#8722;)</td><td>Ongoing</td><td>NCT01787500</td></tr><tr><td>BRAF + EGFR + CT</td><td>Cetuximab + irinotecan &#177; Vemurafenib</td><td>BRAFmut</td><td>II (RCT)</td><td>78 *</td><td>(&#8722;)</td><td>(&#8722;)</td><td>(&#8722;)</td><td>Ongoing</td><td>NCT02164916</td></tr><tr><td>BRAF + EGFR + MEK</td><td>Dabrafenib + Panitumumab + Trametinib</td><td>BRAFmut</td><td>I/II</td><td>83</td><td>18</td><td>(&#8722;)</td><td>(&#8722;)</td><td>Ongoing</td><td>NCT01750918 [85]</td></tr><tr><td>BRAF + EGFR &#177; MEK</td><td>Encorafenib + Cetuximab &#177; Binimetinib</td><td>None</td><td>III</td><td>645 *</td><td>(&#8722;)</td><td>(&#8722;)</td><td>(&#8722;)</td><td>Ongoing</td><td>NCT02928224</td></tr><tr><td>BRAF + EGFR + PI3K</td><td>Encorafenib + Cetuximab + Alpelisib</td><td>BRAFmut</td><td>II</td><td>52</td><td>27</td><td>5.4</td><td>13.1</td><td>Ongoing</td><td>NCT01719380 [90]</td></tr><tr><td>MEK + CT</td><td>Selumetinib + irinotecan</td><td>Kras mut or BRAF mut</td><td>II</td><td>32</td><td>9</td><td>(&#8722;)</td><td>(&#8722;)</td><td>Complete</td><td>NCT01116271 [95]</td></tr><tr><td>MEK + EGFR</td><td>Binimetinib + Panitumumab</td><td>RAS wt or RAS mut</td><td>I/II</td><td>90 *</td><td>(&#8722;)</td><td>(&#8722;)</td><td>(&#8722;)</td><td>Ongoing</td><td>NCT01927341</td></tr><tr><td>MEK + EGFR</td><td>Panitumumab + Trametinib</td><td>BRAFmut</td><td>I/II</td><td>31</td><td>0</td><td>2.8</td><td></td><td>Ongoing</td><td>NCT01750918 [85]</td></tr><tr><td>MEK + EGFR</td><td>Trametinib + Panitumumab</td><td>KRAS BRAF wt</td><td>II</td><td>26 *</td><td>(&#8722;)</td><td>(&#8722;)</td><td>(&#8722;)</td><td>Ongoing</td><td>NCT02399943</td></tr><tr><td>MET + EGFR + CT</td><td>Cetuximab + irinotecan &#177; Tivantinib</td><td>KRAS wt</td><td>I/II (RCT)</td><td>60</td><td>45</td><td>8.3</td><td>19.8</td><td>Complete</td><td>NCT01075048 [96]</td></tr><tr><td>MEK + AKT</td><td>Selumetinib + MK-2206</td><td>KRAS wt or KRAS mut</td><td>II</td><td>21 *</td><td>(&#8722;)</td><td>(&#8722;)</td><td>(&#8722;)</td><td>Ongoing</td><td>NCT01333475</td></tr></table>
d75b1ad98450517634cf0cbc36463a264616d0653bda0808ef3b8710b47b018a.png
complex
<table><tr><td>Dose level</td><td>N</td><td colspan="3">Radiation therapy dose (Gy)</td><td>Dose delay due to AE</td></tr><tr><td>Level 1</td><td>3</td><td>62</td><td>62<sup>a</sup></td><td>64</td><td>1 (3 days)</td></tr><tr><td rowspan="2">Level 2</td><td>6</td><td>64</td><td>60</td><td>62</td><td rowspan="2">0</td></tr><tr><td></td><td>64</td><td>62</td><td>60</td></tr><tr><td rowspan="2">Level 3</td><td>6</td><td>60</td><td>64</td><td>62</td><td rowspan="2">1 (7 days)</td></tr><tr><td></td><td>64</td><td>60<sup>b</sup></td><td>62</td></tr></table>
649b644ef55b583177367b1f6c97850f70cd90df3e75f8b7d72485c69610723e.png
complex
<table><tr><td>Socio -demographic Characteristic</td><td>Number</td><td>%</td></tr><tr><td colspan="3">Age (in years)</td></tr><tr><td> 15&#8211;34</td><td>109</td><td>25.6</td></tr><tr><td> 25&#8211;34</td><td>166</td><td>39.1</td></tr><tr><td> 35&#8211;44</td><td>150</td><td>35.3</td></tr><tr><td colspan="3">Ethnicity</td></tr><tr><td> Sinhalese</td><td>256</td><td>60.2</td></tr><tr><td> Tamils</td><td>83</td><td>19.5</td></tr><tr><td> Muslims</td><td>80</td><td>18.9</td></tr><tr><td> Burgher &amp; others</td><td>6</td><td>1.4</td></tr><tr><td colspan="3">Religion</td></tr><tr><td> Buddhism</td><td>244</td><td>57.4</td></tr><tr><td> Hindu</td><td>72</td><td>16.9</td></tr><tr><td> Islam</td><td>78</td><td>18.4</td></tr><tr><td> Christianity</td><td>31</td><td>7.3</td></tr><tr><td colspan="3">Current marital Status</td></tr><tr><td> Currently Married</td><td>286</td><td>67.3</td></tr><tr><td> Never Married</td><td>98</td><td>23.1</td></tr><tr><td> Widowed</td><td>24</td><td>5.6</td></tr><tr><td> Divorced/ Separated</td><td>17</td><td>4.0</td></tr><tr><td colspan="3">Highest level of Education</td></tr><tr><td> Never went to school</td><td>48</td><td>11.3</td></tr><tr><td> Primary education</td><td>197</td><td>46.3</td></tr><tr><td> Secondary education or higher</td><td>180</td><td>42.4</td></tr><tr><td colspan="3">Daily family income (in USD)</td></tr><tr><td> Less than 2.4 USD (poor income)</td><td>73</td><td>17.2</td></tr><tr><td> 2.5&#8211;12 USD (low income)</td><td>348</td><td>81.9</td></tr><tr><td> More than 12 USD (middle income)</td><td>4</td><td>0.9</td></tr><tr><td colspan="3">Employment status</td></tr><tr><td> Employed</td><td>224</td><td>52.7</td></tr><tr><td> Unemployed</td><td>201</td><td>47.3</td></tr><tr><td colspan="3">Employment Category (<i>n</i> = 224)</td></tr><tr><td> Professionals</td><td>14</td><td>6.3</td></tr><tr><td> Clerical and sales workers</td><td>34</td><td>15.1</td></tr><tr><td> Elementary occupations</td><td>113</td><td>50.5</td></tr><tr><td> Others</td><td>63</td><td>28.1</td></tr><tr><td colspan="3">Social status</td></tr><tr><td> High social status</td><td>106</td><td>24.9</td></tr><tr><td> Low social status</td><td>319</td><td>75.1</td></tr></table>
70215ebb30461f997317514999302a51e0ea3232e52a013ecb3998522f8416a0.png
simple
<table><tr><td>IR score</td><td>A II(<i>n</i> = 6)</td><td>A III(<i>n</i> = 12)</td><td>GBM (<i>n</i> = 55 )</td><td>Control cortex/autopsy (<i>n</i> = 8)</td><td>Control cortex/surgical (<i>n</i> = 5)</td></tr><tr><td>Kir4.1</td><td>3.6 &#177; 0.85*</td><td>7.18 &#177; 0.41</td><td>5.5 &#177; 0.30</td><td>7.13 &#177; 0.36</td><td>7.03 &#177; 0.26</td></tr><tr><td>IL-1&#946;</td><td>2.46 &#177; 0.67*</td><td>3.9 &#177; 0.9*</td><td>3.75 &#177; 0.45*</td><td>0</td><td>0.02 &#177; 0.02</td></tr><tr><td>HLA-DR</td><td>5.4 &#177; 0.77*</td><td>5.7 &#177; 0.80*</td><td>5.83 &#177; 0.35*</td><td>0.04 &#177; 0.02</td><td>0.03 &#177; 0.02</td></tr></table>
f60d1856027ab837337768cf7760f611689919354b83dfe0d073cd116bd7acd0.png
complex
<table><tr><td>Category</td><td>Characteristic</td><td>Comparison</td><td>Pre-campaign</td><td>Mid-campaign</td><td>Post-campaign</td></tr><tr><td rowspan="5">Demographics</td><td rowspan="4">Child&#8217;s age (months)</td><td>12&#8211;23 vs. 0&#8211;11</td><td>1.40 (0.98, 2.01)</td><td>1.13 (0.50, 2.57)</td><td>1.07 (0.63, 1.81)</td></tr><tr><td>24&#8211;35 vs. 0&#8211;11</td><td>1.30 (0.89, 1.89)</td><td>0.60 (0.24, 1.50)</td><td>1.25 (0.72, 2.18)</td></tr><tr><td>36&#8211;47 vs. 0&#8211;11</td><td>1.20 (0.83, 1.74)</td><td>1.25 (0.56, 2.79)</td><td>1.64 (0.95, 2.82)</td></tr><tr><td>48&#8211;59 vs. 0&#8211;11</td><td>1.36 (0.94, 1.95)</td><td>0.43 (0.18, 1.06)</td><td>1.42 (0.85, 2.39)</td></tr><tr><td>Child&#8217;s sex</td><td>Male vs. female</td><td>0.92 (0.73, 1.16)</td><td>1.10 (0.63, 1.91)</td><td>1.04 (0.74, 1.47)</td></tr><tr><td rowspan="4">Housing construction and utilities</td><td>Primary residential building material</td><td>Concrete blocks vs. mud blocks or mud/sticks</td><td>1.05 (0.79, 1.39)</td><td><i>1.84 (1.01</i>, <i>3.36)</i></td><td>0.82 (0.57, 1.18)</td></tr><tr><td>Primary residential flooring material</td><td>Concrete or tile vs. mud</td><td>0.85 (0.64, 1.13)</td><td>0.90 (0.40, 2.04)</td><td>0.67 (0.33, 1.35)</td></tr><tr><td>Electricity in the home</td><td>Yes vs. no</td><td>0.94 (0.72, 1.23)</td><td>2.65 (0.87, 8.13)</td><td><i>0.53 (0.36</i>, <i>0.79)</i></td></tr><tr><td>Approximate distance from drinking water source in meters</td><td>&lt;50 m vs. &#8805;50</td><td>1.01 (0.79, 1.31)</td><td>0.93 (0.51, 1.70)</td><td><i>1.51 (1.05</i>, <i>2.17)</i></td></tr><tr><td rowspan="3">Household health behaviour</td><td>Household treats drinking water with chemicals or filters it</td><td>Yes vs. no</td><td><i>1.71 (1.30</i>, <i>2.25)</i></td><td>1.09 (0.40, 3.00)</td><td>0.64 (0.32, 1.31)</td></tr><tr><td>Child reported to have had measles vaccine</td><td>Yes vs. no</td><td>1.12 (0.75, 1.67)</td><td>0.87 (0.28, 2.86)</td><td><i>5.67 (2.68</i>, <i>11.99)</i></td></tr><tr><td>Child&#8217;s birthplace</td><td>Healthcare facility vs. home</td><td><i>1.34 (1.03</i>, <i>1.72)</i></td><td>1.34 (0.52, 3.46)</td><td><i>0.47 (0.22</i>, <i>0.97)</i></td></tr></table>
c8a7f765f58aa63e6e95b4d899b98a3ccf0541ebc2fe12411088310fdacb2db1.png
simple
<table><tr><td>Assay</td><td></td><td>Primer Sequence 5&#8217;-3&#8217;</td></tr><tr><td><underline>Pyrosequencing</underline></td><td></td><td></td></tr><tr><td>Assay 1 (20 CpGs)</td><td>Forward</td><td>GGATGTGGGGATTTTTTTTTTTTAGTATAG</td></tr><tr><td></td><td>Reverse</td><td>Biotin-ACTTCAACCCCTCCCCCAAAA</td></tr><tr><td></td><td>Sequencing </td><td>TTTTTTAGTATAGTAAAGTTGGT</td></tr><tr><td>Assay 2 (12 CpGs) </td><td>Forward</td><td>TTTCGGGTTTTATAGTTTTTGTATTTAGGT</td></tr><tr><td></td><td>Reverse</td><td>Biotin-ACTCCCGCAACTCAATAAACTCAAACTC</td></tr><tr><td></td><td>Sequencing </td><td>TTTAGTAGTTTAGTTTGGATTTTGG</td></tr><tr><td>MOAP1 </td><td>Forward</td><td>GAGTGTTAGTTAGAGTTTAGGGGAGTTT</td></tr><tr><td></td><td>Reverse</td><td>Biotin-CTCACCCCTCCCAACCCT</td></tr><tr><td></td><td>Sequencing </td><td>AGGGGAGTTTGTTTT</td></tr><tr><td><underline>qRT-PCR</underline></td><td></td><td></td></tr><tr><td>GAPDH </td><td>Forward</td><td>CATGACAACTTTGGTATCGTG</td></tr><tr><td></td><td>Reverse</td><td>GTGTCGCTGTTGAAGTCAGA</td></tr><tr><td>RASSF1a</td><td>Forward</td><td>CCTCTGTGGCGACTTCATCTG</td></tr><tr><td></td><td>Reverse</td><td>CAACAGTCCAGGCAGACGAG</td></tr><tr><td>MOAP-1</td><td>Forward</td><td>CTCAATTGCTCCTCTCTGTACC</td></tr><tr><td></td><td>Reverse</td><td>CATGACAACTTTGGTATCGTG</td></tr><tr><td>RASSF1c</td><td>Forward</td><td>GCTACTGCAGCCAAGAGGAC</td></tr><tr><td></td><td>Reverse</td><td>AGGTGTCTCCCACTCCACAG</td></tr><tr><td>PPIA</td><td>Forward</td><td>GCCGAGGAAAACCGTGTACT</td></tr><tr><td></td><td>Reverse</td><td>TGTCTGCAAACAGCTCAAAGG</td></tr></table>
f2992c4fd7adbcbfdc4390f5ffdadc88c7807d5f4aba8fd45ab3bb351aa5ff8a.png
complex
<table><tr><td rowspan="2">Riparian metric</td><td colspan="2">Mean annual rainfall</td><td colspan="2">Mean annual temperature</td><td colspan="2">Bank height</td><td colspan="2">Proportion of clay</td></tr><tr><td>Estimate</td><td>SE</td><td>Estimate</td><td>SE</td><td>Estimate</td><td>SE</td><td>Estimate</td><td>SE</td></tr><tr><td>SPECIES RICHNESS</td><td>0.0347***</td><td>0.009</td><td>0.0238**</td><td>0.0085</td><td>&#8722;0.0178</td><td>0.009</td><td></td><td></td></tr><tr><td>ABUNDANCE</td><td>12.933**</td><td>3.824</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>NATIVE REGEN</td><td>13.904***</td><td>3.314</td><td>6.708**</td><td>3.824</td><td></td><td></td><td></td><td></td></tr><tr><td>BASAL AREA</td><td>0.631*</td><td>0.299</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>SPECIES RICHNESS NS</td><td>0.047***</td><td>0.012</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>NATIVE REGEN NS</td><td>10.207*</td><td>4.020</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>BASAL AREA NS</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.199**</td><td>0.068</td></tr></table>
b38362e8f00e7a8fca3904814cf986a595233c65b5f6d8fbce48544490e49b80.png
simple
<table><tr><td> </td><td><i>O. scapulalis</i></td><td><i>O. nubilalis</i></td></tr><tr><td>Raw short sequence number</td><td>322,504</td><td>307,622</td></tr><tr><td>Number after filtering</td><td>287,429</td><td>272,490</td></tr><tr><td>Mean read length (bp)</td><td>352</td><td>356</td></tr><tr><td>Number of singletons</td><td>85,070</td><td>87,110</td></tr><tr><td>Number of assembled reads</td><td>145,588</td><td>130,897</td></tr><tr><td>Assembled transcriptome (Mbp)</td><td>10.35</td><td>9.52</td></tr><tr><td>Reads/bp</td><td>9.8</td><td>10.2</td></tr><tr><td>Number of unigenes</td><td>8,892</td><td>8,656</td></tr><tr><td>Number of transcripts (including alternative transcripts)</td><td>11,231</td><td>10,773</td></tr><tr><td>Transcript mean length (bp)</td><td>922</td><td>883</td></tr><tr><td>Transcript median length (bp)</td><td>693</td><td>685</td></tr><tr><td>Transcript N50 length (bp)</td><td>1,036</td><td>991</td></tr><tr><td>Mean exon count per transcript</td><td>1.54</td><td>1.49</td></tr><tr><td>Mean exon* length (bp)</td><td>604</td><td>605</td></tr><tr><td>Median exon length (bp)</td><td>500</td><td>495</td></tr></table>
5864106145a6b3a4e7bd6fc5595e3bd1ed87c1f032026b83c242566896faaabf.png
simple
<table><tr><td></td><td>Total</td><td>Men</td><td>Women</td></tr><tr><td>Camp (n = 538)</td><td>37.8%</td><td>42.7%</td><td>34%</td></tr><tr><td>Somali (n = 248)</td><td>48.1%</td><td>48.1%</td><td>48.1%</td></tr><tr><td>Rwandese (n = 290)</td><td>32%</td><td>38.9%</td><td>27.3%</td></tr></table>
3b870d997043e73b6ff0f08b396ef40c8f7ea4e642bc90964308f8d8ae879485.png
simple
<table><tr><td>Study [reference]: countries</td><td>Population</td><td><i>n</i></td><td>Efficacy</td><td>Lower bound of 95% CI</td><td>Adherence<sup>a</sup></td></tr><tr><td>Partners PrEP [8]: Kenya, Uganda</td><td>Heterosexual couples</td><td>4758</td><td>67% TDF; 75% TDF/FTC</td><td>44% TDF; 55% TDF/FTC</td><td>82%</td></tr><tr><td>TDF2 Study [9]: Botswana</td><td>Young men and women</td><td>1219</td><td>62% TDF/FTC</td><td>21.5%</td><td>80%</td></tr><tr><td>Bangkok TDF [12]: Thailand</td><td>IVDU</td><td>2413</td><td>49% TDF</td><td>9.6%</td><td>67%</td></tr><tr><td>iPrEx [7]: S. America, SA, Thailand, USA</td><td>MSM</td><td>2499</td><td>44% TDF/FTC</td><td>15%</td><td>51%</td></tr><tr><td>FEM-PrEP [10]: Kenya, SA, Tanzania</td><td>Young women</td><td>2120</td><td>6% TDF/FTC</td><td>&#8722;52%</td><td>37%</td></tr><tr><td>VOICE [11]: South Africa, Uganda, Zimbabwe</td><td>Young women</td><td>5029</td><td>&#8722;49% TDF; - 4% TDF/FTC</td><td>&#8722;130% TDF; &#8722;50% TDF/FTC</td><td>30%</td></tr></table>
43164acbcdc1eaea0bce6c68dee39db720b6cf7a8fa5adbe283a5c989b465cbf.png
simple
<table><tr><td>Risk factor</td><td>Crude OR</td><td>Adjusted OR<sup>a</sup></td></tr><tr><td>Own preterm birth<sup>b</sup></td><td>2.10 (1.27&#8211;3.48)</td><td>2.32 (1.34&#8211;4.03)</td></tr><tr><td>PCOS</td><td>1.44 (1.05&#8211;1.97)</td><td>1.07 (0.74&#8211;1.54)</td></tr><tr><td>BMI &#8805;25 kg/m<sup>2</sup></td><td>4.87 (4.07&#8211;5.84)</td><td>4.22 (3.44&#8211;5.18)</td></tr><tr><td>BMI &#8805;30 kg/m<sup>2</sup></td><td>5.47 (4.26&#8211;7.02)</td><td>5.14 (3.87&#8211;6.83)</td></tr><tr><td>Age &#8805;35 years</td><td>2.34 (1.90&#8211;2.88)</td><td>2.58 (1.98&#8211;3.38)</td></tr><tr><td>Participant&#8217;s mother&#8217;s GDM</td><td>2.43 (1.62&#8211;3.65)</td><td>3.05 (1.93&#8211;4.82)</td></tr><tr><td>Participant&#8217;s mother&#8217;s T2D</td><td>2.64 (1.92&#8211;3.62)</td><td>1.85 (1.30&#8211;2.64)</td></tr><tr><td>Participant&#8217;s father&#8217;s T2D</td><td>1.77 (1.37&#8211;2.28)</td><td>1.37 (1.03&#8211;1.83)</td></tr></table>
fe32d5b4520c05a7372ae28165da66dea1875d8218a24a0d3f03432cada3766a.png
simple
<table><tr><td></td><td>PANSS positive subscale score</td><td>PANSS negative subscale score</td><td>PANSS general psychopathology subscale score</td><td>PANSS total score</td></tr><tr><td>Serum S100B level changes</td><td>r=0.3P=0.2</td><td>r=-0.048P=0.8</td><td>r=0.05P=0.8</td><td>r=0.06P=0.7</td></tr><tr><td>Leptin (microg/ml)</td><td>r=-0.3P=0.1</td><td>r=-0.023P=0.9</td><td>r=-0.2P=0.2</td><td>r=-0.3P=0.1</td></tr></table>
d13c93a35fe94e97dfcdc48233d9d8151d4800b18130111fcaad49549a893577.png
complex
<table><tr><td>SH3 domain</td><td>k<sub>a </sub>(M<sup>-1</sup>s<sup>-1</sup>) &#215; 10<sup>5</sup></td><td>k<sub>d </sub>(s<sup>-1</sup>) &#215; 10<sup>-2</sup></td><td>K<sub>D </sub>(&#956;M)</td><td>Nef concentrations (&#956;M)</td></tr><tr><td colspan="5">Nef-SF2</td></tr><tr><td>Human Hck SH3</td><td>1.60 &#177; 0.06</td><td>1.18 &#177; 0.04</td><td>0.07 &#177; 0.01</td><td>0, 0.007, 0.02, 0.062, 0.19, 0.56, 1.67, 5.0</td></tr><tr><td>Mouse Hck SH3</td><td>5.54 &#177; 1.77</td><td>7.00 &#177; 0.36</td><td>0.13 &#177; 0.03</td><td>0, 0.007, 0.02, 0.062, 0.19, 0.56, 1.67</td></tr><tr><td>Mouse Hck HART</td><td>14.20 &#177; 1.40</td><td>1.43 &#177; 0.01</td><td>0.01 &#177; 0.00</td><td>0, 0.002, 0.007, 0.02, 0.062, 0.19</td></tr><tr><td colspan="5">Nef-Consensus*</td></tr><tr><td>Human Hck SH3</td><td>10.00 &#177; 0.80</td><td>11.80 &#177; 0.20</td><td>0.12 &#177; 0.01</td><td>0, 0.02, 0.062, 0.19, 0.56, 1.67, 5.0</td></tr><tr><td>Mouse Hck SH3</td><td>2.41 &#177; 0.05</td><td>1.85 &#177; 0.11</td><td>0.08 &#177; 0.01</td><td>0, 0.007, 0.02, 0.062, 0.19, 0.56, 1.67</td></tr><tr><td>Mouse Hck HART</td><td>15.70 &#177; 0.20</td><td>3.24 &#177; 0.16</td><td>0.02 &#177; 0.00</td><td>0, 0.002, 0.007, 0.02, 0.062, 0.19, 0.56</td></tr></table>
7815e9c50c65dd5ac8ed5848194f01a1a18bb86e191597929d0ac41dd780d156.png
complex
<table><tr><td></td><td colspan="2">Run 1</td><td colspan="2">Run 2</td><td colspan="2">Summary</td></tr><tr><td>HRM</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td> Number of samples</td><td>120</td><td>100.0</td><td>20</td><td>100.0 (16.7)</td><td>120</td><td>100.0</td></tr><tr><td> Analysis passed</td><td>89</td><td>74.2</td><td>18</td><td>90.0</td><td>105</td><td>87.5</td></tr><tr><td>WT (total)</td><td>60</td><td>67.4</td><td>12</td><td>66.7</td><td>71</td><td>67.6</td></tr><tr><td>WT (skewed HRM curve)</td><td>3</td><td>5.0</td><td>2</td><td>16.7</td><td>4</td><td>5.6</td></tr><tr><td>Mutant (total)</td><td>29</td><td>32.6</td><td>6</td><td>33.3</td><td>34</td><td>32.4</td></tr><tr><td>Mutant (skewed HRM curve)</td><td>1</td><td>3.4</td><td>1</td><td>16.7</td><td>1</td><td>2.9</td></tr><tr><td> Analysis failed</td><td>31</td><td>25.8</td><td>2</td><td>10.0</td><td></td><td></td></tr><tr><td>Pyrosequencing</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td> Number of samples</td><td>19</td><td>100.0 (15.8)</td><td>3</td><td>100.0 (2.5)</td><td>19</td><td>100.0</td></tr><tr><td> Analysis passed</td><td>18</td><td>94.7</td><td>2</td><td>66.7</td><td>18</td><td>94.7</td></tr><tr><td>WT</td><td>12</td><td>66.7</td><td>0</td><td>0.0</td><td>13</td><td>72.2</td></tr><tr><td>Potential low level mutation</td><td>2</td><td>11.1</td><td>1</td><td>50.0</td><td>0</td><td>0.0</td></tr><tr><td>Mutant</td><td>4</td><td>22.2</td><td>1</td><td>50.0</td><td>5</td><td>27.8</td></tr><tr><td> Analysis failed</td><td>1</td><td>5.3</td><td>1</td><td>33.3</td><td>1</td><td></td></tr><tr><td>Combined HRM + Pyrosequencing</td><td></td><td></td><td></td><td></td><td>n</td><td>%</td></tr><tr><td> Number of samples</td><td></td><td></td><td></td><td></td><td>120</td><td>100.0</td></tr><tr><td> Number of HRM runs</td><td></td><td></td><td></td><td></td><td>140</td><td>116.7</td></tr><tr><td> Number of pyrosequencing runs</td><td></td><td></td><td></td><td></td><td>22</td><td>18.3</td></tr><tr><td> Analysis passed</td><td></td><td></td><td></td><td></td><td>119</td><td>99.2</td></tr><tr><td> WT</td><td></td><td></td><td></td><td></td><td>81</td><td>68.1</td></tr><tr><td> Mutant</td><td></td><td></td><td></td><td></td><td>38</td><td>31.9</td></tr><tr><td> Analysis failed</td><td></td><td></td><td></td><td></td><td>1</td><td>0.8</td></tr></table>
c6dea827be254382b331763c1a9b420262784d5db6fa347f5f68a583869b54d2.png
simple
<table><tr><td>URL structure</td><td>Get</td><td>Post</td><td>Delete</td></tr><tr><td>/namespace/object_type/</td><td>List objects, apply filters</td><td>Create new object or make bulk update</td><td>Bulk delete</td></tr><tr><td>/namespace/object_type/id/</td><td>Access single object</td><td>Update single object</td><td>Delete single object</td></tr><tr><td>/namespace/object_type/id/acl/</td><td>Get object permissions</td><td>Update object permissions</td><td>405 Not Supported</td></tr></table>
604cd5b58c8272c6f7b1234160448daf00e4b6629db172f3d907e332216e6b34.png
complex
<table><tr><td rowspan="2">Parameters</td><td colspan="4">Groups</td><td colspan="3"><i>p</i>values</td></tr><tr><td>Control</td><td>Control + Ucche</td><td>CCl<sub>4</sub></td><td>CCl<sub>4</sub> + Ucche</td><td>CCl<sub>4</sub></td><td>Treatment</td><td>Interaction</td></tr><tr><td colspan="5">Plasma</td><td></td><td></td><td></td></tr><tr><td>AST(U/L)</td><td>19.0 &#177; 1.6</td><td>21.32 &#177; 1.68</td><td>37.9 &#177; 3.1</td><td>23.3 &#177; 4.0</td><td>0.0374</td><td>0.0012</td><td>0.0062</td></tr><tr><td>ALT(U/L)</td><td>13.8 &#177; 1.7</td><td>16.59 &#177; 2.62</td><td>30.5 &#177; 3.1</td><td>18.7 &#177; 1.9</td><td>0.0831</td><td>0.0012</td><td>0.0082</td></tr><tr><td>ALP(U/L)</td><td>50.8 &#177; 3.3</td><td>50.92 &#177; 2.76</td><td>81.2 &#177; 6.1</td><td>63.9 &#177; 4.7</td><td>0.0731</td><td>0.0001</td><td>0.0690</td></tr><tr><td>MDA(nmol/mL)</td><td>6.34 &#177; 0.37</td><td>3.57 &#177; 0.54</td><td>7.7 &#177; 0.91</td><td>6.71 &#177; 0.77</td><td>0.0731</td><td>0.0001</td><td>0.0690</td></tr><tr><td>NO (nmol/mL)</td><td>3.22 &#177; 0.27</td><td>2.24 &#177; 0.22</td><td>5.8 &#177; 0.3</td><td>1.15 &#177; 0.32</td><td>&lt;0.0001</td><td>0.0195</td><td>&lt;0.0001</td></tr><tr><td>APOP (nmol/mL equivalent to Chloramine-T)</td><td>82.60 &#177; 8.49</td><td>67.0 &#177; 9.2</td><td>164.4 &#177; 15.15</td><td>84.3 &#177; 8.8</td><td>0.0340</td><td>0.0102</td><td>0.3072</td></tr><tr><td>Catalase (U/min)</td><td>6.00 &#177; 0.32</td><td>4.28 &#177; 0.38</td><td>2.93 &#177; 0.60</td><td>5.07 &#177; 0.74</td><td>0.6960</td><td>0.0343</td><td>0.0011</td></tr><tr><td>GSH (ng/mg protein)</td><td>20.05 &#177; 1.81</td><td>18.39 &#177; 1.03</td><td>12.72 &#177; 0.57</td><td>16.39 &#177; 0.57</td><td>0.3788</td><td>0.0005</td><td>0.0270</td></tr><tr><td colspan="5">Liver</td><td></td><td></td><td></td></tr><tr><td>AST(U/L)</td><td>36.18 &#177; 3.22</td><td>31.01 &#177; 3.46</td><td>65.18 &#177; 3.87</td><td>46.51 &#177; 2.11</td><td>0.0023</td><td>&lt;0.0001</td><td>0.0594</td></tr><tr><td>ALT(U/L)</td><td>26.00 &#177; 3.88</td><td>34.67 &#177; 2.24</td><td>77.61 &#177; 4.80</td><td>28.77 &#177; 1.49</td><td>&lt;0.0001</td><td>&lt;0.0001</td><td>&lt;0.0001</td></tr><tr><td>ALP(U/L)</td><td>30.33 &#177; 3.67</td><td>31.42 &#177; 3.54</td><td>113.53 &#177; 3.71</td><td>68.25 &#177; 3.67</td><td>&lt;0.0001</td><td>&lt;0.0001</td><td>&lt;0.0001</td></tr><tr><td>NO (nmol/mL)</td><td>15.87 &#177; 1.56</td><td>20.21 &#177; 0.45</td><td>35.62 &#177; 4.21</td><td>18.11 &#177; 2.17</td><td>0.0225</td><td>0.0036</td><td>0.0006</td></tr><tr><td>MDA (nmol/mL)</td><td>21.85 &#177; 1.86</td><td>24.62 &#177; 4.88</td><td>57.16 &#177; 6.44</td><td>36.92 &#177; 1.98</td><td>0.0741</td><td>&lt;0.0001</td><td>0.0226</td></tr><tr><td>APOP (nmol/mL equivalent to Chloramine-T)</td><td>365.00 &#177; 40.19</td><td>450.0 &#177; 75.83</td><td>1357.62 &#177; 91.06</td><td>977.50 &#177; 63.05</td><td>0.0491</td><td>&lt; 0.0001</td><td>0.0097</td></tr><tr><td>Catalase (U/min)</td><td>52.13 &#177; 4.02</td><td>68.40 &#177; 5.92</td><td>26.32 &#177; 3.82</td><td>50.27 &#177; 2.33</td><td>0.0003</td><td>&lt; 0.0001</td><td>0.3967</td></tr><tr><td>GSH (ng/mg protein)</td><td>21.22 &#177; 1.91</td><td>19.22 &#177; 1.13</td><td>45.98 &#177; 5.05</td><td>32.89 &#177; 1.79</td><td>0.0171</td><td>&lt; 0.0001</td><td>0.0703</td></tr></table>
33e2b7381836411134d88f74b58592624a6371ad295a8e4ac6d4ed8f0d0e73da.png
complex
<table><tr><td rowspan="2"></td><td></td><td>Gender</td><td></td></tr><tr><td>Female</td><td>Male</td><td>Total</td></tr><tr><td colspan="4">Need for treatment</td></tr><tr><td> Discussed and confirmed<sup>a</sup></td><td>17</td><td>36</td><td>53</td></tr><tr><td> Discussed, not confirmed</td><td>0</td><td>0</td><td>0</td></tr><tr><td> Not mentioned</td><td>1</td><td>0</td><td>1</td></tr><tr><td colspan="4">Danger to self</td></tr><tr><td> Discussed and confirmed</td><td>2</td><td>2</td><td>4</td></tr><tr><td> Discussed, not confirmed</td><td>2</td><td>5</td><td>7</td></tr><tr><td> Not mentioned</td><td>14</td><td>29</td><td>43</td></tr><tr><td colspan="4">Danger to others</td></tr><tr><td> Discussed and confirmed</td><td>0</td><td>3</td><td>3</td></tr><tr><td> Discussed, not confirmed</td><td>3</td><td>2</td><td>5</td></tr><tr><td> Not mentioned</td><td>15</td><td>31</td><td>46</td></tr><tr><td colspan="4">Voluntary care unrealistic</td></tr><tr><td> Discussed and confirmed</td><td>5</td><td>5</td><td>10</td></tr><tr><td> Discussed, not confirmed</td><td>0</td><td>2</td><td>2</td></tr><tr><td> Not mentioned</td><td>13</td><td>29</td><td>42</td></tr><tr><td colspan="4">Substance abuse</td></tr><tr><td> Discussed and confirmed</td><td>0</td><td>8</td><td>8</td></tr><tr><td> Discussed, not confirmed</td><td>6</td><td>10</td><td>16</td></tr><tr><td> Not mentioned</td><td>12</td><td>18</td><td>30</td></tr></table>
f5a7b7a517417ce42b722aa065721d4aa28aa9072e24423f4be68e3a6344c32e.png
complex
<table><tr><td colspan="2">RTI/STI symptomatic currently or within last 3 months</td><td>n = 353</td><td>%</td></tr><tr><td>Sought care for RTI/STI symptoms</td><td></td><td></td><td></td></tr><tr><td> Yes</td><td></td><td>238</td><td>67.4</td></tr><tr><td> No</td><td></td><td>115</td><td>32.6</td></tr><tr><td>Time delay until seeking care (days)</td><td>(n = 238)</td><td></td><td></td></tr><tr><td> Mean: 10.2</td><td>(range: 2-60)</td><td></td><td></td></tr><tr><td> &lt; 7</td><td></td><td>137</td><td>57.6</td></tr><tr><td> 7-14</td><td></td><td>55</td><td>23.1</td></tr><tr><td> &gt; 15</td><td></td><td>46</td><td>19.3</td></tr><tr><td>Source of RTI/STI treatment the last time</td><td>(n = 238)</td><td></td><td></td></tr><tr><td> Drop-in centre</td><td></td><td>126</td><td>52.9</td></tr><tr><td> Public hospital</td><td></td><td>56</td><td>23.5</td></tr><tr><td> Private clinic</td><td></td><td>29</td><td>12.2</td></tr><tr><td> Pharmacy/drugstore</td><td></td><td>22</td><td>9.2</td></tr><tr><td> Herbalist</td><td></td><td>5</td><td>2.1</td></tr></table>
b33293758f8d7871b7694dcb800e9b75c904426bc0a9827d35af13c66313490b.png
simple
<table><tr><td>Compound</td><td>IC<sub>50</sub> [&#956;M]</td><td>log P</td></tr><tr><td>2a</td><td>&#8805;100</td><td>3.32</td></tr><tr><td>2b</td><td>58</td><td>3.48</td></tr><tr><td>2c</td><td>&#8805;100</td><td>3.88</td></tr><tr><td>2d</td><td>&#8805;100</td><td>3.81</td></tr><tr><td>3a</td><td>49</td><td>3.89</td></tr><tr><td>3b</td><td>63</td><td>3.48</td></tr><tr><td>3d</td><td>103</td><td>4.38</td></tr><tr><td>4</td><td>&gt;1000</td><td>4.28</td></tr><tr><td>5</td><td>&#8805;100</td><td>4.74</td></tr><tr><td>cisplatin</td><td>5</td><td></td></tr></table>
5b4a815eb52c7d71ed6298ee568235340a7827618c35ec6a7d59561b07fc091f.png
simple
<table><tr><td> </td><td>LBD alone (<i>n</i> = 62)</td><td>EST plus LBD (<i>n</i> = 69)</td><td><i>P </i>value</td></tr><tr><td>Diameter of inflated balloon (mm)</td><td>15.9 &#177; 2.3 (12-20)</td><td>16.2 &#177; 2.5 (12-20)</td><td>0.444</td></tr><tr><td>Complete stone removal irrespective of whether ML was used, no. (%)</td><td>60 (96.8)</td><td>66 (95.7)</td><td>0.738</td></tr><tr><td>Complete stone removal without ML, no. (%)</td><td>50 (80.6)</td><td>51 (73.9)</td><td>0.360</td></tr></table>
907b22656c1991f098faf8a4ce2099836189cd9db54fd1a51b53775ee926caa1.png
simple
<table><tr><td>Disease class</td><td>Nt</td><td>Nur</td><td>F<sub>IC</sub></td></tr><tr><td>Gastrointestinal</td><td>17</td><td>145</td><td>0.88</td></tr><tr><td>Respiratory</td><td>5</td><td>15</td><td>0.71</td></tr><tr><td>Wound healing</td><td>2</td><td>3</td><td>0.50</td></tr><tr><td>Dermatological</td><td>1</td><td>2</td><td>1.00</td></tr><tr><td>Kidney problems</td><td>2</td><td>4</td><td>0.66</td></tr><tr><td>Blood diseases</td><td>4</td><td>10</td><td>0.66</td></tr><tr><td>Cardiovascular</td><td>1</td><td>3</td><td>1.00</td></tr><tr><td>Inflammations</td><td>1</td><td>1</td><td>1.00</td></tr><tr><td>Hepatic problems</td><td>2</td><td>5</td><td>0.75</td></tr><tr><td>General pain</td><td>3</td><td>6</td><td>0.60</td></tr><tr><td>Fever</td><td>1</td><td>3</td><td>1.00</td></tr><tr><td>Dental</td><td>1</td><td>3</td><td>1.00</td></tr></table>
3172a15af89116a592dc0f927ef943af8afd74f658da1ebeec33374911710b25.png
simple
<table><tr><td>Phenotype</td><td>n</td><td>CaseAverageRelatedness</td><td>MeanControlAverageRelatedness</td><td>Empiricalp-valueGIF</td><td>Empiricalp-valueDistantGIF</td></tr><tr><td>CFS</td><td>811</td><td>3.15</td><td>2.31</td><td>&lt; 0.001</td><td>0.010</td></tr></table>
054d70103d536544e30fc98e71598062247069f890796dd5e2c02190180919cd.png
simple
<table><tr><td>Variable</td><td>1<sup>st</sup> quarterN (%)</td><td>2<sup>nd</sup> quarterN (%)</td><td>3<sup>rd</sup> quarter(N%)</td><td>4<sup>th</sup> quarter(N%)</td><td>TotalN (%)</td><td>P value</td></tr><tr><td>Age(years)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>&#8804; 15</td><td>200 (12.3)</td><td>201 (12.9)</td><td>275 (17.5)</td><td>150 (11.9)</td><td>826 (13.7)</td><td>&lt; 0.001</td></tr><tr><td>16 - 30</td><td>661 (40.6)</td><td>605 (38.9)</td><td>582 (37.1)</td><td>525 (41.8)</td><td>2,373 (39.5)</td><td></td></tr><tr><td>31 - 45</td><td>407 (25.0)</td><td>363 (23.3)</td><td>327 (20.9)</td><td>270 (21.5)</td><td>1,367 (22.8)</td><td></td></tr><tr><td>46 - 60</td><td>198 (12.1)</td><td>223 (14.3)</td><td>228 (14.6)</td><td>191 (15.2)</td><td>840 (14.0)</td><td></td></tr><tr><td>&#8805; 60</td><td>164 (10.1)</td><td>163 (10.5)</td><td>155 (9.9)</td><td>120 (9.6)</td><td>602 (10.0)</td><td></td></tr><tr><td>Total</td><td>1,630 (100.0)</td><td>1,555 (100.0)</td><td>1,567 (100.0)</td><td>1,256 (100.0)</td><td>6,008 (100.0)</td><td></td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Male</td><td>737 (45.2)</td><td>691 (44.4)</td><td>687 (43.8)</td><td>549 (43.9)</td><td>2,664 (44.3)</td><td>0.83</td></tr><tr><td>Female</td><td>893 (54.8)</td><td>864 (55.6)</td><td>880 (56.2)</td><td>707 (56.1)</td><td>3,344 (55.7)</td><td></td></tr><tr><td>Total</td><td>1,630 (100.0)</td><td>1,555 (100.0)</td><td>1567(100.0)</td><td>1,256 (100.0)</td><td>6,008 (100.0)</td><td></td></tr><tr><td>Occupation</td><td></td><td></td><td></td><td></td><td></td><td>0.03</td></tr><tr><td>Students</td><td>642 (39.4)</td><td>613 (39.4)</td><td>679 (43.3)</td><td>516 (41.1)</td><td>2,450 (40.8)</td><td></td></tr><tr><td>Civil servants</td><td>331 (20.3)</td><td>321 (20. 6)</td><td>327 (20.9)</td><td>258 (20. 5)</td><td>1,237 (20. 6)</td><td></td></tr><tr><td>Private workers</td><td>466 (28.6)</td><td>413 (26.6)</td><td>395 (25.2)</td><td>303 (24.1)</td><td>1,577 (26.2)</td><td></td></tr><tr><td>Unemployed</td><td>164 (10.1)</td><td>187 (12.0)</td><td>151 (9.6)</td><td>11 (12.8)</td><td>663 (11.0)</td><td></td></tr><tr><td>Clergymen</td><td>27 (1.7)</td><td>21 (1.4)</td><td>15 (1.0)</td><td>18 (1.4)</td><td>81 (1.3)</td><td></td></tr><tr><td>Total</td><td>1,630 (100.0)</td><td>1,555 (100.0)</td><td>1,567 (100.0)</td><td>1,256 (100.0)</td><td>6,008 (100.0)</td><td></td></tr></table>
be1adb1b4f443ce4cfed8fe1d683ab9253f58aa4d0e3e2c73444658f468b7fd6.png
simple
<table><tr><td> </td><td> </td><td> </td><td>Normal PI</td><td>Low PI</td></tr><tr><td>Restricted growth parameters</td><td>Subclass of SGA</td><td>N</td><td>no (%)</td><td>no (%)</td></tr><tr><td>Weight, length and OFC</td><td>Symmetrical</td><td>1</td><td>1 (100.0)</td><td>0 (0.0)</td></tr><tr><td>Weight and length alone</td><td>Symmetrical</td><td>25</td><td>23 (92.0)</td><td>2 (8.0)</td></tr><tr><td>Weight alone</td><td>Asymmetrical</td><td>33</td><td>20 (60.6)</td><td>13 (39.4)</td></tr></table>
376063842474141d4d084746ce80b4ee3dfc2cb99660a8cad019ac27655878d8.png
complex
<table><tr><td rowspan="2">Amino acid substituted in Y114</td><td colspan="2">37 &#176;C</td><td colspan="2">65 &#176;C<sup>a</sup></td></tr><tr><td>Isomerase activity (mM/min &#956;g)</td><td>Epimerase activity (mM/min &#956;g)</td><td>Isomerase activity (mM/min &#956;g)</td><td>Epimerase activity (mM/min &#956;g)</td></tr><tr><td>Y (parent)</td><td>15.6 &#177; 1.2</td><td>138 &#177; 2.3</td><td>187 &#177; 4.2</td><td>37.0 &#177; 3.6</td></tr><tr><td>V</td><td>9.74 &#177; 1.4</td><td>nd</td><td>29.2 &#177; 3.3</td><td>nd</td></tr><tr><td>N</td><td>5.84 &#177; 0.71</td><td>nd</td><td>9.73 &#177; 2.2</td><td>nd</td></tr><tr><td>S</td><td>1.95 &#177; 0.39</td><td>nd</td><td>17.5 &#177; 4.0</td><td>nd</td></tr><tr><td>A</td><td>9.74 &#177; 2.0</td><td>nd</td><td>25.3 &#177; 3.2</td><td>nd</td></tr><tr><td>K</td><td>9.74 &#177; 0.98</td><td>nd</td><td>15.6 &#177; 2.1</td><td>nd</td></tr><tr><td>G</td><td>3.90 &#177; 1.3</td><td>nd</td><td>15.6 &#177; 2.2</td><td>nd</td></tr><tr><td>D</td><td>11.7 &#177; 1.9</td><td>nd</td><td>17.5 &#177; 2.1</td><td>nd</td></tr><tr><td>C</td><td>5.84 &#177; 1.0</td><td>nd</td><td>15.6 &#177; 1.9</td><td>nd</td></tr><tr><td>L</td><td>nd</td><td>nd</td><td>29.2 &#177; 2.6</td><td>nd</td></tr><tr><td>E</td><td>17.5 &#177; 2.3</td><td>nd</td><td>208 &#177; 3.9</td><td>11.7 &#177; 2.2</td></tr><tr><td>P</td><td>1.95 &#177; 0.55</td><td>nd</td><td>17.5 &#177; 1.2</td><td>nd</td></tr><tr><td>I</td><td>7.79 &#177; 1.9</td><td>nd</td><td>17.5 &#177; 1.1</td><td>nd</td></tr><tr><td>W</td><td>nd</td><td>nd</td><td>11.7 &#177; 1.2</td><td>nd</td></tr><tr><td>T</td><td>3.90 &#177; 0.2</td><td>nd</td><td>7.81 &#177; 2.1</td><td>nd</td></tr><tr><td>R</td><td>nd</td><td>nd</td><td>13.6 &#177; 1.0</td><td>nd</td></tr><tr><td>F</td><td>1.95 &#177; 0.13</td><td>9.74 &#177; 2.1</td><td>48.7 &#177; 3.2</td><td>9.77 &#177; 3.2</td></tr><tr><td>M</td><td>3.90 &#177; 0.22</td><td>nd</td><td>17.5 &#177; 2.9</td><td>nd</td></tr><tr><td>Q</td><td>1.92 &#177; 0.08</td><td>nd</td><td>23.4 &#177; 3.4</td><td>nd</td></tr><tr><td>H</td><td>nd</td><td>nd</td><td>15.6 &#177; 2.8</td><td>nd</td></tr></table>
f77a8e6ff504f979461164daaecef32f8de435c7ab7abed306d93d065f2f86ba.png
simple
<table><tr><td>References</td><td>Primary outcomes</td><td>Secondary outcomes</td></tr><tr><td>Song (weak)<sup>1</sup>[44]</td><td>Recalled stocking and sales scores were higher in intervention stores than in control stores.</td><td>There was improvement in some specific mediator factors but not in overall mediator factors.</td></tr><tr><td>Gittelsohn 2010b (weak) [42]</td><td></td><td>No changes were shown in most mediator factors between intervention and control stores.</td></tr><tr><td>Ayala 2013 (moderate)<sup>2</sup>[29]</td><td>The intervention increased availability of vegetables but not fruit.</td><td>Self-efficacy for consuming more fruits decreased.</td></tr></table>
92f1b1c950f23997695b7d8a44b0711c5491a63b373486acb3a40527221d36ae.png
simple
<table><tr><td></td><td>Tree 1</td><td>Tree 2</td><td>Tree 3</td><td>Pfam</td></tr><tr><td>Average sequence identity</td><td>19%</td><td>30%</td><td>42%</td><td>-</td></tr><tr><td>Alignment length</td><td>1080</td><td>629</td><td>597</td><td>404</td></tr><tr><td>Sequence length</td><td>173</td><td>177</td><td>169</td><td>171</td></tr><tr><td>Original number of sequences</td><td>32</td><td>33</td><td>46</td><td>-</td></tr><tr><td>Average number of sequences after MaxAlign</td><td>14.1</td><td>22.6</td><td>28.8</td><td>-</td></tr><tr><td>Average number of indels per sequence</td><td>66.6</td><td>54.3</td><td>48.5</td><td>32</td></tr><tr><td>Average length of indels</td><td>13.6</td><td>8.3</td><td>8.8</td><td>7</td></tr></table>
be8f3e5397e2ce1b30a90e3cdcd2dca43d9ebdbb9fcc8b958b0ee608c351a84d.png
complex
<table><tr><td><i>Expression level</i></td><td colspan="3"><i>Overall survival</i></td></tr><tr><td> </td><td><i>Median survival (95% CI, months)</i></td><td><i>Log-rank P</i></td><td><i>HR (95% CI)</i></td></tr><tr><td>Low ERCC1</td><td>11.7(2.6-15.3)</td><td>-</td><td>-</td></tr><tr><td>High ERCC1</td><td>17.4(4.3-22.6)</td><td>0.03</td><td>0.63(0.35-0.88)</td></tr><tr><td>Low RRM1</td><td>13.5(3.2-16.4)</td><td>-</td><td>-</td></tr><tr><td>High RRM1</td><td>15.4(3.6-18.4)</td><td>0.08</td><td>0.77(0.42-1.54)</td></tr><tr><td>Low ERCC1/Low RRM1</td><td>10.6(3.0-15.7)</td><td>-</td><td>-</td></tr><tr><td>High ERCC1/ Low RRM1</td><td>16.2(3.2-18.9)</td><td>0.06</td><td>0.67(0.36-1.03)</td></tr><tr><td>Low ERCC1/ High RRM1</td><td>12.5(3.1-15.8)</td><td>0.54</td><td>0.85(0.61-1.56)</td></tr><tr><td>High ERCC1/ High RRM1</td><td>18.7(4.5-23.1)</td><td>0.004</td><td>0.31(0.13-0.62)</td></tr></table>
977b950dafe6d713aef1d078ef9484b02d7240c6f521a8191519fdf76be03ec1.png
simple
<table><tr><td>Compounds</td><td>KB <sup>b</sup></td><td>A549 <sup>b</sup></td><td>Compounds</td><td>KB <sup>b</sup></td><td>A549 <sup>b</sup></td></tr><tr><td>Etoposide <sup>c</sup></td><td>0.85 &#177; 0.08</td><td>0.99 &#177; 0.09</td><td>C5</td><td>2.45 &#177; 0.41</td><td>5.24 &#177; 1.12</td></tr><tr><td>T2</td><td>0.58 &#177; 0.07</td><td>&gt;50</td><td>C6</td><td>8.52 &#177; 1.41</td><td>12.88 &#177; 1.32</td></tr><tr><td>S1</td><td>&gt;50</td><td>&gt;50</td><td>C7</td><td>3.80 &#177; 0.46</td><td>3.67 &#177; 0.66</td></tr><tr><td>S2</td><td>&gt;50</td><td>&gt;50</td><td>C8</td><td>3.64 &#177; 0.55</td><td>&gt;50</td></tr><tr><td>S3</td><td>&gt;50</td><td>&gt;50</td><td>C9</td><td>&gt;50</td><td>&gt;50</td></tr><tr><td>S4</td><td>&gt;50</td><td>&gt;50</td><td>N1</td><td>&gt;50</td><td>&gt;50</td></tr><tr><td>C1</td><td>3.21 &#177; 0.6</td><td>4.17 &#177; 0.51</td><td>N2</td><td>&gt;50</td><td>&gt;50</td></tr><tr><td>C2</td><td>8.26 &#177; 1.22</td><td>&gt;50</td><td>M1</td><td>&gt;50</td><td>&gt;50</td></tr><tr><td>C3</td><td>2.08 &#177; 0.33</td><td>2.24 &#177; 0.44</td><td>M2</td><td>&gt;50</td><td>&gt;50</td></tr><tr><td>C4</td><td>1.29 &#177; 0.31</td><td>8.48 &#177; 1.39</td><td>M3</td><td>&gt;50</td><td>&gt;50</td></tr></table>
5c15c19cf7e291e9646d4f8ceff67e0376cea3aa2a5b24f638883c75bd6384ea.png
simple
<table><tr><td>Baseline</td><td>Pre App</td><td>App</td><td>Post App</td></tr><tr><td>Complete DASS-21</td><td>Rate subjective wellbeing and distress daily for 7 days</td><td>Rate subjective wellbeing and distress daily for 7 days</td><td>Complete DASS-21</td></tr><tr><td></td><td>Complete DASS-21 after 7 days</td><td>Record answers to MOL-style questions received as text messages</td><td>Attend short, semi-structured interview to describe the experience of receiving and answering questions</td></tr></table>
fb294d05a9ed9031692615c6c2842cdf80418e2909214da526a87debf5fbd0d9.png
simple
<table><tr><td>Parameter</td><td>Value</td></tr><tr><td>Maximum data rate</td><td>250 kbps</td></tr><tr><td>Discovery packet time</td><td>10 s</td></tr><tr><td>Transmission power</td><td>0 dBm</td></tr><tr><td>Receiver sensitivity</td><td>&#8722;85 dBm</td></tr><tr><td>Average frame length</td><td>22 Bytes</td></tr><tr><td>MAC layer</td><td>CSMA/CA</td></tr><tr><td>Maximum number of backoffs</td><td>4</td></tr><tr><td>Packet loss</td><td>1%</td></tr><tr><td>Coverage radio</td><td>50 m</td></tr><tr><td>Mode</td><td>Active</td></tr><tr><td>Jamming</td><td>Reactive</td></tr><tr><td>Scenario</td><td>Static</td></tr><tr><td>Area</td><td>150 m &#215; 150 m</td></tr></table>
4fa7d322e8c516a4d7b810fb09d09bd53cf33d6e0a1912c4a8f015556d28dc08.png
simple
<table><tr><td>Primers and probes</td><td>Gene sequence</td></tr><tr><td>GAPDH sense</td><td>TGCACCACCAACTGCTTAG</td></tr><tr><td>GAPDH antisense</td><td>GGATGCAGGGATGATGTTC</td></tr><tr><td>GAPDH probe</td><td>CAGAAGACTGTGGATGGCCCCTC</td></tr><tr><td>IL-1&#946; sense</td><td>TCCTGAACTCAACTGTGAAATGC</td></tr><tr><td>IL-1&#946; antisense</td><td>AGCCCAGGTCAAAGGTTTGG</td></tr><tr><td>IL-1&#946; probe</td><td>AGCAGCCCTTCATCTTTTGGGGTCCG</td></tr><tr><td>IL-6 sense</td><td>CCGGAGAGGAGACTTCACAGA</td></tr><tr><td>IL-6 antisense</td><td>GTTGTTCATACAATCAGAATTGCCATT</td></tr><tr><td>IL-6 probe</td><td>ACCACTCCCAACAGACCTGTCTATACCACT</td></tr><tr><td>CCL2 sense</td><td>TCTGGGCCTGCTGTTCACA</td></tr><tr><td>CCL2 antisense</td><td>CCAGCCTACTCATTGGGATCA</td></tr><tr><td>CCL2 probe</td><td>TTGGCTCAGCCAGATGCAGTTAACGC</td></tr><tr><td>CCL3 sense</td><td>ATTCCACGCCAATTCATCGT</td></tr><tr><td>CCL3 antisense</td><td>TTGGAGTCAGCGCAGATCTG</td></tr><tr><td>CCL3 probe</td><td>CCTTTGCTCCCAGCCAGGTGTCATT</td></tr></table>
eae019914a52ba4dc62549da57ee485444cea950fc1be387d30a8eb080a8c5a9.png
complex
<table><tr><td></td><td colspan="4">Mother</td><td colspan="4">Newborn</td></tr><tr><td></td><td colspan="3">DNA</td><td>Serum<sup>3</sup></td><td colspan="3">DNA</td><td>Serum<sup>3</sup></td></tr><tr><td></td><td>Cervical</td><td>Oral<sup>5</sup></td><td>Cervical/Oral</td><td></td><td>Genital</td><td>Oral</td><td>Genital/Oral</td><td></td></tr><tr><td>HPV status</td><td><i>N</i> (%)</td><td><i>N</i> (%)</td><td><i>N</i> (%)</td><td><i>N</i> (%)</td><td><i>N</i> (%)</td><td><i>N</i> (%)</td><td><i>N</i> (%)</td><td><i>N</i> (%)</td></tr><tr><td>HPV+<sup>1</sup></td><td>93 (27.9)</td><td>10 (3.0)</td><td>99 (29.7)</td><td>108 (32.4)</td><td>2 (0.6)</td><td>3 (0.9)</td><td>5 (1.5)</td><td>103 (30.9)</td></tr><tr><td>HPV-LR<sup>1,2</sup></td><td>27 (8.1)</td><td>3 (0.9)</td><td>26 (7.8)</td><td></td><td>2 (0.6)</td><td>1 (0.3)</td><td>3 (0.9)</td><td>0 (0.0)</td></tr><tr><td> 6</td><td>3 (0.9)</td><td>1 (0.3)</td><td>4 (1.2)</td><td>0 (0.0)</td><td></td><td></td><td>0 (0.0)</td><td></td></tr><tr><td> 11</td><td>2 (0.6)</td><td></td><td>2 (0.6)</td><td>0 (0.0)</td><td></td><td></td><td>0 (0.0)</td><td></td></tr><tr><td>HPV-HR<sup>1,2</sup></td><td>66 (19.8)</td><td>7 (2.1)</td><td>73 (21.9)</td><td>108 (32.4)</td><td></td><td>2 (0.6)</td><td>2 (0.6)</td><td>103 (30.9)</td></tr><tr><td> 16</td><td>22 (6.6)</td><td>2 (0.6)</td><td>24 (7.2)</td><td>47 (14.1)</td><td></td><td>1 (0.3)</td><td></td><td>49 (14.7)</td></tr><tr><td> 18</td><td>8 (2.4)</td><td></td><td>8 (2.4)</td><td>46 (13.8)</td><td></td><td></td><td></td><td>45 (13.5)</td></tr><tr><td> 31</td><td>19 (5.7)</td><td>2 (0.6)</td><td>21 (6.3)</td><td>41 (12.3)</td><td></td><td></td><td></td><td>39 (11.7)</td></tr><tr><td> 33</td><td>2 (0.6)</td><td>1 (0.3)</td><td>3 (0.9)</td><td>40 (12.0)<sup>4</sup></td><td></td><td></td><td></td><td>36 (10.8)<sup>4</sup></td></tr><tr><td>HPV-6,11,16,18</td><td>35 (10.5)</td><td>2 (0.6)</td><td>37 (11.1)</td><td></td><td>0 (0.0)</td><td>1 (0.3)</td><td>1 (0.3)</td><td></td></tr></table>
06b99d5eccdd013f431a7e70ab92973f5ad28a61d05f87152270e960e6d347d5.png
simple
<table><tr><td></td><td></td><td>Baseline</td><td>Reexamination</td></tr><tr><td></td><td>N</td><td>27</td><td>25</td></tr><tr><td></td><td>Mean dmft &#177; SD</td><td>5.1 &#177; 1.8</td><td>8.8 &#177; 0.7</td></tr><tr><td>ECC stages</td><td>Initial stage (N, %)</td><td>(27) 100%</td><td>(0) 0%</td></tr><tr><td></td><td>Circular stage (N, %)</td><td>/</td><td>(7) 28%</td></tr><tr><td></td><td>Destructive stage (N, %)</td><td>/</td><td>(5) 20%</td></tr><tr><td></td><td>Radix relicta stage (N, %)</td><td>/</td><td>(9) 36%</td></tr><tr><td></td><td>Extraction (N, %)</td><td>/</td><td>(4) 16%</td></tr></table>
b21c99c994a35a71287bc59ac0e093f2f893589ec526d19367cef77b76609741.png
complex
<table><tr><td>Characteristic</td><td>Total population<sup><i>a</i></sup> [<i>n</i> (%)]</td><td>No tree canopy (%)</td><td> &#8805;50% impervious surface (%)</td><td>Both conditions (%)</td></tr><tr><td>Total population</td><td>81,517,417 (100.0)</td><td>42.1</td><td>62.2</td><td>36.5</td></tr><tr><td>Metro area segregation</td></tr><tr><td>0.13&lt;D<sub>m</sub>&lt;0.40 (97 CBSAs)</td><td>7,168,971 (8.8)</td><td>15.2</td><td>54.9</td><td>10.5</td></tr><tr><td>0.40&#8804;D<sub>m</sub>&lt;0.50 (105 CBSAs)</td><td>17,696,848 (21.7)</td><td>40.7</td><td>54.9</td><td>33.9</td></tr><tr><td>0.50&#8804;D<sub>m</sub>&lt;0.60 (78 CBSAs)</td><td>28,334,868 (34.8)</td><td>52.4</td><td>60.5</td><td>43.0</td></tr><tr><td>0.60&#8804;D<sub>m</sub>&lt;0.76 (24 CBSAs)</td><td>28,326,730 (34.7)</td><td>38.9</td><td>69.2</td><td>37.7</td></tr><tr><td>Race/ethnicity</td></tr><tr><td>Hispanic</td><td>21,360,877 (26.2)</td><td>56.8</td><td>72.3</td><td>49.8</td></tr><tr><td>Non-Hispanic</td></tr><tr><td>Asian</td><td>5,555,510 (6.8)</td><td>58.8</td><td>76.5</td><td>53.7</td></tr><tr><td>Black</td><td>15,343,325 (18.8)</td><td>34.2</td><td>61.8</td><td>31.1</td></tr><tr><td>White</td><td>39,257,705 (48.2)</td><td>34.4</td><td>54.0</td><td>28.6</td></tr><tr><td>Housing tenure</td></tr><tr><td>Rented housing unit</td><td>39,409,709 (48.3)</td><td>46.2</td><td>72.0</td><td>42.4</td></tr><tr><td>Owner occupied</td><td>42,117,708 (51.7)</td><td>37.9</td><td>52.2</td><td>30.6</td></tr><tr><td>Household income relative to poverty</td></tr><tr><td>Below poverty</td><td>14,038,788 (17.2)</td><td>46.1</td><td>68.7</td><td>41.3</td></tr><tr><td>Near poverty</td><td>16,283,421 (20.0)</td><td>44.8</td><td>65.4</td><td>39.4</td></tr><tr><td>At least twice poverty level</td><td>51,205,208 (62.8)</td><td>39.8</td><td>58.7</td><td>34.0</td></tr><tr><td colspan="5"><sup><i>a</i></sup>Total of 81,517,417 individuals in 63,436 block groups in 304 metropolitan areas.</td></tr></table>
32221a5753cd209202b3cc07b119179bf6d8d0d87d7bc926bd6f55e4bff53af1.png
simple
<table><tr><td><i>Number (%) of </i></td><td>Pre-eclamptic (<i>N </i>= 143)</td><td>Controls(<i>N </i>= 143)</td><td><i>P</i></td></tr><tr><td>Primigravidae</td><td>49(34.3)</td><td>27(18.9)</td><td>0.01</td></tr><tr><td>lack of antenatal care</td><td>21(14.7)</td><td>33(23.1)</td><td>0.02</td></tr><tr><td>Educational level &lt; secondary</td><td>36(25.2)</td><td>24(16.8)</td><td>0.8</td></tr><tr><td>Bednets coverage</td><td>21(14.7)</td><td>23 (16.1)</td><td>0.6</td></tr><tr><td>History of malaria</td><td>31(21.7)</td><td>11(7.7)</td><td>0.001</td></tr><tr><td>Family history of hypertension</td><td>122(85.3)</td><td>81(56.6)</td><td>0.001</td></tr><tr><td>Placental malaria</td><td>28(19.6)</td><td>16(11.2)</td><td>0.04</td></tr></table>
a5256a7d1279d96f895d8ab5c426e1f4d016cd71e5e060743b7878d1e75d949d.png
simple
<table><tr><td> </td><td>Am &#916;</td><td>Cm &#916;</td><td>Cf &#916;</td><td> </td><td>Am &#923;</td><td>Cm &#923;</td><td>Cf &#923;</td></tr><tr><td>O13</td><td>2.472 (3)</td><td>2.462 (3)</td><td>2.455 (4)</td><td>O1</td><td>2.507 (3)</td><td>2.496 (3)</td><td>2.476 (4)</td></tr><tr><td>O14</td><td>2.491 (3)</td><td>2.483 (3)</td><td>2.443 (4)</td><td>O2</td><td>2.441 (3)</td><td>2.433 (3)</td><td>2.413 (4)</td></tr><tr><td>O15</td><td>2.430 (3)</td><td>2.417 (3)</td><td>2.387 (4)</td><td>O3</td><td>2.405 (3)</td><td>2.389 (3)</td><td>2.363 (3)</td></tr><tr><td>O16</td><td>2.468 (3)</td><td>2.459 (3)</td><td>2.422 (3)</td><td>O4</td><td>2.512 (3)</td><td>2.501 (3)</td><td>2.476 (3)</td></tr><tr><td>O17</td><td>2.516 (3)</td><td>2.508 (3)</td><td>2.494 (4)</td><td>O5</td><td>2.494 (3)</td><td>2.480 (3)</td><td>2.441 (3)</td></tr><tr><td>O18</td><td>2.499 (3)</td><td>2.481 (3)</td><td>2.411 (4)</td><td>O6</td><td>2.457 (3)</td><td>2.448 (3)</td><td>2.417 (4)</td></tr><tr><td>N1</td><td>2.550 (4)</td><td>2.533 (4)</td><td>2.512 (4)</td><td>N2</td><td>2.556 (3)</td><td>2.520 (4)</td><td>2.518 (4)</td></tr><tr><td>N3</td><td>2.551 (4)</td><td>2.536 (4)</td><td>2.508 (4)</td><td>N4</td><td>2.531 (4)</td><td>2.535 (4)</td><td>2.506 (4)</td></tr><tr><td>N5</td><td>2.591 (3)</td><td>2.581 (4)</td><td>2.545 (4)</td><td>N6</td><td>2.573 (4)</td><td>2.569 (4)</td><td>2.526 (4)</td></tr></table>
54023a094939eaea3cc34a26f0e16afd8ebd5db406b003959308afad306a5b01.png
complex
<table><tr><td>Test</td><td>Cutoff for &#8220;abnormal&#8221;</td><td>All Stages (<i>N</i> = 5731)</td><td>Stage 1 (<i>N</i> = 4058)</td><td>Stage 2 (<i>N</i> = 981)</td><td>Stage 3 (<i>N</i> = 692)</td></tr><tr><td colspan="6">Urine Tests</td></tr><tr><td>Eosinophils</td><td>&#8805;1 %</td><td>6.9</td><td>5.8</td><td>7.2</td><td>7.5</td></tr><tr><td>Total Protein</td><td>&gt;15 mg/dl</td><td>70.8</td><td>63.0</td><td>64.3</td><td>83.3</td></tr><tr><td>UPEP</td><td>M spike</td><td>7.9</td><td>5.0</td><td>9.8</td><td>10.0</td></tr><tr><td colspan="6">Blood Tests</td></tr><tr><td>ANCA</td><td>Titer &gt; 1:20</td><td>10.6</td><td>8.0</td><td>3.7</td><td>14.9</td></tr><tr><td>Anti-GBM</td><td>&#8805;1.0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Cryoglobulin</td><td>&gt;0 %</td><td>21.8</td><td>26.3</td><td>0</td><td>21.2</td></tr><tr><td>C3</td><td>&lt;90 mg/dl</td><td>36.5</td><td>26.9</td><td>21.1</td><td>45.6</td></tr><tr><td>C4</td><td>&lt;10 mg/dl</td><td>12.9</td><td>11.6</td><td>10.5</td><td>14.3</td></tr><tr><td>Free Light Chains</td><td>See below</td><td>41.6</td><td>44.7</td><td>42.9</td><td>36.7</td></tr><tr><td>SPEP</td><td>M spike</td><td>19.1</td><td>16.4</td><td>23.9</td><td>19.7</td></tr><tr><td colspan="6">Radiology Tests</td></tr><tr><td>Renal Ultrasound</td><td>See Methods</td><td>34.6</td><td>40.6</td><td>23.4</td><td>34.9</td></tr><tr><td>CT Abdomen/Pelvis</td><td>See Methods</td><td>33.3</td><td>26.7</td><td>27.3</td><td>39.3</td></tr></table>
918a57999f4a1bf8e04d94bffb85ecb106cd98c705a206987010190390d65c31.png
complex
<table><tr><td>Variable</td><td>Median (25th, 75th percentile)</td></tr><tr><td colspan="2">Sleep</td></tr><tr><td> Time in bed (hours:minutes)</td><td>9:31 (9:02, 9:58)</td></tr><tr><td> Sleep duration (hours:minutes)</td><td>8:29 (7:59, 8:59)</td></tr><tr><td> Sleep midpoint (hours:minutes)</td><td>2:44 (2:14, 3:29)</td></tr><tr><td> Sleep efficiency (%)</td><td>90.0 (86.3, 92.5)</td></tr><tr><td colspan="2">Physical activity (minutes/day)</td></tr><tr><td> Outdoor active play (minutes/day)</td><td>32.7 (15.8, 54.2)</td></tr><tr><td> Organized sports (minutes/day)</td><td>18.8 (0.0, 48.6)</td></tr><tr><td> Curriculum-based physical activity (minutes/day)</td><td>9.8 (2.1, 16.6)</td></tr><tr><td> Active transportation (minutes/day)</td><td>12.2 (5.4, 21.3)</td></tr></table>
07771bb2485b4ee8681d498896cc9bb36b269c96800612b4aafd738869dbd21c.png
simple
<table><tr><td>Pre-SBRT factors</td><td>G4-5 RP</td><td>G0-3 RP</td><td>Total</td><td>X2 test</td><td>1-year cumulative incidence of G4-5 RP</td><td>log-rank</td></tr><tr><td>Serum KL-6</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>high value</td><td>6</td><td>17</td><td>23</td><td><i>p </i>= 0.0002</td><td>32%</td><td><i>p </i>&lt; 0.0001</td></tr><tr><td>within normal level</td><td>2</td><td>78</td><td>80</td><td></td><td>3%</td><td></td></tr><tr><td>not available</td><td>1</td><td>13</td><td>14</td><td></td><td></td><td></td></tr><tr><td>Serum SP-D</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>high value</td><td>5</td><td>14</td><td>19</td><td><i>p </i>= 0.0002</td><td>29%</td><td><i>p </i>= 0.0001</td></tr><tr><td>within normal level</td><td>2</td><td>79</td><td>81</td><td></td><td>3%</td><td></td></tr><tr><td>not available</td><td>2</td><td>15</td><td>17</td><td></td><td></td><td></td></tr><tr><td>IP shadow in CT</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(+)</td><td>7</td><td>6</td><td>13</td><td><i>p </i>&lt; 0.0001</td><td>57%</td><td><i>p </i>&lt; 0.0001</td></tr><tr><td>(-)</td><td>2</td><td>102</td><td>104</td><td></td><td>2%</td><td></td></tr></table>
36d4e747bc5f54d18586b48e5917454846ccf3f05e6577e4c4ac43570c653979.png
complex
<table><tr><td></td><td colspan="6">Cross-section 2004</td><td>Panel 2002&#8211;2004</td></tr><tr><td>Variable</td><td>Average for treated</td><td>Average for untreated</td><td>Single difference in averages</td><td>% difference</td><td>Boot-strapped Std. Err.</td><td>P-value</td><td>Double differences/differences-in-differences (absolute)</td></tr><tr><td>No. of outpatient (OP) visits in the 12-month recall period</td><td>0.818</td><td>0.786</td><td>0.033</td><td>4%</td><td>0.060</td><td>0.585</td><td>0.06</td></tr><tr><td>no. of OP visits at commune level clinics</td><td>0.380</td><td>0.308</td><td>0.072</td><td>23%</td><td>0.034</td><td>0.034</td><td>0.10</td></tr><tr><td>no. of OP visits at district hospital</td><td>0.144</td><td>0.078</td><td>0.066</td><td>85%</td><td>0.022</td><td>0.003</td><td>Not available</td></tr><tr><td>no. of OP visits at provincial/central hospital</td><td>0.051</td><td>0.029</td><td>0.022</td><td>74%</td><td>0.009</td><td>0.018</td><td>Not available</td></tr><tr><td>no. of OP visits at govt. hospital</td><td>0.195</td><td>0.107</td><td>0.088</td><td>82%</td><td>0.025</td><td>0.000</td><td>0.08</td></tr><tr><td>no. of OP visits at private facility</td><td>0.222</td><td>0.357</td><td>-0.135</td><td>-38%</td><td>0.039</td><td>0.000</td><td>-0.12</td></tr><tr><td>No. of inpatient (IP) admissions in the 12-month recall period</td><td>0.125</td><td>0.118</td><td>0.007</td><td>6%</td><td>0.012</td><td>0.557</td><td>0.00</td></tr><tr><td>no. of IP admissions at commune level clinics</td><td>0.026</td><td>0.037</td><td>-0.010</td><td>-28%</td><td>0.004</td><td>0.020</td><td>0.00</td></tr><tr><td>no. of IP admissions at district hospital</td><td>0.060</td><td>0.038</td><td>0.023</td><td>60%</td><td>0.008</td><td>0.003</td><td>Not available</td></tr><tr><td>no. of IP admissions at provincial/central hospital</td><td>0.035</td><td>0.038</td><td>-0.002</td><td>-6%</td><td>0.006</td><td>0.721</td><td>Not available</td></tr><tr><td>no. of IP admissions at govt. hospital</td><td>0.096</td><td>0.075</td><td>0.021</td><td>27%</td><td>0.011</td><td>0.065</td><td>0.02</td></tr></table>
3e97976fc3b025a3c88eb47ac3b62fd383c6fb92a47a8831dc1803699315f51e.png
simple
<table><tr><td>Variables</td><td>No. of patientsn(%)</td><td>Western medicinen(%)</td><td>Chinese medicine n(%)</td><td><i>P</i>-value</td></tr><tr><td>Total</td><td>786(100)</td><td>337(42.9)</td><td>449(57.1)</td><td></td></tr><tr><td>Conventional treatment</td><td>781(99.4)</td><td>337(100)</td><td>444(98.9)</td><td>0.052</td></tr><tr><td>Surgery</td><td>453(57.6)</td><td>196(58.2)</td><td>257(57.2)</td><td>0.796</td></tr><tr><td>Chemotherapy</td><td>501(63.7)</td><td>184(54.6)</td><td>317(70.6)</td><td>&lt; 0.001</td></tr><tr><td>Radiotherapy</td><td>487(62.0)</td><td>208(61.7)</td><td>279(62.1)</td><td>0.905</td></tr><tr><td>Endocrine therapy</td><td>84(10.7)</td><td>36(10.7)</td><td>48(10.7)</td><td>0.997</td></tr><tr><td>Palliative therapy</td><td>12(1.5)</td><td>1(0.3)</td><td>11(2.4)</td><td>0.015</td></tr><tr><td>Chinese medicine</td><td>449(57.1)</td><td>---</td><td>449(100)</td><td>---</td></tr><tr><td>treatment</td><td>424(53.9)</td><td>---</td><td>424(94.4)</td><td></td></tr><tr><td>Chinese Herbal Medicine</td><td>21(2.7)</td><td>---</td><td>21(4.7)</td><td></td></tr><tr><td>Acupuncture and Moxibustion</td><td>11(1.4)</td><td>---</td><td>11(2.4)</td><td></td></tr><tr><td>Therapeutic Massage</td><td>40(5.1)</td><td>---</td><td>40(8.9)</td><td></td></tr><tr><td><i>Qigong</i></td><td>75(9.5)</td><td>---</td><td>75(16.7)</td><td></td></tr><tr><td>Chinese Dietary Therapy</td><td></td><td></td><td></td><td></td></tr></table>
9bb2952d205a99f191a33e557ae7bb21504a34ce2d7373d2dbb5d71d63d1ee0a.png
simple
<table><tr><td>Strain of <i>C. jejuni</i></td><td>Rate of growth (&#956;<sub>max</sub>) in microaerobic conditions</td><td>Death times (D-values) in aerobic conditions</td></tr><tr><td>Bf</td><td>0.5763</td><td>\**</td></tr><tr><td>subsp. <i>jejuni</i> NCTC 11168</td><td>0.7714*</td><td>0.9737</td></tr><tr><td>subsp. <i>jejuni</i> 00-2538</td><td>0.9198*</td><td>1.1039</td></tr><tr><td>subsp. <i>jejuni</i> 00-2426</td><td>0.8964*</td><td>1.5442</td></tr><tr><td>subsp. <i>jejuni</i> 00-2544</td><td>0.8303*</td><td>1.4554</td></tr><tr><td>subsp. <i>jejuni</i> 00-2425</td><td>0.9085*</td><td>1.3785</td></tr><tr><td>subsp. <i>jejuni</i> 81-176</td><td>0.9477*</td><td>0.4765</td></tr><tr><td>subsp. <i>jejuni</i> NCTC 11828</td><td>0.7899*</td><td>1.3417</td></tr><tr><td>subsp. <i>doylei</i> 269.97</td><td>0.7765*</td><td>2.2691</td></tr><tr><td>subsp. <i>jejuni</i> RM 1221</td><td>0.6793*</td><td>1.9276</td></tr></table>
397dcadb8fc4b69232d78c0e70da0f4e73cca264640dc846a56ed6007a839e0a.png
complex
<table><tr><td rowspan="3">Quality-of-care category<sup>a</sup></td><td colspan="6">Summary score</td></tr><tr><td colspan="3">Baseline</td><td colspan="3">End of the study</td></tr><tr><td>Intervention group, mean (SD)</td><td>Control group, mean (SD)</td><td>Intervention versus control group, mean difference (95% CI)</td><td>Intervention group, mean (SD)</td><td>Control group, mean (SD)</td><td>Intervention versus control group, mean difference (95% CI)</td></tr><tr><td>Hospital support systems</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Information systems and statistics</td><td>1.85 (0.44)</td><td>1.70 (0.53)</td><td>0.15 (&#8722;0.30 to 0.60)</td><td>2.68 (0.24)</td><td>1.55 (0.52)</td><td>1.26 (0.85 to 1.66)</td></tr><tr><td>Drugs and equipment</td><td>2.27 (0.61)</td><td>2.00 (0.73)</td><td>0.27 (&#8722;0.36 to 0.90)</td><td>2.94 (0.11)</td><td>1.68 (0.60)</td><td>1.13 (0.74 to 1.51)</td></tr><tr><td>Laboratory</td><td>2.50 (0.46)</td><td>2.33 (0.57)</td><td>0.17 (&#8722;0.31 to 0.66)</td><td>2.93 (0.12)</td><td>2.28 (0.80)</td><td>0.65 (0.11 to 1.18)</td></tr><tr><td>Emergency support</td><td>1.69 (0.28)</td><td>1.51 (0.33)</td><td>0.18 (&#8722;0.10 to 0.46)</td><td>2.85 (0.13)</td><td>1.27 (0.50)</td><td>1.58 (0.23 to 1.92)</td></tr><tr><td>Paediatric ward</td><td>1.65 (0.40)</td><td>1.54 (0.55)</td><td>0.11 (&#8722;0.34 to 0.56)</td><td>2.85 (0.19)</td><td>1.60 (0.50)</td><td>1.25 (0.89 to 1.60)</td></tr><tr><td>Case management</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Cough and breathing difficulties</td><td>1.02 (0.63)</td><td>0.99 (0.51)</td><td>0.01 (&#8722;0.52 to &#8722;0.54)</td><td>2.53 (0.33)</td><td>1.17 (0.62)</td><td>1.36 (0.89 to 1.82)</td></tr><tr><td>Diarrhoea</td><td>0.65 (0.58)</td><td>0.60 (0.54)</td><td>0.05 (&#8722;0.47 to 0.57)</td><td>2.70 (0.21)</td><td>1.12 (0.48)</td><td>1.58 (0.23 to 1.92)</td></tr><tr><td>Anaemia</td><td>1.12 (0.37)</td><td>1.09 (0.43)</td><td>0.03 (&#8722;0.25 to 0.31)</td><td>2.28 (0.31)</td><td>0.98 (0.70)</td><td>1.30 (0.79 to 1.80)</td></tr><tr><td>Febrile conditions</td><td>0.87 (0.43)</td><td>0.96 (0.39)</td><td>&#8722;0.09 (&#8722;0.47 to 0.29)</td><td>2.12 (0.31)</td><td>1.16 (0.37)</td><td>0.96 (0.63 to 1.28)</td></tr><tr><td>Chronic conditions</td><td>1.72 (0.67)</td><td>2.17 (0.29)</td><td>&#8722;0.45 (&#8722;0.93 to 0.03)</td><td>1.73 (0.35)</td><td>0.97 (0.31)</td><td>1.76 (0.44 to 1.07)</td></tr><tr><td>Surgery</td><td>1.46 (0.39)</td><td>1.29 (0.26)</td><td>0.17 (&#8722;0.14 to 0.48)</td><td>2.88 (0.17)</td><td>1.40 (0.59)</td><td>1.48 (1.07 to 1.88)</td></tr><tr><td>Policies and organization of care</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Supportive care</td><td>1.00 (0.56)</td><td>1.08 (0.48)</td><td>&#8722;0.08 (&#8722;0.57 to 0.41)</td><td>2.87 (0.13)</td><td>1.25 (0.55)</td><td>1.62 (0.24 to 1.99)</td></tr><tr><td>Child-friendly services</td><td>1.25 (0.32)</td><td>1.43 (0.36)</td><td>&#8722;0.18 (&#8722;0.50 to 0.14)</td><td>2.69 (0.26)</td><td>1.20 (0.44)</td><td>1.49 (1.15 to 1.82)</td></tr><tr><td>Monitoring</td><td>0.96 (0.78)</td><td>1.20 (0.57)</td><td>&#8722;0.24 (&#8722;0.88 to 0.40)</td><td>2.76 (0.21)</td><td>0.91 (0.57)</td><td>1.85 (1.84 to 2.25)</td></tr><tr><td>Auditing and guidelines</td><td>1.74 (0.51)</td><td>1.69 (0.31)</td><td>0.05 (&#8722;0.34 to 0.44)</td><td>2.73 (0.19)</td><td>1.56 (0.74)</td><td>1.17 (0.66 to 1.67)</td></tr><tr><td>Access to hospital</td><td>2.00 (0.28)</td><td>2.03 (0.43)</td><td>&#8722;0.03 (&#8722;0.37 to 0.31)</td><td>2.76 (0.26)</td><td>1.85 (0.37)</td><td>0.91 (0.60 to 1.21)</td></tr><tr><td>Mothers&#8217; satisfaction</td><td>1.72 (0.62)</td><td>1.70 (0.32)</td><td>0.02 (&#8722;0.44 to 0.48)</td><td>2.83 (0.19)</td><td>1.89 (0.23)</td><td>0.94 (0.74 to 1.13)</td></tr></table>
5f115f3814e4534701b6882a32c4186f929761ab1b216ffe027fa2c74d4beafe.png
complex
<table><tr><td></td><td colspan="3">SCC</td></tr><tr><td>Herd size</td><td>&lt; = 200</td><td>201-400</td><td>&gt; 400</td></tr><tr><td>Q1</td><td>35.52</td><td>42.35</td><td>22.12</td></tr><tr><td>Q2</td><td>33.06</td><td>46.99</td><td>19.96</td></tr><tr><td>Q3</td><td>31.38</td><td>49.47</td><td>19.15</td></tr><tr><td>Q4</td><td>26.50</td><td>54.74</td><td>18.76</td></tr></table>
a22955d998f27a1d688fc11e4aaca3e73da42a5aac7e4977380bd8881961373c.png
simple
<table><tr><td>Level of Adaptation to Heat</td><td>% Who Reported Adverse Health Impacts</td><td>Confidence Interval</td><td>Coeff. of Variation</td><td>Odds Ratio</td><td>Confidence Interval</td><td>Pr &gt; &#967;<sup>2</sup></td></tr><tr><td>Individuals who adapt well</td><td>45.77</td><td>(41.78&#8211;49.76)</td><td>4.44</td><td>1.37</td><td>(1.13&#8211;1.66)</td><td>0.0011</td></tr><tr><td>Individuals who do not adapt as well </td><td>38.11</td><td>(33.66&#8211;42.56)</td><td>5.95</td><td>1.00</td><td></td><td></td></tr></table>
963edf2849e67766811093909ce7efc133f824a65c12e7899a6249c212f76a84.png
simple
<table><tr><td></td><td>Blood</td><td>Brain</td><td>Liver</td><td>Tongue</td><td>Skin</td><td>Lung</td><td>Muscle</td><td>Intestine</td><td>Tumour</td></tr><tr><td>L-BPA (&#956;g/g)</td><td>13.42 &#177; 1.26</td><td>4.97 &#177; 0.54</td><td>12.11 &#177; 1.82</td><td>13.62 &#177; 5.15</td><td>15.65 &#177; 2.77</td><td>15.82 &#177; 1.51</td><td>12.41 &#177; 1.19</td><td>16.45 &#177; 2.91</td><td>21.11 &#177; 3.15</td></tr><tr><td>L-FBPA (&#956;g/g)</td><td>13.19 &#177; 1.18</td><td>4.61 &#177; 2.28</td><td>15.63 &#177; 3.15</td><td>12.14 &#177; 1.08</td><td>13.75 &#177; 3.08</td><td>14.78 &#177; 1.64</td><td>9.69 &#177; 1.3</td><td>15.33 &#177; 0.88</td><td>20.17 &#177; 6.49</td></tr><tr><td><i>p</i> value</td><td>0.81</td><td>0.81</td><td>0.18</td><td>0.61</td><td>0.45</td><td>0.43</td><td>0.052</td><td>0.51</td><td>0.83</td></tr></table>
529aeace101415f48ef3b932fed92a1aaf4406218a557ff474a0dac0535fd7eb.png
complex
<table><tr><td></td><td>Kidney</td><td>Kidney pancreas</td></tr><tr><td>Number recruited</td><td>42</td><td>19</td></tr><tr><td>Sex male/female</td><td>31M/11F</td><td>9M/10F</td></tr><tr><td>Median age (range)</td><td>54 (26&#8211;74)</td><td>47 (30&#8211;59)</td></tr><tr><td colspan="3">Donor type</td></tr><tr><td>Living (male/female)</td><td>16 (11M/5F)</td><td>n/a</td></tr><tr><td>DBD (male/female)</td><td>11 (7M/4F)</td><td>16 (7M/9F)</td></tr><tr><td>DCD (male/female)</td><td>15 (13M/ F)</td><td>3 (2M/1F)</td></tr><tr><td colspan="3">Drug treatment regimen</td></tr><tr><td>Alemtuzumab</td><td>19</td><td>19</td></tr><tr><td>Basiliximab + MMF</td><td>13</td><td>n/a</td></tr><tr><td>Basiliximab + Aza</td><td>10</td><td>n/a</td></tr></table>
e2f612d274a1e8229b8d463f5ed036805eb3979dd4aeece33f00d2d695bd4762.png
complex
<table><tr><td colspan="2">Demographic</td><td>Physicians (n = 13)</td><td>Nursing staff (n = 13)</td><td>Overall (n = 26)</td></tr><tr><td rowspan="2">Sex</td><td>Male</td><td>4</td><td>1</td><td>5</td></tr><tr><td>Female</td><td>9</td><td>12</td><td>21</td></tr><tr><td>Age (yr)</td><td>Mean (range)</td><td>45 (25&#8211;60)</td><td>45 (24&#8211;61)</td><td>45 (24&#8211;61)</td></tr><tr><td>Years of professional experience</td><td>Mean (range)</td><td>15 (0&#8211;36)</td><td>17 (0&#8211;32)</td><td>16 (0&#8211;36)</td></tr><tr><td rowspan="2">Type of facility</td><td>Nursing home</td><td>10</td><td>9</td><td>19</td></tr><tr><td>Residential care home</td><td>3</td><td>4</td><td>7</td></tr><tr><td rowspan="2">Facility location</td><td>Urban area</td><td>8</td><td>7</td><td>15</td></tr><tr><td>Rural area</td><td>5</td><td>6</td><td>11</td></tr><tr><td rowspan="5">Professional specialism</td><td rowspan="4">Nursing home</td><td>Elderly care physician (7)</td><td rowspan="2">Nurse<sup>*</sup> (4)</td><td rowspan="4">-</td></tr><tr><td>Elderly care physician in training (1)</td></tr><tr><td>Junior doctor (1)</td><td rowspan="2">Nurse assistant<sup>*</sup> (5)</td></tr><tr><td>Physician assistant (1)</td></tr><tr><td>Residential care home</td><td>General practitioner (3)</td><td>Nurse assistant<sup>*</sup> (4)</td><td></td></tr></table>